JOURNAL OF PHARMACEUTICAL SCIENCES

A publication of the American Pharmaceutical Association—
the National Professional Society of Pharmacists

INDEX TO AUTHORS
INDEX TO SUBJECTS

VOLUME 65
JANUARY TO DECEMBER, 1976

Published monthly under the supervision of the Board of Trustees

MARY H. FERGUSON
Editor

L. LUAN CORRIGAN
Assistant Editor

SHELLY ELLIOTT
Production Editor

JANET D. SHOFF
Copy Editor

EDWARD G. FELDMANN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

LELAND J. ARNEY
Director of Publications

EDITORIAL ADVISORY BOARD

John Autian
Lynn R. Brady
William O. Foye
William J. Jusko
Harry B. Kostenbauder
Carl J. Lintner, Jr.
David E. Mann, Jr.
Gerald J. Papariello

© Copyright 1976 by the American Pharmaceutical Association; all rights reserved.

AUTHOR INDEX

A

Abdine, H., *see* Soliman, S. A., 424
Abdou, H. M., *see* Cioffi, F. J., 1234
Aboul-Enein, N., and Sam, J., epimeric 5-hydroxy-5-phenyl-1-azabicyclo[5.4.0]undecanes, 1389
Abramson, H. N., Huang, C. L., Wu, T. F., and Tobin, T., thiocardenolides I: synthesis and biological actions of 3β-thiocyanato-14β-hydroxy-5β-card-20(22)-enolide, 765
Abu-Eittah, R., and El-Nasr, M. S., spectrophotometric study of complex formation between oxovanadium(IV) and antiamebic drugs, 1364
Agharkar, S., Lindenbaum, S., and Higuchi, T., enhancement of solubility of drug salts by hydrophilic counterions: properties of organic salts of an antimalarial drug, 747
Agrawal, K. C., Clayman, S., and Sartorelli, A. C., synthesis of site-directed chelating agents II: 2-formyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine thiosemicarbazone, 297
Ahuja, S., derivatization in gas chromatography, 163
Ajemian, R. S., *see* Warner, V. D., 1070
Akers, M. J., and Lach, J. L., evaluation of emulsion stability by diffuse reflectance spectroscopy, 216
Aldrich, H. S., and Clagett, D. C., molecular orbital studies of antischistosomal agents, 1704
Alexander, K., *see* Dixon, W. R., 701
Alexander, K. S., Petersen, H., Jr., Turcotte, J. G., and Paruta, A. N., molecular orbital calculations for parabens: a possible mechanism of action, 851
——*see* Laprade, B., 277
Ali, B., *see* Singh, S. P., 391
Alicino, J. F., *N*-bromosuccinimide assay of penicillins and cephalosporins, 300
Alkalay, D., Volk, J., and Bartlett, M. F., conversion of biguanides into substituted *s*-triazines assayable by GC or mass fragmentography, 525
Allen, L. V., Jr., *see* Levinson, R. S., 1265
Allen, M. A., *see* Stenchever, M. A., 1648
Al-Obeidi, F. A., and Borazan, H. N., interactions of adenine, thymine, and uracil with epinephrine: UV studies, 982
——and Borazan, H. N., interactions of nucleic acid bases with catechol: UV studies, 892
Alvino, T. P., *see* Schwartz, J. B., 572
Amann, A. H., effect of absorbents on water vapor transmission of free and applied polymer films, 521
Amaro, A. A., *see* Chowhan, Z. T., 1669
Amidon, G. L., and Anik, S. T., comparison of several molecular topological indexes with molecular surface area in aqueous solubility estimation, 801
——*see* Yalkowsky, S. H., 1488
Amin, M. I., Koshy, K. T., and Bryan, J. T., stability of aqueous solutions of mibolerone, 1777
Amin, Y. M., and Nagwekar, J. B., rationale for apparent differences in pharmacokinetic aspects of model compounds determined from blood level data and urinary excretion data in rats, 1341
Andrade, J. D., *see* Chen, C. N., 717
Angelucci, L., Petrangeli, B., Celletti, P., and Favilli, S., bioavailability of flufenamic acid in hard and soft gelatin capsules, 455
Anhoury, M. L., Crooy, P., De Neys, R., and Laridant, A., rapid determination of dimethyl polysiloxane by proton magnetic resonance spectroscopy, 590
Anik, S. T., *see* Amidon, G. L., 801
——*see* Carstensen, J. T., 158
Arita, T., *see* Nakano, M., 709
——*see* Yamamoto, K., 1484
Armstrong, N. A., and Clarke, C. D., adsorption sites of kaolin, 373
——and March, G. A., quantitative assessment of factors contributing to mottling of colored tablets II: formulation variables, 200
——and March, G. A., quantitative assessment of factors contributing to mottling of colored tablets I: manufacturing variables, 198
Arndts, D., *see* Pook, K.-H., 1513
Ary, I. E., *see* Atkinson, E. R., 1682
Ashida, K., *see* Theeuwes, F., 648
Asleson, G. L., *see* Stoel, L. J., 1794
Astley, J. P., and Levine, M., effect of dimethyl sulfoxide on permeability of human skin *in vitro*, 210
Athanikar, N., *see* Chiou, W. L., 1702
Atkinson, E. R., and Granchelli, F. E., antimalarials V: aminobenzothiazoles, 618
——Battista, S. P., Ary, I. E., Richardson, D. G., Harris, L. S., and Dewey, W. L., derivatives of apomorphine and of other *N*-substituted norapomorphines, 1682
Attwood, D., and Udeala, O. K., aggregation of antihistamines in aqueous solution: effect of counterions on self-association of pyridine derivatives, 1053
Aufrère, M. B., and Benson, H., progesterone: an overview and recent advances, 783
Auslander, D. E., and Gilbert, S. G., hermetic packaging of drugs: optimized sealing of foil pouches, 1061
Auyong, T. K., *see* Singh, S. P., 391
Awang, D. V. C., and Vincent, A., mass spectral and pyrolytic behavior of the two main products of phenylbutazone degradation: simulation of unusual mass spectral fragmentation, 68
Aynilian, G. H., *see* Chang, P. T. O., 561
Ayres, J. W., Lorskulsint, D., Lock, A., Kuhl, L., and Laskar, P. A., absorption and distribution of radioactivity from suppositories containing ^{3}H-benzocaine in rats, 832

B

Badii, F., *see* Yazdany, S., 745
Baggot, J. D., *see* Ludden, T. M., 712
Baker, H. A., *see* Dimmock, J. R., 38
Baltezor, M. J., *see* Repta, A. J., 238
Banerjee, S., and Mitra, C., muscle relaxant properties of chloramphenicol, 704
Banker, G. S., *see* Larson, A. B., 838
Bansal, P. C., *see* Repta, A. J., 238
Bansinath, M., *see* Ramabadran, K., 1245
Barfknecht, C. F., *see* Smith, R. V., 412
Barthwal, J. P., *see* Chaudhary, S. K., 1010
——*see* Misra, R. S., 405
Bartlett, M. F., *see* Alkalay, D., 525
Bass, G. E., Powers, L. J., and Dillingham, E. O., inhibition of *Streptococcus faecalis* by long chain aliphatic monoamines: quantitative structure–activity studies, 1525
Battista, S. P., *see* Atkinson, E. R., 1682
Bavda, L. T., *see* Kochhar, M. M., 137
Baweja, R., *see* Shimada, K., 1057
Bayne, W. F., Chu, L.-C., and Tao, F. T., subnanogram assay for pilocarpine in biological fluids, 1724
Beam, C. F., Shealy, K. D., Harris, C. E., Shealy, N. L., Dasher, L. W., Hollinger, W. M., Sandifer, R. M., and Reames, D. C., preparation of tri- and tetramethyleneisoxazoles, 1408
Beaudoin, N., *see* Sved, S., 1356
Becktel, J., *see* Oester, Y. T., 1673
Behl, C. R., Block, L. H., and Borke, M. L., aqueous solubility of ^{14}C-triamcinolone acetonide, 429
Behn, R. M., *see* Casey, D. L., 1412
Belvedere, G., Pantarotto, C., Rovei, V., and Frigerio, A., identification of 10,11-epoxide and other cyclobenzaprine metabolites isolated from rat urine, 815
——*see* Rovei, V., 810
Benet, L. Z., *see* Gustafson, J. H., 243
Benson, G. A., and Spillane, W. J., determination of the nonnutritive sweetener sodium cyclopentylsulfamate and three of its metabolites, cyclopentylamine, cyclopentanone, and cyclopentanol, in urine of rats and rabbits, 1841
Benson, H., *see* Aufrère, M. B., 783
Benson, H. D., *see* Ernst, S., 148
——*see* Richardson, A., Jr., 1545
Benson, W. R., *see* Sheinin, E. B., 280
Bentley, J., *see* Norton, T. R., 1368
Bevill, R. F., *see* Sharma, J. P., 1606
Beyer, W. F., high-pressure liquid chromatographic determination of chlorphenesin carbamate and the β-isomeric carbamate, 1802
Bhatnagar, S. P., *see* Midha, K. K., 188
Bhattacharya, S. K., Reddy, P. K. S. P., Ghosal, S., Singh, A. K., and Sharma, P. V., chemical constituents of Gentianaceae XIX: CNS-depressant effects of swertiamarin, 1547
Bianchi, C., *see* Ghielmetti, G., 905
Bianchi, E., *see* Trumbull, E. R., 1407
Biber, M. Z., and Rhodes, C. T., improved transport apparatus for examining diffusion of drugs across isolated tissues and synthetic membranes, 564
Biehl, E. R., *see* Graham, R. E., 1048
Biggs, J. T., Holland, W. H., Chang, S., Hipps, P. P., and Sherman, W. R., electron beam ionization mass fragmentographic analysis of tricyclic antidepressants in human plasma, 261
Birch, G. G., *see* Lee, C. K., 1222
Birrenbach, G., and Speiser, P. P., polymerized micelles and their use as adjuvants in immunology, 1763
Birss, S., *see* Longwell, A., 1654
Bisaillon, S., and Tawashi, R., retardation of dissolution and growth of calcium oxalate monohydrate, 222
Bishara, R. H., *see* Rutherford, B. S., 1322
Blaha, J. M., Knevel, A. M., Kessler, D. P., Mincy, J. W., and Hem, S. L., kinetic analysis of penicillin degradation in acidic media, 1165
Blake, M. I., *see* Pluta, P. L., 362
——*see* Uphaus, R. A., 1097
Blanton, C. D., Jr., *see* Paul, K., 1527
——*see* Sowell, J. W., Sr., 908
Block, L. H., *see* Behl, C. R., 429
Bloedow, D. C., and Hayton, W. L., effects of lipids on bioavailability of sulfisoxazole acetyl, dicumarol, and griseofulvin in rats, 328
——and Hayton, W. L., saturable first-pass metabolism of sulfisoxazole N^{1}-acetyl in rats, 334
Blumenthal, M. N., *see* Wu, W. L., 102
Bodey, D. M., *see* Rubinstein, M. H., 1749
Bodin, J. I., *see* Reisberg, P., 592
Bodor, N., *see* Kaminski, J. J., 553, 1733, 1737
——*see* Kosugi, M., 1743
——*see* Yuan, S.-S., 929
Boggiano, B. G., and Gleeson, M., gastric acid inactivation of erythromycin stearate in solid dosage forms, 497
Bondi, J. V., Hucker, H. B., Yeh, K. C., and Kwan, K. C., bioavailability assessment under quasi- and nonsteady-state conditions III: application, 1657
Boots, M. R., Marecki, P. E., Boots, S. G., and Guyer, K. E., hypocholesterolemic agents IV: inhibition of β-hydroxy-β-methylglutaryl coenzyme A reductase by arylalkenyl and arylepoxy hydrogen succinates and glutarates, 724
——*see* Boots, S. G., 1374
——*see* Guyer, K. E., 548
Boots, S. G., Boots, M. R., Guyer, K. E., and Marecki, P. E., hypocholesterolemic agents V: inhibition of β-hydroxy-β-methylglutaryl coenzyme A reductase by substituted 4-biphenylylalkyl carboxylic acids and methyl esters, 1374
——*see* Boots, M. R., 724
——*see* Guyer, K. E., 548
Borazan, H. N., *see* Al-Obeidi, F. A., 892, 982
Borke, M. L., *see* Behl, C. R., 429
Borman, C. B., *see* Lukas, G., 86
Bouche, R., *see* Poupaert, J., 1258
Bowman, M. C., *see* Nony, C. R., 1810
Boxenbaum, H. G., *see* Cotler, S., 822
Brannon, W. L., *see* Sheinin, E. B., 280

Brant, J. P., *see* Stewart, J. T., 1536
Brecht, D., *see* Kowarski, C. R., 450
Brenner, I. A., *see* Reisberg, P., 592
Bresee, R. R., *see* Patrick, T. B., 1066
Briley, M. R., *see* Otani, T. T., 534
Brooke, D., *see* Kensler, T. T., 763
Brooks, M. A., D'Arconte, L., and de Silva, J. A. F., determination of nitroimidazoles in biological fluids by differential pulse polarography, 112
Brown, J. A., *see* Roseman, T. J., 22
Brown, K. F., *see* Pedersen, P. V., 1437, 1442
Browner, S. M., Cockerill, A. F., Maidment, R. J., Rackham, D. M., and Snook, G. F., GLC and NMR analysis of isomeric impurities in the new anti-inflammatory agent benoxaprofen, 1305
Bruscato, F. N., *see* Shen, W.-W., 1780
Bruzzese, T., *see* Ghielmetti, G., 905
Bryan, J. T., *see* Amin, M. I., 1777
Buchanan, N., Van Der Walt, L. A., and Strickwold, B., pharmacology of malnutrition III: binding of digoxin to normal and kwashiorkor serum, 914
Buehler, J. D., *see* Chemburkar, P. B., 529
Bulger, W. H., Wells, P. R., and Roche, E. B., pharmacological assessment of 3-*tert*-butylsydnone, 109
Buller, R. H., *see* Colburn, W. A., 997
Bundgaard, H., and Larsen, C., intramolecular and intermolecular transformations of aspirin in nonhydroxylic solvents, 776
Burgio, J., *see* Horhota, S. T., 1746
Burkhart, J., *see* Siegel, I. A., 129
Buswink, A. A., *see* Counsell, R. E., 285
Butler, S. S., *see* Roseman, T. J., 673
Byrn, S. R., mechanisms of solid-state reactions of drugs, 1
Byron, P. R., and Notari, R. E., critical analysis of "flip-flop" phenomenon in two-compartment pharmacokinetic model, 1140

C

Cadwallader, D. E., *see* Chen, L.-K., 868
——*see* Underwood, F. L., 697
Cantrell, J. S., *see* Ernst, S., 148
Caputo, J. F., *see* Sabo, M., 932
Carapellotti, R. A., *see* Coburn, R. A., 1505
Cardinal, J. R., *see* Mukerjee, P., 882
Carpenter, J. F., *see* Ellis, K. O., 1359
Carstensen, J. T., and Anik, S. T., consistency relations in solid solution melting-point diagrams, 158
——and Dhupar, K., dissolution rate equations in column-confined dissolution, 1634
——and Nelson, E., terminology regarding labeled and contained amounts in dosage forms, 311
——Lai, T., Flickner, D. W., Huber, H. E., and Zoglio, M. A., physical aspects of wet granulations I: distribution kinetics of water, 992
——*see* Zoglio, M. A., 1205
Casey, D. L., Beihn, R. M., Digenis, G. A., and Shambhu, M. B., method for monitoring hard gelatin capsule disintegration times in humans using external scintigraphy, 1412
Cassady, J. M., *see* Williams, M., 912
Castagnoli, N., Jr., *see* Tenforde, T. S., 631
Catalano, T., *see* Rorke, C. V., 774
Cates, L. A., and Cramer, M. B., phosphorus–nitrogen compounds XIX: distribution of ^{32}P and effect of an active oncolytic on intracerebral leukemia in rodents, 439
Catsoulacos, P., new compounds: derivatives of methyl 2-aminoacetyl-4,5-dimethoxyphenylacetate, 626
Cavill, R. H., *see* Richards, R. M. E., 76
Celletti, P., *see* Angelucci, L., 455
Cerimele, B. J., *see* Indelicato, J. M., 1175
Cervoni, P., *see* Li, H., 1352
Chae, Y. S., and Shelver, W. H., quantitative determination of theophylline in pharmaceutical dosage forms by differential spectrophotometry, 1178
Chafetz, L., *see* Gaglia, C. A., Jr., 1691
——*see* Goodhart, F. W., 1466
Chakrabarti, D. K., *see* Ghosal, S., 160
Chan, P. L., *see* Zoglio, M. A., 1205
Chang, C.-J., and Peck, G. E., carbon-13 magnetic resonance spectroscopy of drugs II: antihistamines, 1019
Chang, K., and Chiou, W. L., fluorocarbon aerosol propellants IX: adsorption on activated charcoal, 56
——and Chiou, W. L., fluorocarbon aerosol propellants VIII: solubility of trichloromonofluoromethane in dog blood and tissue homogenates, 53
——and Chiou, W. L., kinetics of butaperazine adsorption onto quartz cells, 630
Chang, P. T. O., Aynilian, G. H., Cordell, G. A., Tin-Wa, M., Fong, H. H. S., Perdue, R. E., Jr., and Farnsworth, N. R., isolation of flindersiamine, isoflindersiamine, and a new alkaloid, heliparvifoline, from *Helietta parvifolia* (Rutaceae), 561
Chang, S., *see* Biggs, J. T., 261
Chang, Z. L., and Papendick, V. E., simple and rapid determination of a new pharmaceutically active amine hydrochloride, 1543
Chao, A. Y., Sanvordeker, D. R., Zagarella, J., Mattes, K., Nicholova, B., and Karim, A., *in vitro* and *in vivo* availability of spironolactone from oral dosage forms, 1630
Charette, C., *see* Midha, K. K., 576
Chatten, L. G., Moskalyk, R. E., Locock, R. A., and Huang, K-S., dc polarographic assay of tetracyclines, 1315
Chaturvedi, A. K., Rama Sastry, B. V., Chaudhari, A., and Parmar, S. S., synthesis of *N,N'*-bis(3-substituted benzylideneaminopropyl)piperazines and their anti-inflammatory, antiproteolytic, and anticonvulsant properties, 409
——*see* Chaudhary, M., 443
Chaudhari, A., Kumar, S., Singh, S. P., Parmar, S. S., and Stenberg, V. I., antihemolytic and antiproteolytic properties of substituted thiosemicarbazidophenothiazines and thiazolidonylphenothiazines, 758
——*see* Chaturvedi, A. K., 409
——*see* Singh, S. P., 1678
Chaudhary, K. C. B., *see* Ghosal, S., 160
Chaudhary, M., Parmar, S. S., Chaudhary, S. K., Chaturvedi, A. K., and Rama Sastry, B. V., CNS depressant activity of pyrimidylthiazolidones and their selective inhibition of NAD-dependent pyruvate oxidation, 443
——*see* Chaudhary, S. K., 1010
Chaudhary, S. K., Parmar, S. S., Chaudhary, M., and Barthwal, J. P., anticonvulsant activity and inhibition of cellular respiratory activity by substituted imidazolocarbamides, 1010
——*see* Chaudhary, M., 443
Chaudhuri, R. K., *see* Ghosal, S., 1549
Chemburkar, P. B., Smyth, R. D., Buehler, J. D., Shah, P. B., Joslin, R. S., Polk, A., and Reavey-Cantwell, N. H., correlation between dissolution characteristics and absorption of methaqualone from solid dosage forms, 529
Chen, C. N., and Andrade, J. D., pharmacokinetic model for simultaneous determination of drug levels in organs and tissues, 717
Chen, L.-K., Cadwallader, D. E., and Jun, H. W., nitrofurantoin solubility in aqueous urea and creatinine solutions, 868
Chen, S.-J., *see* Chiou, W. L., 1702
Cheng, C. C., *see* MacFarlane, J. O., 1689
Cheng, P. C., *see* Granade, H. R., 1414
Chien, Y. W., electrochemistry of drug action I: electroreduction of ferredoxins, 1471
——and Lau, E. P. K., controlled drug release from polymeric delivery devices IV: *in vitro–in vivo* correlation of subcutaneous release of norgestomet from hydrophilic implants, 488
——Hofmann, L. M., Lambert, H. J., and Tao, L. C., binding of spirolactones to human plasma proteins, 1337
Chiou, W. L., and Niazi, S., pharmaceutical applications of solid dispersion systems: dissolution of griseofulvin–succinic acid eutectic mixture, 1212
——Chen, S.-J., and Athanikar, N., enhancement of dissolution rates of poorly water-soluble drugs by crystallization in aqueous surfactant solutions I: sulfathiazole, prednisone, and chloramphenicol, 1702
——*see* Chang, K., 53, 56, 630
——*see* Niazi, S., 60
Cho, A. K., *see* Schaeffer, J. C., 122
Chowhan, Z. T., and Amaro, A. A., pulmonary absorption studies utilizing *in situ* rat lung model: designing dosage regimen for bronchial delivery of new drug entities, 1669
——and Palagyi, L., starch paste granulations: factors causing binder dilution effects on granulations and tablets, 1559
Chrai, S. S., and Robinson, J. R., binding of sulfisoxazole to protein fractions of tears, 437
Chremos, A. N., Shen, D., Gibaldi, M., Proctor, J. D., and Newman, J. H., time-dependent change in renal clearance of bethanidine in humans, 140
Chrzanowski, F., Niebergall, P. J., Mayock, R., Taubin, J., and Sugita, E., interference by butyl rubber stoppers in GLC analysis for theophylline, 735
Chu, L.-C., *see* Bayne, W. F., 1724
Cicero, T. J., *see* Mason, N., 847
Cioffi, F. J., Abdou, H. M., and Warren, A. T., computerized automated system for determining dissolution rate profiles for solid dosage forms, 1234
Claeys, A. E., *see* de Sagher, R. M., 878
Clagett, D. C., *see* Aldrich, H. S., 1704
Clark, M. L., *see* Kaul, P. N., 689, 694
Clarke, C. D., *see* Armstrong, N. A., 373
Clarke, D. E., and Sampath, S. S., neurogenic influences of bilateral adrenalectomy on monoamine oxidase, 92
Clayman, S., *see* Agrawal, K. C., 297
Coburn, R. A., and Carapellotti, R. A., synthesis and properties of mesoionic pyrimido[1,2-*b*]pyridazine-2,4-diones and mesoionic pyridazine[2,3-*a*]-*s*-triazine-2,4-diones: mesoionic analogs structurally related to fervenulin, 1505
Cockerill, A. F., *see* Browner, S. M., 1305
Cohen, D. M., and Munnelly, K. P., high-pressure liquid chromatographic determination of polythiazide in pharmaceutical dosage forms, 1413
——*see* Wong, C. K., 1090
Cohen, J. L., *see* Fung, K. K., 596
Colaizzi, J. L., *see* Wivagg, R. T., 916
Colburn, W. A., Sibley, C. R., and Buller, R. H., comparative serum prednisone and prednisolone concentrations following prednisone or prednisolone administration to beagle dogs, 997
Cole, J. R., *see* Trumbull, E. R., 1407
Collett, J. H., and Koo, L., correlations between substituent parameters of 4-substituted benzoic acids and their *in vitro* dissolution and partitioning, 753
Colombo, C., Colombo, S., and Steinetz, B., vinyl acetate casts of emphysematous rat lungs, 1082
Colombo, S., *see* Colombo, C., 1082
Connors, K. A., and Lipari, J. M., effect of cycloamyloses on apparent dissociation constants of carboxylic acids and phenols: equilibrium analytical selectivity induced by complex formation, 379
Conway, W. D., *see* Melethil, S., 861
Cooper, E. R., pharmacokinetics of skin penetration, 1396
Cooper, J. K., *see* Midha, K. K., 188, 387
Cordell, G. A., and Farnsworth, N. R., *Catharanthus* alkaloids XXXII: isolation of alkaloids from *Catharanthus trichophyllus* roots and structure elucidation of cathaphylline, 366
——*see* Chang, P. T. O., 561
Cotler, S., Holazo, A., Boxenbaum, H. G., and Kaplan, S. A., influence of route of administration on physiological availability of levodopa in dogs, 822
Counsell, R. E., Ranade, V. V., Kline, W., Hong, B. H., and Buswink, A. A., potential organ or tumor imaging agents XV: radioiodinated phenytoin derivatives, 285
Covinsky, J. O., *see* Mason, W. D., 1325
Cramer, M. B., *see* Cates, L. A., 439
Crawford, F. W., *see* Riley, T. N., 544
Crawford, H. T., *see* Skinner, W. A., 1404
Crespi, H. L., *see* Pluta, P. L., 362
Crooy, P., *see* Anhoury, M. L., 590

Cruze, C. A., and Meyer, M. C., binding of salicylate and sulfathiazole by whole blood constituents, 33
Cumiskey, W. R., *see* Levitt, M., 1556
Cusimano, V., *see* Kumbar, M., 1014

D

Dahl, S. G., and Jacobsen, S., GLC determination of methotrimeprazine and its sulfoxide in plasma, 1329
Dakkuri, A., and Ecanow, B., filtration rates of pharmaceutical suspension systems, 420
Dal Piaz, V., *see* Pinzauti, S., 1251
Daly, R. E., *see* Goodhart, F. W., 1466
Danti, A. G., *see* Shen, W.-W., 1780
Dar, M. S., Ikram, M., and Fakouhi, T., pharmacology of *Quercus infectoria*, 1791
D'Arconte, L., *see* Brooks, M. A., 112
Darling, C. M., and Rose, E. K., Synthesis of histamine analogs, 98
Darnowski, R. J., *see* Zalipsky, J. J., 460
Dasher, L. W., *see* Beam, C. F., 1408
Dauvois, M., *see* Turi, P., 806
Davies, R., *see* Hasegawa, J., 508
Davis, B. R., *see* Naik, D. V., 274
Davis, C. S., *see* Goldenberg, M. M., 1398
Davis, M. A., *see* Sadeh, T., 623
Day, D. K., Williamson, H. E., and Roberts, R. J., failure of prednisone to alter plasma salicylate concentrations in dogs, 773
DeAngelis, R. J., *see* Gillis, P. P., 1001
De Boer, B., *see* Singh, S. P., 391
DeLeenheer, A. P., *see* de Sagher, R. M., 878
DeLisser-Matthews, L. A., and Khalaj, A., electrochemical evidence for interaction between chlorpromazine hydrochloride and trifluoperazine hydrochloride and the flavin coenzymes, 1758
DeLuca, P., *see* Rebagay, T., 1645
Demeter, J., *see* Martens, F. K., 1393
De Neys, R., *see* Anhoury, M. L., 590
DeRitter, E., *see* Rubin, S. H., 963
de Sagher, R. M., De Leenheer, A. P., and Claeys, A. E., identification and quantitative GLC determination of iproniazid in human urine, 878
DeSantis, F., and Nieforth, K. A., synthesis of potential mescaline antagonists, 1479
de Silva, J. A. F., Meyer, J. C., and Puglisi, C. V., spectrofluorometric determination of bufuralol in blood and urine, 1230
——*see* Brooks, M. A., 112
Devani, M. B., Shishoo, C. J., Pathak, U. S., Parikh, S. H., Shah, G. F., and Padhya, A. C., synthesis of 3-substituted thieno[2,3-*d*]pyrimidin-4(3*H*)-one-2-mercaptoacetic acids and their ethyl esters for pharmacological screening, 660
Dewey, W. L., *see* Atkinson, E. R., 1682
Dey, A. S., *see* Jacobs, P. M., 604
DeYoung, J. L., *see* Streng, W. H., 1034
Dhupar, K., *see* Carstensen, J. T., 1634
Digenis, G. A., Shakhshir, S., Miyamoto, M. A., and Kostenbauder, H. B., anaerobic photodecomposition of an acridan drug through energy transfer, 247
——*see* Casey, D. L., 1412
Dillingham, E. O., *see* Bass, G. E., 1525
Dimmock, J. R., Hamon, N. W., Hindmarsh, K. W., Mills, D. G., Negrave, L. E., Rank, G. H., and Robertson, A. J., evaluation of Mannich bases and related compounds as inhibitors of mitochondrial function in yeast and inhibition of blood platelet aggregation, blood clotting, and *in vitro* metabolism of 5-dimethylamino-1-phenyl-1-penten-3-one hydrochloride, 482
——Hamon, N. W., Hindmarsh, K. W., Sellar, A. P., Turner, W. A., Rank, G. H., and Robertson, A. J., evaluation of 2-benzylidenecyclohexanones and 2,6-bis(benzylidene)cyclohexanones for antitumor and cytotoxic activity and as inhibitors of mitochondrial function in yeast: metabolism studies of (*E*)-2-benzylidenecyclohexanone, 538
——Qureshi, A. M., Noble, L. M., Smith, P. J., and Baker, H. A., comparison of antimicrobial activity of nuclear-substituted aromatic esters of 5-dimethylamino-1-phenyl-3-pentanol and 3-dimethylamino-1-phenyl-1-propanol with related cyclic analogs, 38
Dinner, A., *see* Souter, R. W., 457
Dinovo, E. C., Gottschalk, L. A., Nandi, B. R., and Geddes, P. G., GLC analysis of thioridazine mesoridazine, and their metabolites, 667
Dixon, W. R., Young, R. L., Holazo, A., Jack, M. L., Weinfeld, R. E., Alexander, K., Liebman, A., and Kaplan, S. A., bumetanide: radioimmunoassay and pharmacokinetic profile in humans, 701
Doluisio, J. T., *see* Yakatan, G. J., 1456
Doorenbos, N. J., *see* Granade, H. J., 1414
——*see* Hufford, C. D., 778
Douglas, S. L., *see* Roseman, T. J., 673
Draper, J. R., *see* Goodhart, F. W., 1072
Dreyfuss, J., Ross, J. J., Jr., Shaw, J. M., Miller, I., and Schreiber, E. C., release and elimination of ^{14}C-fluphenazine enanthate and decanoate esters administered in sesame oil to dogs, 502
——Shaw, J. M., and Ross, J. J., Jr., fluphenazine enanthate and fluphenazine decanoate: intramuscular injection and esterification as requirements for slow-release characteristics in dogs, 1310
Driscoll, J. S., *see* Hirata, T., 1699
Driscoll, P., *see* Valentine, J. L., 96
Duca, A., *see* Goldstein, S., 1831
Dugar, S. M., *see* Rorke, C. V., 774
Dunham, J. M., *see* Kirschbaum, J., 433
Dyer, L., *see* Hikal, A. H., 621
Dziedzic, S. W., Gitlow, S. E., and Krohn, D. L., GLC determination of pilocarpine, 1262
Dzus, G., *see* Hanna, S., 1522

E

Ecanow, B., *see* Dakkuri, A., 420
——*see* Levinson, R. S., 1265
——*see* Stanaszek, W. F., 142
Eckert, D. J., *see* Trumbull, E. R., 1407
Eichman, M. L., *see* Goodhart, F. W., 935, 1101
Eldawy, M. A., Tawfik, A. S., and Elshabouri, S. R., rapid and sensitive colorimetric determination of cobalt(II), 664
Ellis, K. O., Wessels, F. L., and Carpenter, J. F., effects of intravenous dantrolene sodium on respiratory and cardiovascular functions, 1359
Ellis, L. F., *see* Pikal, M. J., 1278
El-Masry, S., *see* Khalil, S. A. H., 614
El-Nasr, M. S., *see* Abu-Eittah, R., 1364
Elshabouri, S. R., *see* Eldawy, M. A., 664
Elsohly, M. A., Knapp, J. E., Schiff, P. L., Jr., and Slatkin, D. J., chemical constituents of fruit of *Cocculus carolinus* D.C. (Menispermaceae), 132
Emami, M., *see* Ghabgharan, F., 1085
Endecott, B. R., *see* Robinson, C. P., 595
Enever, R. P., correlation of phase inversion temperature with kinetics of globule coalescence for emulsions stabilized by a polyoxyethylene alkyl ether, 517
——*see* Summers, M. P., 1613
Engdahl, A., Karlberg, B., and Thelander, S., automated *in vitro* dissolution rate analysis of potassium in plastic matrix slow release tablets, 349
Erhardt, P. W., *see* Smith, R. V., 412
Ernst, S., Hite, G., Cantrell, J. S., Richardson, A. Jr., and Benson, H. D., stereochemistry of geometric isomers of clomiphene: a correction of the literature and a reexamination of structure–activity relationships, 148

F

Fakouhi, T., *see* Dar, M. S., 1791
Farhadieh, B., drug release from methyl acrylate–methyl methacrylate copolymer matrix III: simultaneous release of noninteracting drug–excipient mixtures, 1333
Farnsworth, N. R., *see* Chang, P. T. O., 561
——*see* Cordell, G. A., 366
——*see* Tin-Wa, M., 755
Favilli, S., *see* Angelucci, L., 455
Fawwaz, R. A., *see* Tenforde, T. S., 631
Fee, J. V., Grant, D. J. W., and Newton, J. M., effect of solvent flow Reynolds number on dissolution rate of a nondisintegrating solid (potassium chloride), 48
——Grant, D. J. W., and Newton, J. M., influence of hydrophobic materials on dissolution of a nondisintegrating hydrophilic solid (potassium chloride), 182
Feldman, S., and Reinhard, M., interaction of sodium alkyl sulfates with everted rat small intestinal membrane, 1460
Fell, J. T., *see* Lerk, C. F., 843
Ferguson, G. G., *see* Keller, W. J., 1539
Fischer, J. F., *see* Schaeffer, J. C., 122
Fitzpatrick, F. A., high-performance liquid chromatographic analysis of prostaglandins formed during *in vitro* incubations with prostaglandin 15-dehydrogenase, 1609
Flann, B., sample size changes in USP XIX and NF XIV, 312
Flickner, D. W., *see* Carstensen, J. T., 992
Florence, A. T., Jenkins, A. W., and Loveless, A. H., effect of formulation of intramuscular injections of phenothiazines on duration of activity, 1665
Flynn, G. L., Ho, N. F. H., Higuchi, W. I., and Kent, J., analysis of diffusion through concentric right circular cylinders and concentric spheres, 154
——*see* Ho, N. F. H., 1578
——*see* Hwang, S., 1574
Fong, H. H. S., *see* Chang, P. T. O., 561
Forist, A. A., *see* Kaiser, D. G., 1767
Foye, W. O., Lowe, Y. H., and Lanzillo, J. J., antiradiation compounds XVI: *N*-heterocyclic aminoethyl disulfides and aminoethanethiosulfuric acids, 1247
——*see* Williams, D. A., 126
Frank, C. W., *see* Newman, E. C., 1728
——*see* Stoel, L. J., 1794
Frank, M. J., Johnson, J. B., and Rubin, S. H., spectrophotometric determination of sodium nitroprusside and its photodegradation products, 44
Frank, S. G., *see* Ludden, T. M., 712
Frantz, B. M., iodometric and spectrophotometric assays for cephradine after its hydrolysis with a β-lactamase, 887
Frazier, W. F., and Nuessle, N. O., correlation of absorption of sulfamethazine boluses with dissolution using a new dissolution apparatus for veterinary tablets, 1823
Friedman, T. S., and Patton, T. F., differences in ocular penetration of pilocarpine in rabbits of different ages, 1095
Frigerio, A., *see* Belvedere, G., 815
——*see* Rovei, V., 810
Fu, C.-C., *see* Lee, K. H., 580
Fung, H.-L., Yap, S. K., and Rhodes, C. T., development of a stable sublingual nitroglycerin tablet II: formulation and evaluation of tablets containing povidone, 558
Fung, K. K., Koda, R. T., Maronde, R. F., and Cohen, J. L., rapid GLC determination of fusaric acid in biological fluids, 596

G

Gaglia, C. A., Jr., Lomner, J. J., Leonard, B. L., and Chafetz, L., dissolution testing of nitroglycerin tablets, 1691
Gautieri, R. F., *see* Wolstenholme, W. W., 1498
Geddes, P. G., *see* Dinovo, E. C., 667
Ghabgharan, F., Kooshkabadi, H., Emami, M., Rashidbaigi, A., and Shafiee, A., synthesis and antibacterial and antifungal activities of alkyl and polyhalophenyl esters of benzo[*b*]-3-methyl-2-furancarbamic acid, 1085
Ghielmetti, G., Bruzzese, T., Bianchi, C., and Recusani, F., relationship between acute toxicity in mice and polymorphic forms of polyene antibiotics, 905
Ghosal, S., Chakrabarti, D. K., and Chaudhary, K. C. B., toxic substances produced by *Fusarium* I: trichothecene derivatives from two strains of *Fusarium oxysporum* f. sp. *carthami*, 160
——Reddy, J. P., and Lal, V. K., shilajit I: chemical constituents, 772
——Singh, A. K., and Chaudhuri, R. K., chemical constituents of Gentianaceae XX: natural occur-

rence of (−)-loliolide in *Canscora decussata*, 1549
——*see* Bhattacharya, S. K., 1547
Giacomoni, D., *see* Rubenstein, M., 756
Giancatarino, C., *see* Kowarski, C. R., 450
Gibaldi, M., *see* Chremos, A. N., 140
——*see* Harrison, L. I., 1346
Gibbs, I. S., Heald, A., Jacobson, H., Wadke, D., and Weliky, I., physical characterization and activity *in vivo* of polymorphic forms of 7-chloro-5,11-dihydrodibenz[*b,e*][1,4]oxazepine-5-carboxamide, a potential tricyclic antidepressant, 1380
Giese, R. W., *see* Sadeh, T., 623
Gilbert, S. G., *see* Auslander, D. E., 1061
Gillis, P. P., DeAngelis, R. J., and Wynn, R. L., nonlinear pharmacokinetic model of intravenous anesthesia, 1001
Gitlow, S. E., *see* Dziedzic, S. W., 1262
Gleeson, M., *see* Boggiano, B. G., 497
Goldenberg, M. M., Honkomp, L. J., and Davis, C. S., antinauseant and antiemetic properties of bismuth subsalicylate in dogs and humans, 1398
Goldstein, S., and Duca, A., determination of cyanocobalamin by thermal decomposition of the cyano group using an ion-selective electrode, 1831
Gomaa, C. S., *see* Taha, A. M., 986
Goodhart, F. W., and Eichman, M. L., pharmaceutical sciences—1975: literature review of pharmaceutics I, 935
——and Eichman, M. L., pharmaceutical sciences—1975: literature review of pharmaceutics II, 1101
——Draper, J. R., Killeen, M. J., and Ninger, F. C., calibration of a horizontal pendulum-type tablet breaking strength tester, 1072
——Gucluyildiz, H., Daly, R. E., Chafetz, L., and Ninger, F. C., stabilized compressed nitroglycerin tablets, 1466
Gottschalk, L. A., *see* Dinovo, E. C., 667
Gouda, M. W., *see* Jodhka, G. S., 1319
——*see* Reddy, R. K., 115, 1753
Gracy, R. W., *see* Izaddoost, M., 352
Grady, L. T., and Reamer, J. T., testing of heat sealing by thermal analysis, 628
——*see* Wyatt, D. K., 680
Graham, R. E., Biehl, E. R., and Kenner, C. T., effect of solvent on tetrazolium reaction, 1048
Granade, H. R., Cheng, P. C., and Doorenbos, N. J., ciguatera I: brine shrimp (*Artemia salina* L.) larval assay for ciguatera toxins, 1414
Granchelli, F. E., *see* Atkinson, E. R., 618
Grand, N. G., *see* Hakim, A. A., 339
Grant, D. J. W., *see* Fee, J. V., 48, 182
Green, J. R., *see* Pitlick, W. H., 462
Grier, N., and Strelitz, R. A., synthesis and biological evaluation of 1-(4-hydroxy-2-oxo-2*H*-1-benzopyran-3-yl)pyridinium hydroxide inner salt derivatives, 616
Gringauz, A., synthesis of 2′-acetoxybiphenyl-2-carboxylic acid and its derivatives as potential anti-inflammatory and analgesic agents, 291
Grunewald, G. L., Ruth, J. A., Kroboth, T. R., Kamdar, B. V., Patil, P. N., and Salman, K. N., conformationally defined adrenergic agents I: potentiation of levarterenol in rat vas deferens by *endo*- and *exo*-2-aminobenzobicyclo[2.2.2]-octenes, conformationally defined analogs of amphetamine, 920
Gucluyildiz, H., *see* Goodhart, F. W., 1466
Guerrero, R. O., *see* Hufford, C. D., 778
Gupta, S. K., and Marathe, S. A., mild and safe procedure for hydrolyzing oximes: improved synthesis of 1,2-indandione, 134
Gupta, V. D., quantitative determination of morphine in paregoric USP by high-pressure liquid chromatography, 1697
——quantitative determination of resorcinol in presence of phenol, 144
——quantitative determinations of phenol and resorcinol in pharmaceutical dosage forms by high-pressure liquid chromatography, 1706
Guruswami, M. N., *see* Ramabadran, K., 1245
Gustafson, J. H., Schoenwald, R. D., and Benet, L. Z., limitations in interpretation of digoxin absorption using averaged pharmacological response intensities, 243
Guyer, K. E., Boots, S. G., Marecki, P. E., and Boots, M. R., hypocholesterolemic agents III: inhibition of β-hydroxy-β-methylglutaryl coenzyme A reductase by half acid esters of 1-(4-biphenylyl)pentanol, 548
——*see* Boots, M. R., 724
——*see* Boots, S. G., 1374

H

Hakim, A. A., and Grand, N. G., mechanism of action of BCG vaccine on neoplastic proliferation and host immune responses, 339
Hale, J. L., simultaneous semiautomated assay of pyrrobutamine phosphate, cyclopentamine hydrochloride, and methapyrilene hydrochloride in pharmaceutical mixtures, 1590
Haleblian, J. K., bioassays used in development of topical dosage forms, 1417
Hall, L. H., *see* Kier, L. B., 1226, 1806
Ham, N. S., conformational populations for antihistamines and antihypertensives in solution, 612
Hamburg, E. L., *see* Valentine, J. L., 96
Hamon, N. W., *see* Dimmock, J. R., 482, 538
Hamrick, M. E., *see* Kochhar, M. M., 137
Han, S. K., *see* Schott, H., 975, 979
Han, W. W., Yakatan, G. J., and Maness, D. D., kinetics and mechanisms of hydrolysis of 1,4-benzodiazepines I: chlordiazepoxide and demoxepam, 1198
Handy, R. W., *see* Zweidinger, R. A., 427
Haney, W. G., Jr., *see* Korpi, J., 1087
Hanna, S., Dzus, G., Rasero, L., and Lachman, L., automated analysis of warfarin sodium tablets, 1522
Harris, B. G., *see* Izaddoost, M., 352
Harris, C. E., *see* Beam, C. F., 1408
Harris, H. A., *see* Rorke, C. V., 774
Harris, L. S., *see* Atkinson, E. R., 1682
Harrison, L. I., and Gibaldi, M., influence of cholestasis on drug elimination: pharmacokinetics, 1346
Hartvig, P., Näslund, B., and Vessman, J., electron-capture GC determination of subnanogram amounts of emeproniun bromide in serum, 1707
Hasegawa, J., Hurwitz, A., Krol, G., and Davies, R., analysis of butaclamol in serum by fluorescence induction, 508
Hause, W., *see* Smyth, R. D., 1045
Hayashi, S.-I., *see* Matsuda, Y., 1155
Hayton, W. L., *see* Bloedow, D. C., 328, 334
Hazemoto, N., Kamo, N., and Kobatake, Y., electrode sensitive to sulfa drugs, 435
Heald, A. F., Ita, C. E., and Schreiber, E. C., fluorometric determination of cephradine in plasma, 768
——*see* Gibbs, I. S., 1380
Hem, S. L., *see* Blaha, J. M., 1165
——*see* Nail, S. L., 231, 1188, 1192, 1195, 1255, 1391
Henderson, W. M., *see* Irgens, T. R., 608
Herald, C. L., *see* Pettit, G. R., 1558
Herald, D. L., *see* Pettit, G. R., 1558
Herczeg, T., *see* Smyth, R. D., 1045
Heyndrickx, A., *see* Martens, F. K., 1393
Higuchi, T., *see* Agharkar, S., 747
——*see* Kaminski, J. J., 553, 1733, 1737
——*see* Kosugi, M., 1743
——*see* Theeuwes, F., 648
Higuchi, W. I., *see* Flynn, G. L., 154
——*see* Ho, N. F. H., 1578
——*see* Hwang, S., 1574
——*see* Prakongpan, S., 685
——*see* Simonelli, A. P., 355
——*see* Yeh, K. C., 80, 743
Hikal, A. H., Dyer, L., and Wong, S.-W., effect of polysorbate 80 on apparent partition coefficient of salicylic acid and its absorption from the rat intestine, 621
Hilgendorf, N. K., *see* Parker, G. R., 585
Hill, P. M., effect of compression force and corn starch on tablet disintegration time, 1694
——starch paste granulations: binder dilution effects on granulations and tablets, 313
——starch paste granulations: factors causing binder dilution effects on granulations and tablets—a response, 1561
Hinderling, P. H., biased bioavailability estimates, 1099
Hindmarsh, K. W., *see* Dimmock, J. R., 482, 538
Hinsvark, O. N., *see* O'Brien, J. E., 1068
Hipps, P. P., *see* Biggs, J. T., 261
Hirata, T., and Driscoll, J. S., potential CNS antitumor agents—phenothiazines I: nitrogen mustard derivatives, 1699
Hirsch, C. A., *see* Lappas, L. C., 1301
Hite, G., *see* Ernst, S., 148
——*see* Richardson, A., Jr., 1545
Ho, N. F. H., Suhardja, L., Hwang, S., Owada, E., Molokhia, A., Flynn, G. L., Higuchi, W. I., and Park, J. Y., systems approach to vaginal delivery of drugs III: simulation studies interfacing steroid release from silicone matrix and vaginal absorption in rabbits, 1578
——*see* Flynn, G. L., 154
——*see* Hwang, S., 1574
Hodnett, C. N., McCormack, J. J., and Sabean, J. A., oxidation of selected pteridine derivatives by mammalian liver xanthine oxidase and aldehyde oxidase, 1150
Hofmann, L. M., *see* Chien, Y. W., 1337
Holazo, A., *see* Cotler, S., 822
——*see* Dixon, W. R., 701
——*see* Weinfeld, R. E., 1827
Holder, C. L., *see* Nony, C. R., 1810
Holland, D. R., and Quay, J. F., intestinal secretion of erythromycin base, 417
Holland, W. H., *see* Biggs, J. T., 261
Hollinger, W. M., *see* Beam, C. F., 1408
Hong, B. H., *see* Counsell, R. E., 285
Honigberg, I. L., *see* Stewart, J. T., 1536
Honkomp, L. J., *see* Goldenberg, M. M., 1398
Horhota, S. T., Burgio, J., Lonski, L., and Rhodes, C. T., effect of storage at specified temperature and humidity on properties of three directly compressible tablet formulations, 1746
Hori, R., Sunayashiki, K., and Kamiya, A., pharmacokinetic analysis of renal handling of sulfamethizole, 463
Houston, J. B., and Levy, G., drug biotransformation interactions in man VI: acetaminophen and ascorbic acid, 1218
Howard, S., *see* Mauger, J., 1042
Howell, J. R., orthogonal least squares, 1562
Howell, S. M., *see* McAllister, R. G., 431
Hoyois, J., *see* Vanhaelen, M., 1774
Hsu, M.-F. H., *see* Turner, C. E., 1084
Huang, C. L., *see* Abramson, H. N., 765
Huang, K-S., *see* Chatten, L. G., 1315
Hubbard, J. W., *see* Midha, K. K., 387
Huber, H. E., *see* Carstensen, J. T., 992
——*see* Streng, W. H., 1034
——*see* Zoglio, M. A., 1205
Hucker, H. B., and Stauffer, S. C., GLC analysis of lidocaine in plasma using a novel nitrogen-sensitive detector, 926
——and Stauffer, S. C., GLC determination of cyclobenzaprine in plasma and urine, 1253
——*see* Bondi, J. V., 1657
Hudson, M., *see* Tarlin, H., 1463
Hufford, C. D., Guerrero, R. O., and Doorenbos, N. J., two new diterpenes from *Stemodia maritima* L., 778
Hurwitz, A., *see* Hasegawa, J., 508
Hussain, A., and Truelove, J. E., prodrug approaches to enhancement of physicochemical properties of drugs IV: novel epinephrine prodrug, 1510
Huycke, M. M., *see* Kaminski, J. J., 1737
Hwang, S., Owada, E., Yotsuyanagi, T., Suhardja, L., Ho, N. F. H., Flynn, G. L., and Higuchi, W. I., systems approach to vaginal delivery of drugs II: *in situ* vaginal absorption of unbranched aliphatic alcohols, 1574
——*see* Ho, N. F. H., 1578

I

Ibrahim, H. G., and Rippie, E. G., microenviron-

mental kinetic effects within a lyotropic smectic biophase model: conformational restrictions in Fischer indole cyclization, 1639
Ikram, M., *see* Dar, M. S., 1791
Imakura, Y., *see* Lee, K.-H., 1410
Indelicato, J. M., Wilham, W. L., and Cerimele, B. J., conversion of cefamandole nafate to cefamandole sodium, 1175
Irgens, T. R., Henderson, W. M., and Shelver, W. H., GLC analysis of lidocaine in blood using an alkaline flame-ionization detector, 608
Ita, C. E., *see* Heald, A. F., 768
Izaddoost, M., Harris, B. G., and Gracy, R. W., structure and toxicity of alkaloids and amino acids of *Sophora secundiflora*, 352
Izutsu, K. T., *see* Siegel, I. A., 129

J

Jack, M. L., *see* Dixon, W. R., 701
Jacobs, P. M., Sneath, R. L., Jr., Soloway, A. H., and Dey, A. S., protein-binding polyhedral boranes II: DL-*S*-(10-dimethylsulfidooctahydrodecaborane)-methionine, 604
Jacobsen, S., *see* Dahl, S. G., 1329
Jacobson, A. E., *see* Yeh, H. J. C., 902
Jacobson, H., *see* Gibbs, I. S., 1380
Jaffe, J. M., *see* Wivagg, R. T., 916
James, K. C., Ng, C. T., and Noyce, P. R., solubilities of testosterone propionate and related esters in organic solvents, 656
Jenkins, A. W., *see* Florence, A. T., 1665
Jeromínski, L., *see* Stenchever, M. A., 1648
Jhawar, A. K., *see* Kuehn, P. B., 1593
——*see* Smolen, V. F., 1600
Jodhka, G. S., Khalil, S. A., and Gouda, M. W., inhibitory effect of dioctyl sodium sulfosuccinate on pepsin activity, 1319
Johnson, B. J., *see* Kempner, D. H., 1799
Johnson, J. B., *see* Frank, M. J., 44
——*see* Rubin, S. H., 963
Jordan, N., *see* Loo, J. C. K., 461
Joslin, R. S., *see* Chemburkar, P. B., 529
Jun, H. W., pharmacokinetic studies of pentylenetetrazol in dogs, 1038
——*see* Chen, L.-K., 868
Jung, M., *see* Lee, K. H., 580
Juni, K., *see* Nakano, M., 709

K

Kado, M., *see* Kojima, M., 1551
Kaiser, D. G., Liggett, W. F., and Forist, A. A., fluorometric determination of trifluoromethyl-substituted 2,3-bis(4-methoxyphenyl)indoles in biological materials, 1767
——VanGiessen, G. J., Reischer, R. J., and Wechter, W. J., isomeric inversion of ibuprofen (*R*)-enantiomer in humans, 269
——*see* Slattery, J. T., 1710
Kalatzis, E., and Zarbi, I., spectrophotometric determination of *p*-aminophenol alone or in the presence of acetaminophen, 71
Kamdar, B. V., *see* Grunewald, G. L., 920
Kaminski, J. J., Bodor, N., and Higuchi, T., *N*-halo derivatives III: stabilization of nitrogen–chlorine bond in *N*-chloroamino acid derivatives, 553
——Bodor, N., and Higuchi, T., *N*-halo derivatives IV: synthesis of low chlorine potential soft *N*-chloramine systems, 1733
——Huycke, M. M., Selk, S. H., Bodor, N., and Higuchi, T., *N*-halo derivatives V: comparative antimicrobial activity of soft *N*-chloramine systems, 1737
——*see* Kosugi, M., 1743
Kamiya, A., *see* Hori, R., 463
Kamo, N., *see* Hazemoto, N., 435
Kaplan, S. A., *see* Cotler, S., 822
——*see* Dixon, W. R., 701
——*see* Weinfeld, R. E., 1827
Karim, A., *see* Chao, A. Y., 1630
Karlberg, B., *see* Engdahl, A., 349
Kashiwagi, M., *see* Norton, T. R., 1368
Kates, R. E., and Tozer, T. N., biliary secretion of methotrexate in rats and its inhibition by probenecid, 1348
Katz, J. J., *see* Pluta, P. L., 362
——*see* Uphaus, R. A., 1096
Kaul, P. N., Whitfield, L. R., and Clark, M. L., chlorpromazine metabolism VIII: blood levels of chlorpromazine and its sulfoxide in schizophrenic patients, 694
——Whitfield, L. R., and Clark, M. L., chlorpromazine metabolism VII: new quantitative fluorometric determination of chlorpromazine and its sulfoxide, 689
Kawashima, Y., reduced acid-neutralizing velocity of spray-dried agglomerated magnesium carbonate: a response, 771
Kay, D. R., *see* Wagner, J. G., 152
Kellaway, I. W., *see* Marriott, C., 828
Keller, N., *see* Longwell, A., 1654
Keller, W. J., and Ferguson, G. G., selectivity of 4-methoxyphenethylamine derivatives as inhibitors of monoamine oxidase, 1539
Kelly, K. L., *see* Mason, W. D., 1325
Kempner, D. H., and Johnson, B. J., lipid–protein interactions: enhancement of enzyme activity of L-glutamic acid dehydrogenase by nonionic detergents, 1799
Kenner, C. T., *see* Graham, R. E., 1048
Kensler, T. T., Brooke, D., and Walker, D. M., application of trihydroxyindole reaction to methanesulfonanilides: fluorometric analysis for soterenol and mesuprine, 763
Kent, J. S., implant pellets I: effects of compression pressure on *in vivo* dissolution of delmadinone acetate pellets, 89
——*see* Flynn, G. L., 154
Keresztes-Nagy, S., *see* Oester, Y. T., 1673
Kessler, D. P., *see* Blaha, J. M., 1165
Khalaj, A., *see* DeLisser-Matthews, L. A., 1758
Khalil, S. A., *see* Jodhka, G. S., 1319
——*see* Reddy, R. K., 115, 1753
Khalil, S. A. H., and El-Masry, S., determination of hyoscyamine in BPC mixtures, 614
Khalil, S. K. W., and Shelver, W. H., high-speed liquid chromatographic determination of procaine in pharmaceuticals, 606
Khan, K. A., and Rhodes, C. T., effect of variation in compaction force on properties of six direct compression tablet formulations, 1835
Kier, L. B., and Hall, L. H., molecular connectivity VII: specific treatment of heteroatoms, 1806
——Murray, W. J., Randić, M., and Hall, L. H., molecular connectivity V: connectivity series concept applied to density, 1226
Killeen, M. J., *see* Goodhart, F. W., 1072
Kim, S. W., Petersen, R. V., and Lee, E. S., effect of phthalate plasticizer on blood compatibility of polyvinyl chloride, 670
Kirschbaum, J., and Dunham, J. M., homogeneity of *Pasteurella avicida* bacteria, 433
Kishore, V., Kumar, S., Parmar, S. S., and Stenberg, V. I., anti-inflammatory and antiproteolytic properties of 1-(1-naphthylacetyl)-3-substituted carbamides, 1078
Klee, W. A., *see* Yeh, H. J. C., 902
Klein, M., *see* Pluta, P. L., 362
Kline, W., *see* Counsell, R. E., 285
Knapp, J. E., *see* Elsohly, M. A., 132
——*see* Turner, C. E., 1084
Knevel, A. M., *see* Plaha, J. M., 1165
Kobatake, Y., *see* Hazemoto, N., 435
Kochhar, M. M., Hamrick, M. E., and Bavda, L. T., rapid TLC determination of methadyl acetate and some *in vitro* metabolites, 137
Koda, R. T., *see* Fung, K. K., 596
Koehne, G., *see* Zoglio, M. A., 1205
Kojima, M., and Kado, M., antimicrobial activity of newly synthesized isothiocyanate derivatives against pathogenic plant microorganisms, 1551
Kokpol, U., *see* Miles, D. H., 284
Koo, L., *see* Collett, J. H., 753
Kooshkabadi, H., *see* Chabgharan, F., 1085
Korol, B., McLaughlin, L. J., and Miller, L. D., orthostatic influence on cardiovascular responses to nitroglycerin in conscious dogs, 308
Korpi, J., Wittmer, D. P., Sandmann, B. J., and Haney, W. G., Jr., simultaneous analysis of hydrocortisone and hydrocortisone phosphate by high-pressure liquid chromatography: reversed-phase ion-pairing approach, 1087
Koshy, K. T., *see* Amin, M. I., 1777
Kostenbauder, H. B., *see* Digenis, G. A., 247
——*see* Neelakantan, L., 740
——*see* Ong, J. T. H., 1713
Kosugi, M., Kaminski, J. J., Selk, S. H., Pitman, I. H., Bodor, N., and Higuchi, T., *N*-halo derivatives VI: microbiological and chemical evaluations of 3-chloro-2-oxazolidinones, 1743
Kourounakis, P., and Selye, H., influence of steroids and stress on toxicity and disposition of tetraethylammonium bromide, 1838
——*see* Terzis, A., 1092
Kowalski, R. L., *see* Leeling, J. L., 447
Kowalski, T. L., *see* Leeling, J. L., 447
Kowarski, A., *see* Kowarski, C. R., 450
Kowarski, C. R., Giancatarino, C., Kreamer, R., Brecht, D., and Kowarski, A., measurement of sulfamethizole clearance rate by nonthrombogenic constant blood-withdrawal system, 450
Kreamer, R., *see* Kowarski, C. R., 450
Kreuter, J., and Speiser, P. P., *in vitro* studies of poly(methyl methacrylate) adjuvants, 1624
Kroboth, T. R., *see* Grunewald, G. L., 920
Krohn, D. L., *see* Dziedzic, S. W., 1262
Krol, G., *see* Hasegawa, J., 508
Kuehn, P. B., Jhawar, A. K., Weigand, W. A., and Smolen, V. F., pharmacokinetics of chlorpromazine-induced miotic response in rabbits, 1593
——*see* Smolen, V. F., 1600
Kuhl, L., *see* Ayres, J. W., 832
Kulshreshtha, D. K., *see* Pal, R., 918
Kumar, S., *see* Chaudhari, A., 758
——*see* Kishore, V., 1078
Kumbar, M., Cusimano, V., and Siva Sankar, D. V., quantum chemical studies on drug action V: involvement of structure–activity, quantum chemical, and hydrophobicity factors in thrombocyte uptake of 5-hydroxytryptamine, 1014
Kwan, K. C., *see* Bondi, J. V., 1657
——*see* Yeh, K. C., 512
Kwan, K. H., *see* Prakongpan, S., 685

L

Lach, J. L., *see* Akers, M. J., 216
——*see* McGinity, J. W., 896
Lachman, L., *see* Hanna, S., 1522
Lai, T., *see* Carstensen, J. T., 992
Lal, V. K., *see* Ghosal, S., 772
Lalezari, I., Shafiee, A., and Mahjour, M., major alkaloids of *Glaucium flavum* Grantz, population Ghom, 923
——*see* Shafiee, A., 304
Lambert, H. J., *see* Chien, Y. W., 1337
Lanouette, M., Legault, D., and Lodge, B. A., application of trichloroacetyl isocyanate to NMR analysis of steroids of pharmaceutical interest I: corticosteroids and chemically related compounds, 1214
Lanzillo, J. J., *see* Foye, W. O., 1247
La Porta, E., *see* Pinzauti, S., 1251
Lappas, L. C., Hirsch, C. A., and Winely, C. L., substituted 5-nitro-1,3-dioxanes: correlation of chemical structure and antimicrobial activity, 1301
Laprade, B., Mauger, J. W., Petersen, H., Jr., Alexander, K. S., and Paruta, A. N., solubility of straight-chain and branched alkyl barbiturates in straight-chain alcohols, 277
Laridant, A., *see* Anhoury, M. L., 590
Larsen, C., *see* Bundgaard, H., 776
Larson, A. B., and Banker, G. S., attainment of highly uniform solid drug dispersions employing molecular scale drug entrapment in polymeric latices, 838
Laskar, P. A., *see* Ayres, J. W., 832
Lau, E. P. K., *see* Chien, Y. W., 488
Leach, R. H., *see* Vaughan, D. P., 601
Ledis, S. L., *see* Miller, E. E., 384
Lee, C. K., and Birch, G. G., structural functions of taste in the sugar series VII: taste properties of ketoses, 1222
Lee, E. S., *see* Kim, S. W., 670

Lee, J. W., *see* MacFarlane, J. O., 1689
Lee, K. H., Fu, C.-C., and Jung, M., mechanism of action of retinyl compounds on wound healing IV: effect of desmethylretinoic acid and its vinylogs on granuloma formation, 580
Lee, K.-H., Imakura, Y., and Sims, D., antitumor agents XVII: structure and stereochemistry of microhelenin-A, a new antitumor sesquiterpene lactone from *Helenium microcephalum,* 1410
Lee, S.-W., and Sciarra, J. J., development of an aerosol dosage form containing insulin, 567
Leeling, J. L., Phillips, B. M., Kowalski, T. L., and Kowalski, R. L., influence of aspirin formulation and dose on concentration of total salicylate in rat kidney, 447
Legault, D., *see* Lanouette, M., 1214
Leh, F. K. V., and Wolf, W., platinum complexes: a new class of antineoplastic agents, 315
Lenkiewicz, R. S., *see* Turner, W. R., 118
Leon, N. H., new compounds: synthesis of carboxymethyl carbodithioates, 146
Leonard, B. L., *see* Gaglia, C. A., Jr., 1691
Leonard, G. S., *see* Shotton, E., 1170
le Petit, G. F., medazepam pKa determined by spectrophotometric and solubility methods, 1094
Lerk, C. F., Schoonen, A. J. M., and Fell, J. T., contact angles and wetting of pharmaceutical powders, 843
Levine, M., *see* Astley, J. P., 210
Levinson, R. S., Allen, L. V., Jr., Vishnupad, K. S., and Ecanow, B., appearance of myelin forms in rheopexic dispersions of dioctyl sodium sulfosuccinate, 1265
——*see* Stanaszek, W. F., 142
Levitt, M., Cumiskey, W. R., McGrath, M. B., and Shargel, L., rapid procedure for assessment of compounds that modify uptake and release of tritiated norepinephrine, 1556
Levy, G., effect of plasma protein binding of drugs on duration and intensity of pharmacological activity, 1264
——*see* Houston, J. B., 1218
——*see* Slattery, J. T., 1710
Levy, R. H., *see* Pitlick, W. H., 462
Li, H., and Cervoni, P., GLC determination of nylidrin in human urine samples, 1352
Liebman, A., *see* Dixon, W. R., 701
Lien, E. J., *see* Tong, G. L., 1651
Lieu, S.-Y., *see* Wormser, H. C., 397
Liggett, W. F., *see* Kaiser, D. G., 1767
Lindberg, J. G., *see* Parker, G. R., 585
Lindenbaum, S., *see* Agharkar, S., 747
Lipari, J. M., *see* Connors, K. A., 379
Lo, K. W., *see* Miller, E. E., 384
Lock, A., *see* Ayres, J. W., 832
Locock, R. A., *see* Chatten, L. G., 1315
Lodge, B. A., *see* Lanouette, M., 1214
Lohrisch, D., Shull, S. C., and Smith, M. C., constant returns to scale for prescription dispensing in U.S. community pharmacy, 204
Lomner, J. J., *see* Gaglia, C. A., Jr., 1691
Longwell, A., Birss, S., Keller, N., and Moore, D., effect of topically applied pilocarpine on tear film pH, 1654
Lonski, L., *see* Horhota, S. T., 1746
Loo, J. C. K., Vilim, A. B., Jordan, N., and Moffatt, J., application of Girard reagent T to radioimmunological assay of prednisolone in plasma, 461
Lorskulsint, D., *see* Ayres, J. W., 832
Loveless, A. H., *see* Florence, A. T., 1665
Lovering, E. G., Mainville, C. A., and Rowe, M. L., drug permeation through membranes V: interaction of diazepam with common excipients, 207
Lowe, Y. H., *see* Foye, W. O., 1247
Ludden, T. M., Malspeis, L., Baggot, J. D., Sokoloski, T. D., Frank, S. G., and Reuning, R. H., tritiated naltrexone binding in plasma from several species and tissue distribution in mice, 712
Ludemann, W. B., *see* Mutha, S. C., 1400
Lukas, G., and Redalieu, E., *in vivo* loss of tritium from labeled drugs: determinations in urine and plasma, 1261
——Borman, C. B., and Zak, S. B., fully automated analysis of phenylbutazone in plasma and urine, 86
Lukes, A. L., *see* Pikal, M. J., 1269, 1278
Lustgarten, R. K., high-performance liquid chromatographic separation of C-15-epimers of 15-methylprostaglandin E_2 methyl ester and 15-methylprostaglandin E_2, 1533
Lynch, D. M., *see* Warner, V. D., 1070

M

MacFarlane, J. O., Lee, J. W., and Cheng, C. C., colorimetric assay for guaiacol *O*-methyltransferase, 1689
Madan, D. K., *see* Madan, P. L., 1476
Madan, P. L., Madan, D. K., and Price, J. C., clofibrate microcapsules: preparation and release rate studies, 1476
Madrid, V., *see* Schwarz, H. J., 370
Madsen, R. E., and Magin, D. F., simultaneous quantitative GLC determination of chlorpheniramine maleate and phenylpropanolamine hydrochloride in a cold tablet preparation, 924
Maghssoudi, R. H., *see* Shamsa, F. A., 761
Magin, D. F., *see* Madsen, R. E., 924
Magyar, K., *see* Papp, E., 441
Mahjour, M., *see* Lalezari, I., 923
Maibach, H. I., *see* Skinner, W. A., 1404
Maidment, R. J., *see* Browner, S. M., 1305
Mainville, C. A., *see* Lovering, E. G., 207
Mais, R. F., *see* Oester, Y. T., 1673
Makoid, M. C., Sieg, J. W., and Robinson, J. R., corneal drug absorption: an illustration of parallel first-order absorption and rapid loss of drug from absorption depot, 150
Malspeis, L., *see* Ludden, T. M., 712
Maness, D. D., *see* Han, W. W., 1198
——*see* Yakatan, G. J., 1456
Manning, G., *see* Urbányi, T., 257
Marathe, S. A., *see* Gupta, S. K., 134
March, G. A., *see* Armstrong, N. A., 198, 200
Mardens, Y., *see* Vanhaelen, M., 1774
Marecki, P. E., *see* Boots, M. R., 724
——*see* Boots, S. G., 1374
——*see* Guyer, K. E., 548
Maronde, R. F., *see* Fung, K. K., 596
Marriott, C., and Kellaway, I. W., rheological evaluation of hog gastric mucin as a model mucus system, 828
Martens, F. K., Martens, M. A., Demeter, J., and Heyndrickx, A., extraction and GLC analysis of pyrithyldione in highly putrified human postmortem samples, 1393
Martens, M. A., *see* Martens, F. K., 1393
Martz, B. L., *see* Mason, W. D., 1325
Mason, N., Thies, C., and Cicero, T. J., *in vivo* and *in vitro* evaluation of a microencapsulated narcotic antagonist, 847
Mason, W. D., and Sandmann, B., determination of nitrofurantoin in urine by reduction at rotating platinum electrode, 599
——Covinsky, J. O., Valentine, J. L., Kelly, K. L., Weddle, O. H., and Martz, B. L., comparative plasma concentrations of quinidine following administration of one intramuscular and three oral formulations to 13 human subjects, 1325
——*see* Weddle, O. H., 865
Masoud, A. N., systematic identification of drugs of abuse II: TLC, 1585
——and Nittskoff, D. J., spot tests used for systematic identification of drugs of abuse: a response, 775
Mathison, I. W., *see* Morgan, P. H., 467, 635
Matsuda, Y., Minamida, Y., and Hayashi, S.-I., comparative evaluation of tablet lubricants: effect of application method on tablet hardness and ejectability after compression, 1155
Mattes, K., *see* Chao, A. Y., 1630
Mauger, J., and Howard, S., model systems for dissolution of finely divided (multisized) drug powders, 1042
Mauger, J. W., *see* Laprade, B., 277
Mayock, R., *see* Chyzanowski, F., 735
McAllister, R. G., and Howell, S. M., fluorometric assay of verapamil in biological fluids and tissues, 431
McConnell, J. K., *see* Robinson, C. P., 595
McCormack, J. J., *see* Hodnett, C. N., 1150
McEwan, B., *see* Wyatt, D. K., 680
McGilveray, I. J., *see* Midha, K. K., 188, 387, 576, 1240
——*see* Sved, S., 1356
McGinity, J. W., and Lach, J. L., *in vitro* adsorption of various pharmaceuticals to montmorillonite, 896
McGrath, M. B., *see* Levitt, M., 1556
McLaughlin, L. J., *see* Korol, B., 308
Medwick, T., *see* Turczan, J. W., 235
Mehta, S. C., *see* Simonelli, A. P., 355
Melethil, S., and Conway, W. D., urinary excretion of probenecid and its metabolites in humans as a function of dose, 861
Melikian, A. P., *see* Slywka, G. W. A., 1494
——*see* Whyatt, P. L., 652
Meshali, M. M., and Nightingale, C. H., effect of alpha tocopherol (vitamin E) deficiency on intestinal transport of passively absorbed drugs, 344
Meyer, J. C., *see* de Silva, J. A. F., 1230
Meyer, M. C., *see* Cruze, C. A., 33
——*see* Slywka, G. W. A., 1494
——*see* Whyatt, P. L., 652
Michaelis, A. F., *see* Turi, P., 806
Midha, K. K., Hubbard, J. W., Cooper, J. K., and McGilveray, I. J., GLC determination of plasma concentrations of phenprocoumon, 387
——McGilveray, I. J., and Charette, C., GLC determination of plasma levels of intact chlorpropamide or tolbutamide, 576
——McGilveray, I. J., and Wilson, D. L., sensitive GLC procedure for simultaneous determination of phenytoin and its major metabolite from plasma following single doses of phenytoin, 1240
——McGilveray, I. J., Bhatnagar, S. P., and Cooper, J. K., GLC identification and determination of 3,4-methylenedioxyamphetamine (MDA) from plasma and urine, 188
Miles, D. H., and Kokpol, U., tumor inhibitors II: constituents and antitumor activity of *Sarracenia flava,* 284
Miller, E. E., Ledis, S. L., Lo, K. W., and Tsou, K. C., 5′-nucleotide phosphodiesterase activity of floxuridine-resistant mouse glioma, 384
Mille[illegible] I., *see* Dreyfuss, J., 502
Miller, L. D., *see* Korol, B., 308
Millner, O. E., Jr., and Purcell, W. P., partition coefficients of selected pyridine carbamates and comparisons with their acetylcholinesterase and butyrylcholinesterase inhibitory potencies, 910
Mills, D. G., *see* Dimmock, J. R., 482
Minamida, Y., *see* Matsuda, Y., 1155
Mincy, J. W., *see* Blaha, J. M., 1165
Minnet, K. M., *see* Naik, D. V., 274
Misra, R. S., Barthwal, J. P., Parmar, S. S., Singh, S. P., and Stenberg, V. I., synthesis of substituted thiobenzoxazoles/benzothiazoles: inhibition of cellular respiratory and monoamine oxidase activities and anticonvulsant property, 405
Mitra, C., *see* Banerjee, S., 704
Miyamoto, M. A., *see* Digenis, G. A., 247
Moffatt, J., *see* Loo, J. C. K., 461
Molokhia, A., *see* Ho, N. F. H., 1578
——*see* Prakongpan, S., 685
Moore, D., *see* Longwell, A., 1654
Moore, D. E., antioxidant efficiency of polyhydric phenols in photooxidation of benzaldehyde, 1447
Morgan, P. H., and Mathison, I. W., arrhythmias and antiarrhythmic drugs: mechanism of action and structure–activity relationships I, 467
——and Mathison, I. W., arrhythmias and antiarrhythmic drugs: mechanism of action and structure–activity relationships II, 635
Moskalyk, R. E., *see* Chatten, L. G., 1315
Mukerjee, P., and Cardinal, J. R., solubilization as a method for studying self-association: solubility of naphthalene in the bile salt sodium cholate and the complex pattern of its aggregation, 882
Munnelly, K. P., *see* Cohen, D. M., 1413
——*see* Wong, C. K., 1090
Murray, W. A., *see* Stewart, J. T., 1536
Murray, W. J., *see* Kier, L. B., 1226
Mutha, S. C., and Ludemann, W. B., solid-state anomalies in IR spectra of compounds of phar-

maceutical interest, 1400

N

Nagwekar, J. B., *see* Amin, Y. M., 1341
Naik, D. V., Davis, B. R., Minnet, K. M., and Schulman, S. G., fluorescence of hydralazine in concentrated sulfuric acid, 274
Nail, S. L., White, J. L., and Hem, S. L., differential thermal analysis of aluminum hydroxide gel, 1391
——White, J. L., and Hem, S. L., IR studies of development of order in aluminum hydroxide gels, 231
——White, J. L., and Hem, S. L., kinetics of acid neutralization by aluminum hydroxide gel, 1255
——White, J. L., and Hem, S. L., structure of aluminum hydroxide gel II: aging mechanism, 1192
——White, J. L., and Hem, S. L., structure of aluminum hydroxide gel I: initial precipitate, 1188
——White, J. L., and Hem, S. L., structure of aluminum hydroxide gel III: mechanism of stabilization by sorbitol, 1195
Nakai, Y., *see* Yamamoto, K., 1484
Nakano, M., Juni, K., and Arita, T., controlled drug permeation I: controlled release of butamben through silicone membrane by complexation, 709
——*see* Yamamoto, K., 1484
Nandi, B. R., *see* Dinovo, E. C., 667
Näslund, B., *see* Hartvig, P., 1707
Neelakantan, L., and Kostenbauder, H. B., electron-capture GLC determination of phenylpropanolamine as a pentafluorophenyloxazolidine derivative, 740
Negrave, L. E., *see* Dimmock, J. R., 482
Nelson, E., *see* Carstensen, J. T., 311
Neumeyer, J. L., *see* Warner, A. M., 928
Newman, E. C., and Frank, G. W., circular dichroism spectra of tetracycline complexes with Mg^{+2} and Ca^{+2}, 1728
——*see* Stoel, L. J., 1794
Newman, J. H., *see* Chremos, A. N., 140
Newton, J. M., *see* Fee, J. V., 48, 182
Ng, C. T., *see* James, K. C., 656
Niazi, S., comparison of observed and predicted first-pass metabolism of imipramine in humans, 1063
——comparison of observed and predicted first-pass metabolism of nortriptyline in humans, 1535
——effect of polyethylene glycol 4000 on dissolution properties of sulfathiazole polymorphs, 302
——errors involved in instantaneous intravascular input assumptions, 750
——volume of distribution and tissue level errors in instantaneous intravenous input assumptions, 1541
——volume of distribution as a function of time, 452
——and Chiou, W. L., fluorocarbon aerosol propellants X: pharmacokinetics of dichlorotetrafluoroethane in dogs, 60
——*see* Chiou, W. L., 1212
Nicholova, B., *see* Chao, A. Y., 1630
Nichols, D. E., and Shulgin, A. T., sulfur analogs of psychotomimetic amines, 1554
Niebergall, P. J., *see* Chrzanowski, F., 735
——*see* Schnaare, R. L., 1385
Nieforth, K. A., *see* DeSantis, F., 1479
Nightingale, C. H., *see* Meshali, M. M., 344
Ninger, F. C., *see* Goodhart, F. W., 1072, 1466
Nittskoff, D. J., *see* Masoud, A. N., 775
Noble, L. M., *see* Dimmock, J. R., 38
Nony, C. R., Bowman, M. C., Holder, C. L., Young, J. F., and Oller, W. L., trace analysis of 2,4,5-trichlorophenoxyacetic acid, its glycineamide, and their alkaline hydrolyzable conjugates in mouse blood, urine, and feces, 1810
Norton, T. R., Shibata, S., Kashiwagi, M., and Bentley, J., isolation and characterization of the cardiotonic polypeptide anthopleurin-A from the sea anemone *Anthopleura xanthogrammica,* 1368
Notari, R. E., *see* Byron, P. R., 1140
Novick, W. J., Jr., *see* Yakatan, G. J., 1456
Noyce, P. R., *see* James, K. C., 656
Nudelman, N. S., and Nudelman, O., specific colorimetric determination of niacinamide in dosage forms, 65
Nudelman, O., *see* Nudelman, N. S., 65
Nuessle, N. O., *see* Frazier, W. F., 1823

O

O'Brien, J. E., and Hinsvark, O. N., GLC determination of doxepin plasma levels, 1068
Oester, Y. T., Keresztes-Nagy, S., Mais, R. F., Becktel, J., and Zaroslinski, J. F., effect of temperature on binding of warfarin by human serum albumin, 1673
Oller, W. L., *see* Nony, C. R., 1810
Ong, J. T. H., and Kostenbauder, H. B., effect of micellization on rate of cupric-ion-promoted hydrolysis of dicarboxylic acid hemiesters, 1713
Otani, T. T., and Briley, M. R., β-hydroxynorleucine: separation of its isomers and biological studies, 534
Owada, E., *see* Ho, N. F. H., 1578
——*see* Hwang, S., 1574

P

Pachman, L. M., *see* Rubenstein, M., 756
Padhya, A. C., *see* Devani, M. B., 660
Pai, R., Kulshreshtha, D. K., and Rastogi, R. P., antileukemic and other constituents of *Tithonia tagitiflora* Desf., 918
Palagyi, L., *see* Chowhan, Z. T., 1559
Pantarotto, C., *see* Belvedere, G., 815
——*see* Rovei, V., 810
Paolino, R. M., *see* Smolen, V. F., 1600
Papendick, V. E., *see* Chang, Z. L., 1543
Papp, E., Magyar, K., and Schwarz, H. J., liquid–solid chromatographic determination of 6-demethylgriseofulvin in urine, 441
Parikh, S. H., *see* Devani, M. B., 660
Park, J. Y., *see* Ho, N. F. H., 1578
Parker, G. R., Hilgendorf, N. K., and Lindberg, J.G., solvent-dependent conformational system in hydroxyureas detected by NMR spectroscopy, 585
Parmar, S. S., *see* Chaturvedi, A. K., 409
——*see* Chaudhari, A., 758
——*see* Chaudhary, M., 443
——*see* Chaudhary, S. K., 1010
——*see* Kishore, V., 1078
——*see* Misra, R. S., 405
——*see* Singh, S. P., 391, 1678
Parrott, E. L., *see* Sabo, M., 932
——*see* Shah, S. A., 1784
Parsons, D. L., *see* Vallner, J. J., 873
Partovi, T., *see* Shafiee, A., 304
Paruta, A. N., *see* Alexander, K. S., 851
——*see* Laprade, B., 277
——*see* Schwartz, P. A., 252
Patel, D. M., *see* Visalli, A. J., 1686
——*see* Zalipsky, J. J., 460
Patel, M., reduced acid-neutralizing velocity of spray-dried agglomerated magnesium carbonate, 770
Patel, S. P., *see* Sciarra, J. J., 1519
Pathak, U. S., *see* Devani, M. B., 660
Patil, P. N., *see* Grunewald, G. L., 920
——*see* Shimada, K., 1057
Patrick, T. B., and Bresee, R. R., enthalpies of hydrogen bonding in psychotropic drugs, 1066
Patton, T. F., and Robinson, J. R., quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes, 1295
——*see* Friedman, T. S., 1095
Paul, K., and Blanton, C. D., Jr., 5-aryloxy-6-methoxy-8-aminoquinolines as potential prophylactic antimalarials, 1527
Peck, G. E., *see* Chang, C.-J., 1019
——*see* Smith, G. G., 727
Pedersen, P. V., and Brown, K. F., experimental evaluation of three single-particle dissolution models, 1442
——and Brown, K. F., theoretical isotropic dissolution of nonspherical particles, 1437
Perdue, R. E., Jr., *see* Chang, P. T. O., 561
Perkins, E. G., *see* Sharma, J. P., 1606
Perrin, J. H., *see* Vallner, J. J., 1182
Petersen, H., *see* Alexander, K. S., 851
——*see* Laprade, B., 277
Petersen, R. V., *see* Kim, S. W., 670
——*see* Stenchever, M. A., 1648
——*see* Swinyard, E. A., 733
Petrangeli, B., *see* Angelucci, L., 455
Pettit, G. R., Herald, C. L., and Herald, D. L., antineoplastic agents XLV: sea cucumber cytotoxic saponins, 1558
Pfeiffer, F. R., *see* Villani, A. J., 1243
Phillips, B. M., *see* Leeling, J. L., 447
Phillips, W. A., Ratchford, J. M., and Schultz, J. R., effects of colestipol hydrochloride on drug absorption in the rat II, 1285
Piedmont, A., *see* Urbányi, T., 257
Pikal, M. J., and Lukes, A. L., Knudsen, vapor pressure measurements on pure materials and solutions dispersed in porous media: molded nitroglycerin tablets, 1269
——Lukes, A. L., and Ellis, L. F., vapor pressure of nitroglycerin in sublingual molded tablets: implications for stability, 1278
Pinzauti, S., Dal Piaz, V., and La Porta, E., gravimetric determination of chlorhexidine using tetraphenylborate ion, 1251
Pipkin, J. D., *see* Stella, V. J., 1161
Pitlick, W. H., Levy, R. H., Troupin, A. S., and Green, J. R., pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine, 462
Pitman, I. H., *see* Kosugi, M., 1743
Pluta, P. L., Crespi, H. L., Klein, M., Blake, M. I., Studier, M. H., and Katz, J. J., biosynthesis of deuterated riboflavin: structure determination by NMR and mass spectrometry, 362
Polk, A., *see* Chemburkar, P. B., 529
Polónia, J., *see* Serra, T., 737
Pook, K.-H., Rominger, K.-L., and Arndts, D., mass spectral analysis of glucuronides from sympathomimetic hydroxyphenylalkylaminoethanols, 1513
Post, A., *see* Warren, R. J., 738
Poupaert, J., and Bouche, R., IR spectroscopic characterization of 2-thiohydantoins and 2-thiobarbiturates, 1258
Powers, L. J., *see* Bass, G. E., 1525
Prakongpan, S , Higuchi, W. I., Kwan, K. H., and Molokhia, A. M., dissolution rate studies of cholesterol monohydrate in bile acid–lecithin solutions using the rotating-disk method, 685
Preininger, V., Thakur, R. S., and Šantavý, F., isolation and chemistry of alkaloids from plants of the family Papaveraceae LXVII: *Corydalis cava* (L.) Sch. et K. (*C. tuberosa* DC), 294
Price, J. C., *see* Madan, P. L., 1476
——*see* Zia, H., 226
Proctor, J. D., *see* Chremos, A. N., 140
Puglisi, C. V., *see* de Silva, J. A. F., 1230
Purcell, W. P., *see* Millner, O. E., Jr., 910

Q

Quay, J. F., *see* Holland, D. R., 417
Qureshi, A. M., *see* Dimmock, J. R., 38

R

Rackham, D. M., *see* Browner, S. M., 1305
Ramabadran, K., Bansinath, M., and Guruswami, M. N., anticonvulsant activity of enzyme inhibitors in rats, 1245
Rama Sastry, B. V., *see* Chaturvedi, A. K., 409
——*see* Chaudhary, M., 443
Ranade, V. V., *see* Counsell, R. E., 285
Randić, M., *see* Kier, L. B., 1226
Rank, G. H., *see* Dimmock, J. R., 482, 538
Rasero, L., *see* Hanna, S., 1522
Rashidbaigi, A., *see* Ghabgharan, F., 1085
Rastogi, R. P., *see* Pal, R., 918
Ratchford, J. M., *see* Phillips, W. A., 1285

Reamer, J. T., *see* Grady, L. T., 628
Reames, D. C., *see* Beam, C. F., 1408
Reavey-Cantwell, N. H., *see* Chemburkar, P. B., 529
——*see* Smyth, R. D., 1045
——*see* Visalli, A. J., 1686
——*see* Zalipsky, J. J., 460
Rebagay, T., and DeLuca, P., correlation of dielectric constant and solubilizing properties of tetramethyldicarboxamides, 1645
Recusani, F., *see* Ghielmetti, G., 905
Redalieu, E., *see* Lukas, G., 1261
Reddi, G. S., *see* Shridhar, D. R., 1074
Reddy, J. P., *see* Ghosal, S., 772
Reddy, P. K. S. P., *see* Bhattacharya, S. K., 1547
Reddy, R. K., Khalil, S. A., and Gouda, M. W., dissolution characteristics and oral absorption of digitoxin and digoxin coprecipitates, 1753
——Khalil, S. A., and Gouda, M. W., effect of dioctyl sodium sulfosuccinate and poloxamer 188 on dissolution and intestinal absorption of sulfadiazine and sulfisoxazole in rats, 115
Reddy Sastry, C. V., *see* Shridhar, D. R., 1074
Reinhard, M., *see* Feldman, S., 1460
Reisberg, P., Brenner, I. A., and Bodin, J. I., NMR determination of enantiomers of 7-chloro-3,3a-dihydro-2-methyl-2*H*,9*H*-isoxazolo[3,2-*b*][1,3]-benzoxazin-9-one using chiral shift reagent, tris-[3 - (heptafluorobutyryl) - *d* - camphorato]-europium(III), 592
Reischer, R. J., *see* Kaiser, D. G., 269
Repta, A. J., Baltezor, M. J., and Bansal, P. C., utilization of an enantiomer as a solution to a pharmaceutical problem: application to solubilization of 1,2-di(4-piperazine-2,6-dione)propane, 238
Reuning, R. H., *see* Ludden, T. M., 712
Rhodes, C. T., *see* Biber, M. Z., 564
——*see* Fung, H.-L., 558
——*see* Horhota, S. T., 1746
——*see* Khan, K. A., 1835
Richards, R. M. E., and Cavill, R. H., electron microscope study of effect of benzalkonium chloride and edetate disodium on cell envelope of *Pseudomonas aeruginosa*, 76
Richardson, A., Jr., Benson, H. D., and Hite, G., stereochemistries of geometric isomers of 4-(2-bromo-1,2-diphenylvinyl)phenol, 4-(2-bromo-1,2-diphenylvinyl)anisole, and 2-[*p*-(2-bromo-1,2-diphenylvinyl)phenoxy]triethylamine: corrections of the literature, 1545
——*see* Ernst, S., 148
Richardson, D. G., *see* Atkinson, E. R., 1682
Richardson, W. G., *see* Wyatt, D. K., 680
Riley, T. N., and Crawford, F. W., synthesis and α-adrenolytic activity of chiral β-haloethylamines, 544
Rippie, E. G., *see* Ibrahim, H. G., 1639
Ritschel, W. A., *see* Tan, H. S. I., 30
Roberts, R. J., *see* Day, D. K., 773
Robertson, A. J., *see* Dimmock, J. R., 482, 538
Robertson, J. H., *see* Tsuji, K., 400
Robinson, C. P., Smith, P. W., McConnell, J. K., and Endecott, B. R., comparison of protective effects of ethylestrenol, norbolethone, and spironolactone against lethality from acute doses of parathion and paraoxon in female rats, 595
Robinson, J. R., *see* Chrai, S. S., 437
——*see* Makoid, M. C., 150
——*see* Patton, T. F., 1295
——*see* Sieg, J. W., 1816
Roche, E. B., *see* Bulger, W. H., 109
Rominger, K.-L., *see* Pook, K.-H., 1513
Rorke, C. V., Harris, H. A., Catalano, T., and Dugar, S. M., spot tests used for systematic identification of drugs of abuse, 774
Rose, E. K., *see* Darling, C. M., 98
Roseman, T. J., Brown, J. A., and Scothorn, W. W., glass for parenteral products: a surface view using the scanning electron microscope, 22
——Butler, S. S., and Douglas, S. L., high-pressure liquid chromatographic determination of the 15-epimer of dinoprost in bulk drug, 673
Rosenberg, H., *see* Stohs, S. J., 610
Ross, J. J., *see* Dreyfuss, J., 502, 1310
Rovei, V., Belvedere, G., Pantarotto, C., and Frigerio, A., isolation of 10,11-epoxide of protriptyline in rat urine after protriptyline administration, 810
——*see* Belvedere, G., 815
Rowe, M. L., *see* Lovering, E. G., 207
Rubenstein, M., Giacomoni, D., and Pachman, L. M., effect of sodium salicylate on hamster cells *in vitro*, 756
Rubin, S. H., DeRitter, E., and Johnson, J. B., stability of vitamin C (ascorbic acid) in tablets, 963
——*see* Frank, M. J., 44
Rubinstein, M. H., granule consolidation during compaction, 376
——and Bodey, D. M., disaggregation of compressed tablets, 1749
Rudy, B. C., *see* Tartivita, K. A., 1024
Rusterholz, D. B., *see* Smith, R. V., 412
Ruth, J. A., *see* Grunewald, G. L., 920
Rutherford, B. S., and Bishara, R. H., GLC determination of aprindine: quantitation and stability measurement, 1322

S

Sabean, J. A., *see* Hodnett, C. N., 1150
Sabo, M., Caputo, J. F., and Parrott, E. L., loss of fluoride during tablet production, 932
Sadeh, T., Davis, M. A., and Giese, R. W., new compounds: synthesis of aliphatic seleno amino acids as potential pancreatic imaging agents, 623
Sahn, M., *see* Tarlin, H., 1463
Salaheldin, A., *see* Soliman, S. A., 1627
Saleh, A. A. M., *see* York, P., 493
Salman, K. N., *see* Grunewald, G. L., 920
Sam, J., *see* Aboul-Enein, N., 1389
Sampath, S. S., *see* Clarke, D. E., 92
Sanders, P. R., *see* Tan, H. S. I., 30
Sandifer, R. M., *see* Beam, C. F., 1408
Sandmann, B., *see* Mason, W. D., 599
Sandmann, B. J., *see* Korpi, J., 1087
Šantavý, F., *see* Preininger, V., 294
Sanvordeker, D. R., photochromism of an anticonvulsant, 1-diphenylmethyl-4-(6-methyl-2-pyridylmethyleneamino)piperazine, in the solid state, 1452
——*see* Chao, A. Y., 1630
Sartorelli, A. C., *see* Agrawal, K. C., 297
Schaeffer, J. C., Cho, A. K., and Fischer, J. F., inhibition of synaptosomal accumulation of *l*-norepinephrine II: *N*-aryloxyalkylphentermines, quaternary *d*-amphetamines, and 3-aryloxypropylamines, 122
Schiff, P. L., Jr., *see* Elsohly, M. A., 132
——*see* Turner, C. E., 1084
Schnaare, R. L., Sheikh, R. M., Niebergall, P. J., and Sugita, E. T., real flow measurements on time-dependent thixotropic fluids, 1385
Schoenwald, R. D., and Ward, R. L., effect of edetate disodium and reduced glutathione on absorption of acetazolamide from GI tract of rats, 677
——*see* Gustafson, J. H., 243
Scholler, J., *see* Yakatan, G. J., 1456
Schoonen, A. J. M., *see* Lerk, C. F., 843
Schott, H., controlled flocculation of coarse suspensions by colloidally dispersed solids I: interaction of bismuth subnitrate with bentonite, 855
——and Han, S. K., effect of inorganic additives on solutions of nonionic surfactants III: CMC's and surface properties, 975
——and Han, S. K., effect of inorganic additives on solutions of nonionic surfactants IV: Krafft points, 979
Schreiber, E. C., *see* Dreyfuss, J., 502
——*see* Heald, A. F., 768
Schulman, S. G., *see* Naik, D. V., 274
——*see* Sturgeon, R. J., 1833
Schultz, J. R., *see* Phillips, W. A., 1285
Schwan, T. J., *see* White, R. L., 135
Schwartz, J. B., and Alvino, T. P., effect of thermal gelation on dissolution from coated tablets, 572
Schwartz, P. A., and Paruta, A. N., solution thermodynamics of alkyl *p*-aminobenzoates, 252
Schwarz, H. J., Waldman, B. A., and Madrid, V., GLC determination of griseofulvin in human plasma, 370
——*see* Papp, E., 441
Sciarello, J. P., *see* Tartivita, K. A., 1024
Sciarra, J. J., and Patel, S. P., *in vitro* release of therapeutically active ingredients from polymer matrixes, 1519
——*see* Lee, S.-W., 567
Scothorn, W. W., *see* Roseman, T. J., 22
Sedman, A. J., and Wagner, J. G., CSTRIP, a Fortran IV computer program for obtaining initial polyexponential parameter estimates, 1006
——*see* Wagner, J. G., 152
Selk, S. H., *see* Kaminski, J. J., 1737
——*see* Kosugi, M., 1743
Sellar, A. P., *see* Dimmock, J. R., 538
Selye, H., *see* Kourounakis, P., 1838
Serra, T., and Polónia, J., isolation of pinastric acid and ergosterol from *Parmelia caperata* (L.) Arch., 737
Shaath, N. A., Soine, T. O., and Shipchandler, M. T., coumarins XIV: high-resolution mass spectra of 3′,4′-disubstituted 3′,4′-dihydroseselins, 1028
Shafiee, A., Lalezari, I., Yazdani, S., Shahbazian, F. M., and Partovi, T., selenium heterocycles XVIII: synthesis and antibacterial activity of 4-substituted (1,2,3-selenadiazol-5-yl)carbamic acid esters and their sulfur analogs, 304
——*see* Ghabgharan, F., 1085
——*see* Lalezari, I., 923
Shah, G. F., *see* Devani, M. B., 660
Shah, N. B., and Sheth, B. B., effect of polymers on dissolution from drug suspensions, 1618
Shah, P. B., *see* Chemburkar, P. B., 529
Shah, S. A., and Parrott, E. L., dissolution of two-component solids, 1784
Shahbazian, F. M., *see* Shafiee, A., 304
Shakhshir, S., *see* Digenis, G. A., 247
Shambhu, M. B., *see* Casey, D. L., 1412
Shamsa, F. A., and Maghssoudi, R. H., spectrophotometric determination of diphenhydramine hydrochloride using dipicrylamine, 761
Shargel, L., *see* Levitt, M., 1556
Sharma, J. P., Perkins, E. G., and Bevill, R. F., high-pressure liquid chromatographic separation, identification, and determination of sulfa drugs and their metabolites in urine, 1606
Sharma, P. V., *see* Bhattacharya, S. K., 1547
Shaw, J. M., *see* Dreyfuss, J., 502, 1310
Shealy, K. D., *see* Beam, C. F., 1408
Shealy, N. L., *see* Beam, C. F., 1408
Sheikh, R. M., *see* Schnaare, R. L., 1385
Sheinin, E. B., Benson, W. R., and Brannon, W. L., determination of methyl methacrylate in surgical acrylic cement, 280
Shelver, W. H., *see* Chae, Y. S., 1178
——*see* Irgens, T. R., 608
——*see* Khalil, S. K. W., 606
Shen, D., *see* Chremos, A. N., 140
Shen, W.-W., Danti, A. G., and Bruscato, F. N., effect of nonionic surfactants on percutaneous absorption of salicylic acid and sodium salicylate in the presence of dimethyl sulfoxide, 1780
Sherman, W. R., *see* Biggs, J. T., 261
Sheth, B. B., *see* Shah, N. B., 1618
Shibata, S., *see* Norton, T. R., 1368
Shimada, K., Baweja, R., Sokoloski, T., and Patil, P. N., binding characteristics of drugs to synthetic levodopa melanin, 1057
Shipchandler, M. T., *see* Shaath, N. A., 1028
Shishoo, C. J., *see* Devani, M. B., 660
Shotton, E., and Leonard, G. S., effect of intragranular and extragranular disintegrating agents on particle size of disintegrated tablets, 1170
Shridhar, D. R., Reddy Sastry, C. V., Vaidya, N. K., Reddi, G. S., and Thapar, G. S., antimicrobial agents: synthesis and antimicrobial activity of new aryloxyalkyl esters of *p*-hydroxybenzoic acid, 1074
Shulgin, A. T., *see* Nichols, D. E., 1554
Shull, S. C., *see* Lohrisch, D., 204
Sibley, C. R., *see* Colburn, W. A., 997
Sieg, J. W., and Robinson, J. R., mechanistic studies on transcorneal permeation of pilocarpine, 1816
——*see* Makoid, M. C., 150
Siegel, I. A., Izutsu, K. T., and Burkhart, J., transfer of alcohols and ureas across the oral mucosa measured using streaming potentials and radio-

isotopes, 129
Simonelli, A. P., Mehta, S. C., and Higuchi, W. I., dissolution rates of high energy sulfathiazole–povidone coprecipitates II: characterization of form of drug controlling its dissolution rate *via* solubility studies, 355
Sims, D., *see* Lee, K.-H., 1410
Singh, A. K., *see* Bhattacharya, S. K., 1547
——*see* Ghosal, S., 1549
Singh, S. P., Ali, B., Auyong, T. K., Parmar, S. S., and De Boer, B., anticonvulsant activity and selective inhibition of nicotinamide adenine dinucleotide-dependent oxidations by 10-(2-arylimino-3-acetylamino - 4 - thiazolidonyl)phenothiazines, 391
——Chaudhari, A., Stenberg, V. I., and Parmar, S. S., synthesis of substituted anilino-(3-methoxy-4-substituted acetoxy)benzylidenes and their monoamine oxidase inhibitory and anticonvulsant properties, 1678
——*see* Chaudhari, A., 758
——*see* Misra, R. S., 405
Siva Sankar, D. V., *see* Kumbar, M., 1014
Skidmore, D., *see* Skinner, W. A., 1404
Skinner, W. A., Crawford, H. T., Tong, H., Skidmore, D., and Maibach, H. I., topical mosquito repellents IX: quinolines, isoquinolines, and quinoxalines, 1404
Slamnik, M., determination of tinidazole in tablets by dc polarography, 736
Slatkin, D. J., *see* Elsohly, M. A., 132
——*see* Turner, C. E., 1084
Slattery, J. T., Yacobi, A., Levy, G., and Kaiser, D. G., potential problem in GLC determination of ibuprofen caused by solid support, 1710
Slywka, G. W. A., Melikian, A. P., Straughn, A. B., Whyatt, P. L., and Meyer, M. C., bioavailability of 11 sulfisoxazole products in humans, 1494
——*see* Whyatt, P. L., 652
Small, L. D., synthesis and preliminary antimicrobial screening of two thiosulfonates, 1692
Smith, G. G., and Peck, G. E., continuous-flow system for determination of diffusion coefficients: use of a natural membrane, 727
Smith, J. B., *see* Stewart, J. T., 1536
Smith, M. C., *see* Lohrisch, D., 204
Smith, P. J., *see* Dimmock, J. R., 38
Smith, P. W., *see* Robinson, C. P., 595
Smith, R. B., Smith, R. V., and Yakatan, G. J., spectrofluorometric determination of hydroflumethiazide in plasma and urine, 1208
Smith, R. V., Erhardt, P. W., Rusterholz, D. B., and Barfknecht, C. F., NMR study of amphetamines using europium shift reagents, 412
——*see* Smith, R. B., 1208
Smith, R. W., *see* Stehle, R. G., 1844
Smolen, V. F., and Weigand, W. A., optimally predictive *in vitro* drug dissolution testing for *in vivo* bioavailability, 1718
——Jhawar, A. K., Weigand, W. A., Paolino, R. M., and Kuehn, P. B., bioavailability and pharmacokinetic analysis of chlorpromazine-induced rectal temperature depression in rabbits, 1600
——*see* Kuehn, P. B., 1593
Smyth, R. D., Herczeg, T., Wheatley, T. A., Hause, W., and Reavey-Cantwell, N. H., correlation of *in vitro* and *in vivo* methodology for evaluation of antacids, 1045
——*see* Chemburkar, P. B., 529
Sneath, R. L., Jr., *see* Jacobs, P. M., 604
Snook, G. F., *see* Browner, S. M., 1305
Soine, T. O., *see* Shaath, N. A., 1028
Sokoloski, T. D., *see* Ludden, T. M., 712
——*see* Shimada, K., 1057
Soliman, S. A., and Salaheldin, A., rapid spectrophotometric determination of salicylamide in analgesic tablets, 1627
——Abdine, H., and Zakhari, N. A., nonaqueous titration of sulfates of quinine and quinidine using barium acetate, 424
Solomonraj, G., *see* Wong, L. T., 1064
Soloway, A. H., *see* Jacobs, P. M., 604
Souter, R. W., and Dinner, A., GLC determination of degradation of two related amine uptake inhibitors, 457
Sowell, J. W., Sr., and Blanton, C. D., Jr., new synthesis of substituted pyrrolo[1,2-*a*][1,3]diazepine and its pharmacological activity, 908
Speiser, P. P., *see* Birrenbach, G., 1763
——*see* Kreuter, J., 1624
Spillane, W. J., *see* Benson, G. A., 1841
Staba, E. J., *see* Wu, W. L., 102
Staiger, D. B., *see* Warren, R. J., 738
Stanaszek, W. F., Ecanow, B., and Levinson, R. S., oxygen solubilization by lung surfactant, 142
Stauffer, S. C., *see* Hucker, H. B., 926, 1253
Stehle, R. G., and Smith, R. W., relative aqueous stabilities of dinoprostone free acid (prostaglandin E_2) and its carbamoylmethyl ester, 1844
Steinetz, B., *see* Colombo, C., 1082
Stella, V. J., and Pipkin, J. D., phenylbutazone ionization kinetics, 1161
Stenberg, V. I., *see* Chaudhari, A., 758
——*see* Kishore, V., 1078
——*see* Misra, R. S., 405
——*see* Singh, S. P., 1678
Stenchever, M. A., Allen, M. A., Jerominski, L., and Petersen, R. V., effects of bis(2-ethylhexyl) phthalate on chromosomes of human leukocytes and human fetal lung cells, 1648
Stern, P. W., effects of film coatings on tablet hardness, 1291
Sternson, L. A., *see* Vallner, J. J., 873
Stewart, J. T., Honigberg, I. L., Brant, J. P., Murray, W. A., Webb, J. L., and Smith, J. B., liquid chromatography in pharmaceutical analysis V: determination of an isoniazid–pyridoxine hydrochloride mixture, 1536
Stoel, L. J., Newman, E. C., Asleson, G. L., and Frank, C. W., potentiometric and spectral investigations of anhydrotetracycline and its metal-ion complexes, 1794
Stohs, S. J., and Rosenberg, H., onset of enzyme induction with pregnenolone-16α-carbonitrile in male and female rats, 610
Straughn, A. B., *see* Slywka, G. W. A., 1494
Strelitz, R. A., *see* Grier, N., 616
Streng, W. H., Huber, H. E., DeYoung, J. L., and Zoglio, M. A., ionization constants of cephalosporin compounds, 1034
Strickwold, B., *see* Buchanan, N., 914
Strong, J. W., combined assays for vitamins A, D (ergocalciferol), and E in multivitamin preparations with separation by reversed-phase partition chromatography, 968
Studier, M. H., *see* Pluta, P. L., 362
Sturgeon, R. J., and Schulman, S. G., steric inhibition of conjugation in lowest excited singlet state of 9-anthramide by hydrogen bond donor solvents: role of solvent in chemical structure, 1833
Sugita, E., *see* Chrzanowski, F., 735
——*see* Schnaare, R. L., 1385
Suhardja, L., *see* Ho, N. F. H., 1578
——*see* Hwang, S., 1574
Summers, M. P., and Enever, R. P., preparation and properties of solid dispersion system containing citric acid and primidone, 1613
Sunayashiki, K., *see* Hori, R., 463
Sved, S., McGilveray, I. J., and Beaudoin, N., assay of sulfonylureas in human plasma by high-performance liquid chromatography, 1356
Swinyard, E. A., Woodhead, J. H., and Petersen, R. V., nonspecific effect of bis(2-ethylhexyl) phthalate on hexobarbital sleep time, 733

T

Taha, A. M., and Gomaa, C. S., analysis of alkaloid mixtures by charge-transfer complexation, 986
Takayama, Y., *see* Yamamoto, K., 1484
Tam, S. S., *see* Zografi, G., 1145
Tan, H. S. I., Ritschel, W. A., and Sanders, P. R., determination of coumarin and umbelliferone mixtures in whole blood by spectrophotofluorometry, 30
Tao, F. T., *see* Bayne, W. F., 1724
Tao, L. C., *see* Chien, Y. W., 1337
Tarlin, H., Hudson, M., and Sahn, M., automated fluorometric analysis of epinephrine in lidocaine hydrochloride injection, 1463
Tartivita, K. A., Sciarello, J. P., and Rudy, B. C., high-performance liquid chromatographic analysis of vitamins I: quantitation of cholecalciferol or ergocalciferol in presence of photochemical isomers of the provitamin and application to cholecalciferol resins, 1024
Taubin, J., *see* Chrzanowski, F., 735
Tawashi, R., *see* Bisaillon, S., 222
Tawfik, A. S., *see* Eldawy, M. A., 664
Tenforde, T. S., Fawwaz, R. A., and Castagnoli, N., Jr., differing antitumor activities of the hydrochloride and methiodide salts of 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide, 631
Terzis, A., Kourounakis, P., and Theophanides, T., structural features and protective activity of dexamethasone and pregnenolone-16α-carbonitrile, 1092
Thakur, R. S., *see* Preininger, V., 294
Thapar, G. S., *see* Shridhar, D. R., 1074
Theeuwes, F., Ashida, K., and Higuchi, T., programmed diffusional release rate from encapsulated cosolvent system, 648
Thelander, S., *see* Engdahl, A., 349
Theophanides, T., *see* Terzis, A., 1092
Thies, C., *see* Mason, N., 847
Thomas, B. H., *see* Wong, L. T., 1064
Thompson, E. D., *see* Valentine, J. L., 96
Thompson, R. M., permethylation of barbiturates: variation in product ratios with varying methylsulfinylmethide carbanion, 288
Tin-Wa, M., Farnsworth, N. R., and Zirvi, K. A., sinoacutine from *Glaucium contortuplicatum* Boiss, 755
——*see* Chang, P. T. O., 561
Tischio, J. P., determination of salicylates by GLC, 1530
Tobin, T., *see* Abramson, H. N., 765
Tong, G. L., and Lien, E. J., biotransformation of drugs: quantitative structure–activity relationships for barbiturates, tertiary amines, and substituted imidazoles, 1651
Tong, H., *see* Skinner, W. A., 1404
Tozer, T. N., *see* Kates, R. E., 1348
Troupin, A. S., *see* Pitlick, W. H., 462
Truelove, J. E., *see* Hussain, A., 1510
Trumbull, E. R., Bianchi, E., Eckert, D. J., Wiedhopf, R. M., and Cole, J. R., tumor inhibitory agents from *Vauquelinia corymbosa* (Rosaceae), 1407
Tsou, K. C., *see* Miller, E. E., 384
Tsuji, A., *see* Yamana, T., 1563
Tsuji, K., and Robertson, J. H., analysis of tetracycline in pharmaceutical preparations by improved high-performance liquid chromatographic method, 400
Turcotte, J. G., *see* Alexander, K. S., 851
Turczan, J. W., and Medwick, T., NMR analysis of pharmaceuticals XIV: determination of amyl nitrite in its inhalant dosage form, 235
Turi, P., Dauvois, M., and Michaelis, A. F., continuous dissolution rate determination as a function of the pH of the medium, 806
Turner, C. E., Hsu, M.-F. H., Knapp, J. E., Schiff, P. L., Jr., and Slatkin, D. J., isolation of cannabisativine, an alkaloid, from *Cannabis sativa* L. root, 1084
Turner, W. A., *see* Dimmock, J. R., 538
Turner, W. R., and Lenkiewicz, R. S., polarographic determination of isosorbide dinitrate, 118

U

Udeala, O. K., *see* Attwood, D., 1053
Underwood, F. L., and Cadwallader, D. E., effects of various hydrodynamic conditions on dissolution rate determinations, 697
Uphaus, R. A., Katz, J. J., and Blake, M. I., culture of isotopically substituted plants of pharmacological importance: conservation and recycling of stable isotope substrates, 1096
Urbányi, T., Piedmont, A., Willis, E., and Manning, G., simultaneous determination of pilocarpine and isopilocarpine in pharmaceutical preparations by liquid chromatography, 257

V

Vaidya, N. K., *see* Shridhar, D. R., 1074
Valentine, J. L., Driscoll, P., Hamburg, E. L., and

Thompson, E. D., GLC determination of quinidines in human plasma, 96
——*see* Mason, W. D., 1325
Vallner, J. J., Perrin, J. H., and Wold, S., comparison of graphical and computerized methods for calculating binding parameters for two strongly bound drugs to human serum albumin, 1182
——Sternson, L. A., and Parsons, D. L., interaction of dantrolene sodium with human serum albumin, 873
Valvani, S. C., *see* Yalkowsky, S. H., 1488
Van Der Walt, L. A., *see* Buchanan, N., 914
VanGiessen, G. J., *see* Kaiser, D. G., 269
Vanhaelen, M., Vanhaelen-Fastré, R., Hoyois, J., and Mardens, Y., reinvestigation of disulfiram-like biological activity of *Coprinus atramentarius* (Bull. ex Fr.) Fr. extracts, 1774
Vanhaelen-Fastré, R., *see* Vanhaelen, M., 1774
Vaughan, D. P., and Leach, R. H., simple transformation method for predicting plasma drug profiles from dissolution rates, 601
Vessman, J., *see* Hartvig, P., 1707
Vilim, A. B., *see* Loo, J. C. K., 461
Villani, A. J., and Pfeiffer, F. R., synthesis of 1,2-dioleoyl-3-(α-^{14}C-1-adamantoyl)-*sn*-glycerol and 1-^{14}C-adamantanecarboxylic acid, 1243
Vincent, A., *see* Awang, D. V. C., 68
Visalli, A. J., Patel, D. M., and Reavey-Cantwell, N. H., GLC assay for fenclorac, 1686
Vishnupad, K. S., *see* Levinson, R. S., 1265
Volk, J., *see* Alkalay, D., 525

W

Wadke, D., *see* Gibbs, I. S., 1380
Wagner, J. G., Wilkinson, P. K., Sedman, A. J., Kay, D. R., and Weidler, D. J., elimination of alcohol from human blood, 152
——*see* Sedman, A. J., 1006
Waldman, B. A., *see* Schwarz, H. J., 370
Walker, D. M., *see* Kensler, T. T., 763
Walz, D. T., *see* Williams, D. A., 126
Ward, R. L., *see* Schoenwald, R. D., 677
Warner, A. M., and Neumeyer, J. L., synthesis and antimalarial activity of dibenz[*c,e*]azepine derivatives, 928
Warner, V. D., Lynch, D. M., and Ajemian, R. S., synthesis, physicochemical parameters, and *in vitro* evaluation of N^1-*p*-chlorophenyl-N^5-alkylbiguanides, 1070
Warren, A. T., *see* Cioffi, F. J., 1234
Warren, R. J., Zarembo, J. E., Staiger, D. B., and Post, A., quantitative NMR analysis of a four-component mixture of phenylglycine derivatives, 738
Webb, J. L., *see* Stewart, J. T., 1536
Weber, D. J., high-pressure liquid chromatographic analysis of tolbutamide in serum, 1502
Weber, J. D., single-tablet enantiomeric purity assay of amphetamine by rotation enhancement, 105
Wechter, W. J., *see* Kaiser, D. G., 269
Weddle, O. H., and Mason, W. D., rapid determination of theophylline in human plasma by high-pressure liquid chromatography, 865
——*see* Mason, W. D., 1325
Weidler, D. J., *see* Wagner, J. G., 152
Weigand, W. A., *see* Kuehn, P. B., 1593
——*see* Smolen, V. F., 1600, 1718
Weinberg, F. M., *see* Zweidinger, R. A., 427
Weinfeld, R. E., Holazo, A., and Kaplan, S. A., GLC determination of *l*-2-hydroxy-*N*-cyclopropylmethylmorphinan in plasma and urine, 1827
——*see* Dixon, W. R., 701
Weliky, I., *see* Gibbs, I. S., 1380
Wells, P. R., *see* Bulger, W. H., 109
Wessels, F. L., *see* Ellis, K. O., 1359
Wheatley, T. A., *see* Smyth, R. D., 1045
White, J. L., *see* Nail, S. L., 231, 1188, 1192, 1195, 1255, 1391
White, R. L., and Schwan, T. J., synthesis of 5-hydroxy-1-[[5-(*p*-nitrophenyl)furfurylidene]amino]-hydantoin, a metabolite of dantrolene, 135
Whitfield, L. R., *see* Kaul, P. N., 689, 694
Whyatt, P. L., Slywka, G. W. A., Melikian, A. P., and Meyer, M. C., bioavailability of 17 ampicillin products, 652
——*see* Slywka, G. W. A., 1494
Wiedhopf, R. M., *see* Trumbull, E. R., 1407
Wilham, W. L., *see* Indelicato, J. M., 1175
Wilkinson, P. K., *see* Wagner, J. G., 152
Williams, D. A., Walz, D. T., and Foye, W. O., synthesis and biological evaluation of tetrakis-(acetylsalicylato)-μ-dicopper(II), 126
Williams, M., and Cassady, J. M., potential antitumor agents: a cytotoxic cardenolide from *Coronilla varia* L., 912
Williamson, D. E., high-speed liquid chromatographic determination of canrenone in pharmaceutical dosage forms, 138
Williamson, H. E., *see* Day, D. K., 773
Willis, E., *see* Urbányi, T., 257
Wilson, D. L., *see* Midha, K. K., 1240
Wilson, R. S., *see* Yeh, H. J. C., 902
Winely, C. L., *see* Lappas, L. C., 1301
Wishousky, T., *see* Zacchei, A. G., 1770
Wittmer, D. R., *see* Korpi, J., 1087
Wivagg, R. T., Jaffe, J. M., and Colaizzi, J. L., influence of pH and route of injection on acute toxicity of tetracycline in mice, 916
Wold, S., *see* Vallner, J. J., 1182
Wolf, W., *see* Leh, F. K. V., 315
Wolstenholme, W. W., and Gautieri, R. F., effect of certain drugs in perfused human placenta XII: autacoid antagonism by phenothiazines, 1498
Wong, C. K., Cohen, D. M., and Munnelly, K. P., high-pressure liquid chromatographic determination of thiothixene in pharmaceutical formulations, 1090
Wong, L. T., Solomonraj, G., and Thomas, B. H., high-pressure liquid chromatographic determination of acetaminophen in biological fluids, 1064
Wong, S.-W., *see* Hikal, A. H., 621
Woodhead, J. H., *see* Swinyard, E. A., 733
Woodside, J. M., *see* Wyatt, D. K., 680
Wormser, H. C., and Lieu, S.-Y., fragmentation of 3-oximino-4-chromanone, 397
Wu, T. F., *see* Abramson, H. N., 765
Wu, W. L., Staba, E. J., and Blumenthal, M. N., multiliter production and immunochemical cross-reactivity of plant tissue culture antigens, 102
Wyatt, D. K., Richardson, W. G., McEwan, B., Woodside, J. M., and Grady, L. T., GLC assay of belladonna extracts, 680
Wynn, R. L., *see* Gillis, P. P., 1001

X

Y

Yacobi, A., *see* Slattery, J. T., 1710
Yakatan, G. J., Maness, D. D., Scholler, J., Novick, W. J., Jr., and Doluisio, J. T., absorption, distribution, metabolism, and excretion of furosemide in dogs and monkeys I: analytical methodology, metabolism, and urinary excretion, 1456
——*see* Han, W. W., 1198
——*see* Smith, R. B., 1208
Yalkowsky, S. H., Valvani, S. C., and Amidon, G. L., solubility of nonelectrolytes in polar solvents IV: nonpolar drugs in mixed solvents, 1488
Yamamoto, K., Nakano, M., Arita, T., Takayama, Y., and Nakai, Y., dissolution behavior and bioavailability of phenytoin from a ground mixture with microcrystalline cellulose, 1484
Yamana, T., and Tsuji, A., comparative stability of cephalosporins in aqueous solution: kinetics and mechanisms of degradation, 1563
Yap, S. K., *see* Fung, H.-L., 558
Yazdani, S., *see* Shafiee, A., 304
Yazdany, S., and Badii, F., reduction of activity of cyanocobalamin in the presence of methylparaben sodium at autoclave temperature, 745
Yeh, H. J. C., Wilson, R. S., Klee, W. A., and Jacobson, A. E., α- and β-halomorphides: stereochemistry, analgesic potency, toxicity, and interaction with narcotic receptors *in vitro,* 902
Yeh, K. C., and Higuchi, W. I., interpretation of distribution coefficients of *p*-alkylpyridines by a modified regular solution theory, 743
——and Higuchi, W. I., oil–water distribution of *p*-alkylpyridines, 80
——and Kwan, K. C., bioavailability assessment under quasi- and nonsteady-state conditions II: study designs, 512
——*see* Bondi, J. V., 1657
York, P., and Saleh, A. A. M., modification of diffusion rates of benzocaine from topical vehicles using sodium salicylate as complexing agent, 493
Yotsuyanagi, T., *see* Hwang, S., 1574
Young, J. F., *see* Nony, C. R., 1810
Young, R. L., *see* Dixon, W. R., 701
Youngdale, G. A., new compounds: synthesis of *O*-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine hydrochloride, 625
Yuan, S.-S., and Bodor, N., synthesis and activity of (*R*)-(−)-*m*-trimethylacetoxy-α-[(methylamino)methyl]benzyl alcohol hydrochloride: a prodrug form of (*R*)-(−)-phenylephrine, 929

Z

Zacchei, A. G., and Wishousky, T., GLC determination of a novel polyvalent saluretic agent, (6,7-dichloro-2-methyl-1-oxo-2-phenyl-5-indanyloxy)acetic acid, in biological fluids, 1770
Zagarella, J., *see* Chao, A. Y., 1630
Zak, S. B., *see* Lukas, G., 86
Zakhari, N. A., *see* Soliman, S. A., 424
Zalipsky, J. J., Patel, D. M., Darnowski, R. J., and Reavey-Cantwell, N. H., pKa determination of methaqualone, 460
Zarbi, I., *see* Kalatzis, E., 71
Zarembo, J. E., *see* Warren, R. J., 738
Zaroslinski, J. F., *see* Oester, Y. T., 1673
Zia, H., and Price, J. C., binding study of tetracyclines to human serum albumin using difference spectrophotometry, 226
Zirvi, K. A., *see* Tin-Wa, M., 755
Zoglio, M. A., Huber, H. E., Koehne, G., Chan, P. L., and Carstensen, J. T., physical aspects of wet granulations II: factors involved in prolonged and excessive mixing, 1205
——*see* Carstensen, J. T., 992
——*see* Streng, W. H., 1034
Zografi, G., and Tam, S. S., wettability of pharmaceutical solids: estimates of solid surface polarity, 1145
Zweidinger, R. A., Weinberg, F. M., and Handy, R. W., quantitative GLC determination of codeine in plasma, 427

SUBJECT INDEX

A

Absorbents—effect on moisture transmission through free and applied polymer films, 521
Absorption—alcohol and urea series through dog oral mucosa, radioisotope transfer, streaming potential, 129
—benzocaine from suppositories, effect of vehicle, drug concentration, and nonionic surfactants, rats, 832
corneal—pharmacokinetics, pilocarpine nitrate, rabbits, 150
GI—acetazolamide, effect of edetate disodium and reduced glutathione, rats, 677
GI—effect of alpha tocopherol deficiency, rats, 344
GI—various drugs, effect of colestipol hydrochloride, rats, 1285
intestinal—salicylic acid, effect of polysorbate 80, rats, 621
intestinal—sulfadiazine and sulfisoxazole, effect of dioctyl sodium sulfosuccinate and poloxamer 188, rats, 115
oral—digitoxin and digoxin, coprecipitates with inert solid carriers, mice, 1753
percutaneous—salicylic acid and sodium salicylate from ointment bases containing dimethyl sulfoxide, effect of nonionic surfactants, rabbits, 1780
pulmonary—substituted xanthone-2-carboxylic acids and sodium salts, intratracheal administration, solution and suspension compared, rat lungs, 1669
spectrophotometric—maximum wavelength of tetrazolium formazan, effect of varying solvents and dielectric constants of solvents, 1048
—sulfamethazine veterinary bolus tablets, various disintegrating agents evaluated *in vitro*, compared, cattle, 1823
vaginal—progesterone and hydrocortisone from silicone matrix, rabbits, 1578
vaginal—unbranched aliphatic alcohols, rabbits, 1574
Abuse drugs—systematic identification by spot tests, 774, 775
—TLC identification, spray reagents and solvent systems selected and developed, 1585
Acetaminophen—half-life and excretion rate, effect of ascorbic acid, humans, 1218
—high-pressure liquid chromatographic analysis, biological fluids, compared to radioisotope method, 1064
Acetazolamide—GI absorption, effect of edetate disodium and reduced glutathione, rats, 677
2′-Acetoxybiphenyl-2-carboxylic acid and derivatives—synthesized and evaluated for anti-inflammatory and analgesic properties and antimicrobial activity, 291
Acetylcholinesterase—inhibition by substituted pyridine carbamates compared to their partition coefficients, 910
Acid consumption—rate and extent by antacid suspensions and tablets, *in vitro* and *in vivo* evaluations compared, 1045
neutralization—by aluminum hydroxide gel, effect of aging, reactivity related to gel structure, 1255
neutralizing velocity—spray-dried agglomerated magnesium carbonate, 770, 771
Acridans—2 - chloro-2-(3-dimethylaminopropyl)-acridan phosphate converted to acridine derivative in visible light through energy transfer, 247
1-^{14}C-Adamantanecarboxylic acid—synthesized by carboxylation of 1-adamantanol using ^{14}C-sodium formate in sulfuric acid, 1243
Adenosine triphosphatase, sodium and potassium activated—effect of 3β-thiocyanato-14β-hydroxy-5β-card-20(22)-enolide evaluated, 765
Adjuvants, immunological—hydrophilic micelles containing drug molecules, polymerization, 1763
poly(methyl methacrylate)—for influenza vaccine, preparation, evaluation by hemagglutination, antibody binding, and electron microscopy, 1624
Administration route—levodopa, oral, intravenous, and hepatoportal catheter compared, bioavailability, dogs, 822
Adrenalectomy, bilateral—effect on monoamine oxidase activity, rat organs, 92
Adrenergic activity—epinephrine prodrug, screened in rabbit eye homogenate and plasma, human plasma, 1510
agents—conformationally defined analogs of amphetamine, potentiation of lavarterenol in rat vas deferens, 920
agents—epinephrine, automated fluorometric analysis in lidocaine hydrochloride injection, 1463
agents—norepinephrine, liquid scintillation spectroscopic analysis, mouse heart, 1556
agents—phenylpropanolamine, plasma, 740
agents—soterenol and mesuprine, fluorometric analysis, pharmaceutical formulations, 763
β-Adrenergic blocking agents—bufuralol, spectrofluorometric analysis in blood and urine, 1230
α-Adrenolytic activity—stereoselectivity of β-haloethylamines, rats, 544
Adsorption—butaperazine onto quartz cells, kinetics, 630
—various pharmaceuticals to montmorillonite *in vitro*, dissolution and dialysis studies, mechanism of binding, 896
Adsorptive properties—kaolin, effect of pretreatment with anionic and cationic materials, various pH values, 373
Aerosol propellants, fluorocarbon—adsorption on activated charcoal, Langmuir isotherm and Brunnauer, Emmett, and Teller equation compared, 56
fluorocarbon—dichlorotetrafluoroethane, tissue compartment distribution analysis, three-compartment open model, dogs, 60
—solubility of trichloromonofluoromethane in dog blood and tissue homogenates, 53
Aerosols—insulin zinc suspension in fluorocarbon propellant, evaluation of dose dispensed, sedimentation rate, particle-size distribution, and potency, 567
Age, rabbits—effects on ocular penetration of pilocarpine, 1095
Aggregation—antihistaminic pyridine derivatives, aqueous solution, effect of counterions on self-association, 1053
Aging—aluminum hydroxide gels, monitored by differential thermal analysis, 1391
mechanism—aluminum hydroxide gel, effect of anions, 1192
mechanism—aluminum hydroxide gel, effect of sorbitol, 1195
Albumin, human serum—binding of dicumarol and fenoprofen, comparison of graphical and computerized methods of calculation of binding parameters, 1182
human serum—binding of warfarin, effect of temperature, 1673
human serum—binding to dantrolene sodium, fluorescence quenching and difference spectrophotometry, 873
human serum—binding to tetracyclines, related to ring substituents, difference spectrophotometry, spectrophotometric probe, 226
—purified fractions, compared to bovine whole blood and plasma protein binding of salicylate and sulfathiazole, 33
Alcohol—kinetics of elimination from human blood, Michaelis–Menten equation, 152
potentiating activity—evaluated in methanolic fraction of extract of *Coprinus atramentarius* mushroom, 1774
series—absorption through oral mucosa, radioisotope transfer, streaming potential, dogs, 129
Alcohols, straight chain—solubility of 5,5-disubstituted barbiturates, 277
unbranched aliphatic—vaginal absorption, rabbits, 1574
Aldehyde oxidase—mammalian liver, oxidation of pteridine derivatives, 1150
Alkaloids, belladonna—GLC analysis in pharmaceutical formulations, suitability of anhydrous sodium sulfate in isolation, compared to official method, 680
—cannabisativine isolated from ethanol extract of roots of *Cannabis sativa*, 1084
—dicentrine, bulbocapnine, and salutaridine isolated from *Glaucium flavum* whole plant extract, 923
—flindersiamine, isoflindersiamine, and heliparvifoline isolated from *Helietta parvifolia* leaves and twigs, cytotoxicity evaluated, 561
—isolated and characterized from *Cocculus carolinus* fruit, IR, UV, NMR, and mass spectra, TLC, 132
—isolated and identified, *Sophora secundiflora* seeds, toxicity, rats, 352
—isolated from *Catharanthus trichophyllus*, screened for cytotoxic activity, 366
—isolated from *Corydalis cava*, UV, IR, PMR, and mass spectra, 294
—sinoacutine isolated from whole plant extract of *Glaucium contortuplicatum*, 755
—weak and strong UV absorbing in binary mixtures, charge-transfer spectrophotometric analysis, 986
Alkyl *p*-aminobenzoates—solubility in propylene glycol–water mixtures, 1488
Alkylpyridines—distribution between water and six organic solvents, distribution and partition coefficients, 80
—distribution coefficients interpreted, modified regular solution theory, 743
Alpha tocopherol—effect of deficiency on intestinal transport and absorption of barbital, phenolsulfonphthalein, and salicylate, rats, 344
Aluminum hydroxide gel—aging mechanism studied, effect of anions, 1192
—aging mechanism studied, effect of sorbitol, 1195
—deuteration, IR detection of development of order, 231
—differential thermal analysis, development of order during aging, 1391
—kinetics of acid neutralization, effect of aging, reactivity related to gel structure, 1255
—polymer structure of initial precipitate from reaction of aluminum chloride or sulfate with ammonium hydroxide, 1188
Amine drugs—uniformity of distribution in solid dispersions, molecular scale drug entrapment procedure, 838
hydrochlorides—pharmaceutically active substituted benzopyranopyridine, complexation with bromthymol blue, colorimetric analysis, 1543
Amines, long chain aliphatic—inhibition of *Streptococcus faecalis*, structure–activity relationships, 1525
phenylalkyl substituted—sulfur analogs of psychotomimetic agents synthesized, 1554
tertiary—*N*-oxidation, quantitative structure–activity relationships, physicochemical properties, 1651
2-Aminoacetyl-4,5-dimethoxyphenylacetate derivatives—synthesized, evaluated for local anesthetic and anti-inflammatory activity, 626
Amino acids, aliphatic—selenium substituted, synthesis of 3-[(2-aminoethyl)selenyl]alanine, potential pancreatic imaging agent, toxicological evaluation, 623
—isolated and identified, *Sophora secundiflora*

seeds, toxicity, rats, 352
p-Aminobenzoates—equilibrium solubilities of four alkyl esters in alcohols, solution thermodynamics, 252
4-Aminobenzothiazoles, mono- and dialkylated—synthesis, antimalarial activity screened, 618
p-Aminophenol—spectrophotometric analysis of Schiff base derivatives, alone or in presence of degradation products or acetaminophen, TLC separation, 71
Aminophylline tablets and capsules—theophylline content analyzed by differential spectrophotometry, 1178
8-Aminoquinolines, 5- and 6-substituted—series synthesized, screened for antimalarial activity, 1527
Amitriptyline hydrochloride—bioavailability assessment at quasi- and nonsteady state, equations derived, 1657
Amphetamine and methoxylated derivatives—interaction with NMR europium shift reagents, stereospecificity of shifting process, 412
—colorimetric analysis, optical purity assay, commercial tablets, 105
Amphetamines—conformationally defined analogs synthesized, potentiation of levarterenol in rat vas deferens, 920
N-substituted—inhibition of synaptosomal accumulation of *l*-norepinephrine, 122
Ampicillin—bioavailability of 17 products compared, 652
Amyl nitrite—NMR analysis, drug entity and inhalant dosage form, 235
α-Amyrin—isolated from *Sarracenia flava,* screened for antitumor activity, 284
Anabolic–androgenic agents—mibolerone, aqueous solutions, kinetics and mechanism of degradation, GLC evaluation, 1777
Analgesic activity—*Quercus infectoria* extracts of galls screened, mice, rats, and rabbits, 1791
agents—acetaminophen, high-pressure liquid chromatographic analysis, biological fluids, 1064
agents—2′-acetoxybiphenyl-2-carboxylic acid and derivatives synthesized and evaluated, 291
agents—methadyl acetate, TLC analysis and separation from metabolites, rat liver microsomes, 137
agents—methotrimeprazine base and sulfoxide, GLC analysis in plasma, 1329
agents—morphine, high-pressure liquid chromatographic analysis in commercial samples of paregoric, 1697
agents—potency of α- and β-halomorphides compared, 902
agents, potential—epimers of 5-hydroxy-5-phenyl-1-azabicyclo[5.4.0]undecanes synthesized and screened, 1389
agents, potential—thienopyrimidinonemercaptoacetic acids and ethyl esters screened, 660
agents—salicylamide, spectrophotometric analysis in tablets containing other drugs, 1627
agents—sodium salicylate, effect on hamster kidney cells in culture, generation time, RNA synthesis, 756
Analysis—derivative formation in GC, review, 163
—*in vivo* experimental data, different methods of interpretation compared, 243
Anesthesia, intravenous—distribution, nonlinear pharmacokinetic model described, methohexital and thiopental, 1001
Anesthetics, local—lidocaine, GLC analysis, plasma or blood, 926
local, potential—derivatives of 2-aminoacetyl-4,5-dimethoxyphenylacetate synthesized, evaluated, 626
Angiotensin—pressor actions in perfused human placenta, effects of chlorpromazine, prochlorperazine, and trifluoperazine, 1498
Anhydrotetracycline—and various metal-ion complexes, potentiometric and spectral investigation of binding properties, 1794
Aniline hydroxylase activity—effect of pregnenolone-16α-carbonitrile, male and female rats compared, 610
Anion-exchange polymers—colestipol hydrochloride, effect on GI absorption of various drugs, rats, 1285
Antacids—aluminum hydroxide gel, aging mechanism studied, 1192
—aluminum hydroxide gel, aging mechanism studied, effect of sorbitol, 1195
—aluminum hydroxide gel, kinetics of acid neutralization, effect of aging, 1255
—aluminum hydroxide gel, polymer structure of initial precipitate from reaction of aluminum chloride or sulfate with ammonium hydroxide, 1188
—suspensions and tablets, rate and extent of acid consumption, *in vitro* and *in vivo* evaluations compared, 1045
Antagonists, mescaline, potential—synthesized and screened for effect on mescaline-induced CNS stimulation, 1479
narcotic—naltrexone, pharmacokinetics, humans, monkeys, dogs, guinea pigs, rats, and mice, 712
Anthelmintic agents, potential—series of substituted benzopyranylpyridinium salts synthesized, evaluated, 616
Anthopleura xanthogrammica—sea anemone extract, cardiotonic polypeptide anthopleurin-A isolated, 1368
Anthopleurin-A—isolated from sea anemone *Anthopleura xanthogrammica* extract, 1368
9-Anthramide—electronic absorption and fluorescence spectral study, effect of solvent on molecular structure, 1833
Antiamebic drugs—5,7-dibromo- and 5,7-dichloro-8-quinolinols, complex formation with oxovanadium(IV), 1364
Antiarrhythmic agents—aprindine, GLC analysis in pharmaceutical formulations, effect of dry heat, refluxing, UV light, and varying pH on stability, 1322
agents—lidocaine, GLC analysis in blood, 608
agents—quinidine and hydroquinidine, GLC analysis in human plasma, compared to fluorometric analysis, 96
agents—quinidine pharmacokinetics and bioavailability of different dosage forms compared, 1325
agents—verapamil, fluorometric analysis, biological fluids and tissues, 431
drugs—classifications, mechanism of action, structure–activity relationships, review, 467, 635
Antibacterial activity—alkyl and polyhalophenyl esters of furancarbamic acid synthesized and screened, 1085
activity—aryloxyalkyl esters of *p*-hydroxybenzoic acid screened, 1074
agents—benzalkonium chloride, effect on cell envelope of *Pseudomonas aeruginosa,* electron microscopy study, 76
agents—cefamandole nafate, hydrolysis of formyl moiety, effect of pH, temperature, and carbonate or tromethamine concentration, 1175
agents—chloramphenicol, effect on smooth muscle relaxation, guinea pig, 704
agents—nitrofurantoin, electrochemical analysis, urine, 599
agents—penicillin, degradation in acidic media, kinetic analysis, 1165
agents, potential—series of substituted benzopyranylpyridinium salts synthesized, evaluated, 616
agents, potential—4-substituted (1,2,3-selenadiazol-5-yl)carbamic acid esters and sulfur analogs, 304
agents—sulfamethazine, sulfamerazine, and sulfathiazole, high-pressure liquid chromatographic analysis, pure solutions and cattle urine, 1606
agents—sulfisoxazole, weight variation, dissolution, and bioavailability, commercial dosage forms, 1494
agents, urinary—nitrofurantoin suspensions, dissolution–dialysis rates, 1618
Antibiotics—ampicillin, bioavailability of 17 products compared, 652
—anhydrotetracycline, complexation with various metal ions, potentiometric and spectral investigation, 1794
—cephalosporins, stability in aqueous solutions, kinetics and mechanisms of degradation, effect of pH, 1563
—cephradine, fluorometric analysis, plasma, 768
—cephradine, iodometric and spectrophotometric analyses, pharmaceutical formulations, 887
—erythromycin, intestinal secretion, rabbits, 417
—erythromycin stearate, effect of hydrochloric acid at gastric pH, commercial dosage forms, 497
polyene—mepartricin and nystatin, polymorphic forms related to toxicity, mice, 905
—tetracycline, analysis, high-performance liquid chromatography, pharmaceutical preparations, 400
—tetracycline, complexes with Ca^{+2} and Mg^{+2}, circular dichroism spectral investigation of binding properties, 1728
—tetracycline, effect of pH and route of injection on acute toxicity, mice, 916
—tetracycline, oxytetracycline, chlortetracycline, demeclocycline, polarographic analysis in pharmaceutical formulations, 1315
Anticholinergic agents—emepronium bromide, electron-capture GC analysis in human serum, elimination profile described, 1707
Anticoagulants—warfarin, binding to human serum albumin, effect of temperature, 1673
—warfarin sodium, commercial dosage forms, 1522
Anticoccidial agents, potential—series of substituted benzopyranylpyridinium salts synthesized, evaluated, 616
Anticonvulsant activity—evaluation of liver microsomal enzyme inhibitors proadifen and substituted ethylamines, rats, 1245
activity—phenothiazines, synthesized, screened, mice, 391
activity—screened in series of substituted imidazolocarbamides, mice, 1010
activity—screened in substituted thiobenzoxazoles and thiobenzothiazoles, 405
activity—*N,N′*-substituted piperazines synthesized and screened, 409
activity—various substituted anilinobenzylidenes screened, mice, 1678
agents—1-diphenylmethyl-4-(6-methyl-2-pyridylmethyleneamino)piperazine,photochromism studies, 1452
agents—phenytoin, dissolution and bioavailability, ground mixture with microcrystalline cellulose, 1484
agents—phenytoin, GLC analysis, plasma, 1240
agents, potential—thienopyrimidinonemercaptoacetic acids and ethyl esters screened, 660
agents—primidone, solid dispersion with citric acid, effect of concentration, aging, and temperature, 1613
agents—synthesis and evaluation of several thiocarbamides and thiazolidones, 443
Antidepressants—amitriptyline hydrochloride, bioavailability assessment at quasi- and nonsteady state, equations derived, 1657
—doxepin, GLC analysis, plasma, 1068
—imipramine, comparison of observed and predicted first-pass metabolism, 1063
—nortriptyline, first-pass metabolism predicted, compared to observed rates, 1535
—protriptyline, three metabolites isolated from rat urine, characterized by TLC, GLC, and GLC–mass spectrometry, 810
tricyclic—analysis, GLC–mass spectrometry (mass fragmentography), plasma, 261
tricyclic—substituted dibenz[*b,e*][1,4]oxazepine, solubility, dissolution rate, and bioavailability,

1380
Antidiabetic activity—*Quercus infectoria* extracts of galls screened, mice, rats, and rabbits, 1791
agents—chlorpropamide and tolbutamide, GLC analysis, plasma, 576
agents—chlorpropamide and tolbutamide, high-performance liquid chromatographic analysis in presence of metabolites, plasma, 1356
agents—tolbutamide, high-pressure liquid chromatographic analysis in serum, 1502
Antiemetics—bismuth subsalicylate, effect after ipecac dosing, dogs and humans, 1398
Antifungal activity—alkyl and polyhalophenyl esters of furancarbamic acid synthesized and screened, 1085
activity—aryloxyalkyl esters of *p*-hydroxybenzoic acid screened, 1074
agents—griseofulvin bioavailability, use of fractional urinary excretion data questioned, 1099
agents—griseofulvin, dissolution from dispersion in succinic acid, profile evaluated, 1212
agents—griseofulvin, GLC analysis in plasma, 370
agents, potential—series of substituted benzopyranylpyridinium salts synthesized, evaluated, 616
Antigens—proteins isolated from plant tissue cultures, allergenic activity screened, 102
Antihemolytic activity—substituted phenothiazines evaluated, 758
Antihistamine preparations—pyrrobutamine phosphate, cyclopentamine hydrochloride, and methapyrilene hydrochloride, semiautomated analyses, 1590
Antihistamines—carbon-13 magnetic resonance spectra determined using pulse Fourier transform technique, 1019
—containing the XCH_2CH_2N system, rotameric conformations in aqueous solution, 612
—diphenhydramine hydrochloride, spectrophotometric analysis, pharmaceutical formulations, 761
—pyridine derivatives, aggregation in aqueous solution, effect of counterions on self-association, 1053
Antihypertensives—bethanidine, renal clearance compared to blood levels, humans, 140
—containing the XCH_2CH_2N system, rotameric conformations in aqueous solution, 612
Anti-inflammatory activity—1 - (1-naphthylacetyl)-3-substituted carbamides evaluated, 1078
activity—*N,N'*-substituted piperazines synthesized and screened, 409
agents—2′-acetoxybiphenyl-2-carboxylic acid and derivatives synthesized and evaluated, 291
agents—benoxaprofen and four isomeric impurities, GLC and NMR analyses, 1305
agents—fenclorac, GLC analysis in pharmaceutical dosage formulations, 1686
agents—flufenamic acid, bioavailability in hard and soft gelatin capsules, dogs, humans, 455
agents—ibuprofen, GLC analysis in plasma, effect of varying solid support materials, 1710
agents—phenylbutazone, analysis, automated method, human plasma and urine, 86
agents—phenylbutazone, ionization kinetics, 1161
agents, potential—derivatives of 2-aminoacetyl-4,5-dimethoxyphenylacetate synthesized, evaluated, 626
agents, potential—synthesis and biological evaluation of aspirin–copper complex, 126
agents, potential—thienopyrimidinonemercaptoacetic acids and ethyl esters screened, 660
agents—trifluoromethyl-substituted 2,3-bis(4-methoxyphenyl)indoles, fluorometric analysis in serum, urine, and feces, 1767
Antileukemic agents—hydroxyurea, NMR spectra correlated with structural features, 585
agents, potential—alcoholic extract of *Coronilla varia* seeds, cardenolide and three coumarins isolated and screened, 912
agents, potential—constituents isolated from whole plant extract of *Tithonia tagitiflora* screened, 918
Antimalarial agents—α-(2-piperidyl)-3,6-bis(trifluoromethyl)-9-phenanthrenemethanol, salts, effect of hydrophilic counterions on aqueous solubility, 747
agents, potential—5- and 6-substituted 8-aminoquinolines synthesized and screened, 1527
agents, potential—dibenz[*c,e*]azepines synthesized and screened, 928
agents, potential—mono- and dialkylated 4-aminobenzothiazoles screened, 618
Antimicrobial activity—*N*-chloramine derivatives of α-aminoisobutyric acid and 2-amino-2-methyl-1-propanol evaluated, 1737
activity—isothiocyanate derivatives screened, 1551
activity—series of substituted dioxanes synthesized, effect of substituents evaluated, 1301
activity—substituted pyrimido[1,2-*b*]pyridazines and pyridazino[2,3-*a*]-*s*-triazines, 1505
activity—thiosulfonates synthesized and screened, 1692
agents—*N*-chloroamino acid derivatives, synthesis, kinetic stability study, 553
agents, potential—*N*-chloramine series synthesized, 1733
agents, potential—3-chloro-2-oxazolidinones screened, 1743
agents, potential—thienopyrimidinonemercaptoacetic acids and ethyl esters, screened, 660
evaluation—series of nuclear-substituted aromatic esters, compared with cyclic analogs, 38
Antinauseants—bismuth subsalicylate, effect after ipecac dosing, dogs and humans, 1398
Antineoplastic agents—methotrexate, biliary secretion, effect of probenecid, rats, 1348
agents—platinum complexes, activity related to chemical structure, review, 315
agents, potential—2-formyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine thiosemicarbazone synthesized and screened, 297
agents, potential—three saponins isolated from sea cucumbers, structures partially determined, activity evaluated, 1558
Antioxidants—efficiency, various polyhydric phenols, photooxidation of benzaldehyde, 1447
Antiproteolytic activity—1-(1-naphthylacetyl)-3-substituted carbamides evaluated, 1078
activity—substituted phenothiazones evaluated, 758
activity—*N,N'*-substituted piperazines synthesized and screened, 409
Antipyretic agents—2′-acetoxybiphenyl-2-carboxylic acid and derivatives synthesized and evaluated, 291
Antiradiation compounds, potential—series of *N*-heterocyclic aminoethyl disulfides and aminoethanethiosulfuric acids synthesized and screened, 1247
Antischistosomal agents—niridazole, preferred molecular conformation, effect on biological activity, 1704
Antitrichomonal agents—tinidazole, polarographic analysis, commercial tablets, 736
Antitubercular agents—isoniazid, high-pressure liquid chromatographic analysis in mixtures with pyridoxine hydrochloride, 1536
Antitumor activity, CNS—substituted phenothiazines synthesized, screened, 1699
activity—constituents isolated from *Sarracenia flava* screened, 284
agents, potential—alcoholic extract of *Coronilla varia* seeds, cardenolide and three coumarins isolated and screened, 912
agents, potential—1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide, hydrochloride and methiodide salts compared, mice, 631
agents, potential—microhelenin-A, isolated from *Helenium microcephalum*, NMR spectral identification, 1410
agents, potential—substituted benzylidenecyclohexanones evaluated, 538
agents, potential—uvaol, ursolic acid, and betulinic acid isolated from leaves and stems of *Vauquelinia corymbosa*, screened, 1407
drugs—floxuridine and 5-fluorodeoxyuridine-5′-(5-iodo-3-indolyl) phosphate, role of 5′-nucleotide phosphodiesterase in antitumor activity, mice, 384
Apomorphine—*N*-substituted derivatives synthesized, screened for emetic activity, stability, 1682
Aprindine—GLC analysis in pharmaceutical formulations, effect of dry heat, refluxing, UV light, and varying pH on stability, 1322
Arrhythmias—related to changes in normal transmembrane action potential and electrophysiological parameters, antiarrhythmic drugs, review, 467, 635
Ascorbic acid—effect on half-life and excretion rate of acetaminophen, humans, 1218
—stability in emulsions, evaluated by diffuse reflectance spectroscopy, 216
—stability in various tablet formulations, nature and extent of formation of decomposition products, 963
Aspirin—compressed mixtures with salicylic acid, phenacetin, or caffeine, dissolution rates compared, 1784
–copper complex—synthesis, biological evaluation, anti-inflammatory activity, physical properties, 126
—effect of formulation and dose on total salicylate concentration in rat kidney, 447
—intra- and intermolecular transformations in nonhydroxylic solvents, reaction mechanisms, 776
powder—contact angles and wetting determined by *h–ε* method, effect of particle size and porosity of cake, 840
—stability in emulsions, evaluated by diffuse reflectance spectroscopy, 216
Atropine—GLC analysis, pharmaceutical formulations of belladonna extract, 680
Attenuated total reflectance spectroscopy—measurement of effect of phthalate plasticizer on blood compatibility of polyvinyl chloride, 670
Autacoid antagonism—effects of chlorpromazine, prochlorperazine, and trifluoperazine on pressor actions of serotonin, antiotensin, and bradykinin in perfused human placenta, 1498
Automated analyses—pyrrobutamine phosphate, cyclopentamine hydrochloride, and methapyrilene hydrochioride, pharmaceutical mixtures, 1590
analyses—warfarin sodium, commercial dosage forms, 1522
analysis—dissolution rate of potassium chloride slow release tablets, 349
analysis, fluorometric—epinephrine in lidocaine hydrochloride injection, 1463
computer analysis—initial polyexponential parameter estimates for use in pharmacokinetic modeling, Fortran program, 1006
computer system—utilized for determining dissolution rate profiles of solid dosage forms, 1234
methods—analysis of phenylbutazone in human plasma and urine, 86

B

Bacillus Calmette–Guerin vaccine—mechanism of action, effect on spleen weight, neoplastic proliferation, mice, 339
Bacterial vaccine (bacterin)—determination of homogeneity of emulsified suspension of *Pasteurella avicida*, UV measurement of extracted cell contents, 433
Bactericidals, topical—chlorhexidine, gravimetric analysis, pharmaceutical formulations, 1251
Barbital—absorption and intestinal transport, alpha tocopherol-deficient rats, 344
Barbiturates—effect on NADPH oxidation, quantitative structure–activity relationships, physi-

cochemical properties, 1651
—permethylation with methylsulfinylmethide carbanion and methyl iodide, GLC separation, 288
—straight-chain and branched alkyl substituents, solubility in straight-chain alcohols, 277
BCG vaccine—mechanism of action, effect on spleen weight, neoplastic proliferation, mice, 339
Belladonna extract—GLC analysis in pharmaceutical formulations, suitability of anhydrous sodium sulfate in isolation, compared to official method, 680
Benoxaprofen—with four isomeric impurities, GLC and NMR analyses, 1305
Bentonite—colloidal dispersion, controlled flocculation of coarse suspension of bismuth subnitrate, 855
Benzaldehyde—photooxidation, antioxidant efficiency of various polyhydric phenols, 1447
Benzalkonium chloride—effect on cell envelope of *Pseudomonas aeruginosa*, electron microscope study, 76
Benzazocines, substituted—tritium labeled, used in study of *in vivo* loss of tritium, urine and plasma levels compared, 1261
Benzcoumarins—isolated from Shilajit (Indian rock exudate) and *Euphorbia royleana* plant, 772
Benzocaine—absorption and distribution from suppositories, rats, 832
—diffusion from topical vehicles, effect of sodium salicylate as complexing agent, 493
—*in vitro* release from polymer matrixes, effect of plasticizers, 1519
1,4-Benzodiazepines—kinetics and mechanism of hydrolysis evaluated by differential absorbance spectroscopy, 1198
Benzoic acid—dissolution rate, effect of varying hydrodynamic conditions by varying sizes and shapes of dissolution vessels, 697
4-substituted—*in vitro* dissolution and partitioning from nondisintegrating disks, 753
substituted—molecular orbital calculations, pharmacokinetics, structure–activity relationships, 851
Benzopyranopyridine, substituted—pharmaceutically active compound, colorimetric analysis, 1543
Benzopyranylpyridinium salts, substituted—synthesized, antibacterial, antifungal, anticoccidial, anthelmintic activities evaluated, 616
Benzylidenecyclohexanones, substituted—evaluated for antitumor and cytotoxic activity, effect on mitochondrial function in yeast, metabolism studies, 538
Benzylidenes, substituted—synthesized, screened for effect on monoamine oxidase activity and anticonvulsant properties, 1678
Bethanidine—time-dependent change in renal clearance and blood levels, humans, 140
Biguanides—conversion into substituted *s*-triazines, GC and mass fragmentographic analysis, 525
substituted—synthesized, partition coefficients and pKa values determined, ability to inhibit dental plaque screened, 1070
Bile acid–lecithin solutions—in cholesterol monohydrate dissolution rate studies, rotating-disk method, 685
Biliary excretion, impaired—effect on drug half-life and elimination, two-compartment pharmacokinetic model studied, 1346
secretion—methotrexate, effect of coadministration of probenecid, rats, 1348
Binding, drug–melanin—affinity and capacity evaluated, various sympathomimetic amines, 1057
drug–protein—warfarin to human serum albumin, effect of temperature, 1673
parameters—dicumarol and fenoprofen to human serum albumin, comparison of graphical and computerized methods of calculation, 1182
plasma protein—effect on duration and intensity of pharmacological activity of drugs, 1264
plasma protein—spirolactones, quantitatively correlated with lipophilicity, 1337
—salicylate and sulfathiazole to bovine whole blood, plasma proteins, and purified albumin fractions compared, 33
Bioassays—screening for ciguatera toxins using brine shrimp larvae, 1414
—used in development and screening of topical dosage forms, review, 1417
Bioavailability—amitriptyline hydrochloride, assessment at quasi- and nonsteady state, equations derived, 1657
—ampicillin, 17 products compared, 652
—assessment under quasi- and nonsteady-state conditions, mathematical expressions, practical alternatives in study design, 512
—chlorpromazine, evaluated by measurement of rectal temperature depression, rabbits, 1600
—flufenamic acid, hard and soft gelatin capsules, dogs, humans, 455
—griseofulvin, use of fractional urinary excretion data questioned, 1099
—levodopa, effect of route of administration, dogs, 822
—methaqualone, correlated with dissolution of tablets, 529
—nitroglycerin, stabilized compressed tablet compared to commercial products, 1466
—phenytoin, ground mixture with microcrystalline cellulose, 1484
—pilocarpine nitrate, topically applied, effect of tear turnover, instilled solution drainage, and nonproductive absorption, 1295
—predicted using flow-through-type dissolution apparatus, 1718
—prednisone and prednisolone, serum radioimmunoassay, dogs, 997
—quinidine, different dosage forms compared, 1325
—spironolactone, tablet formulations with and without hydrochlorothiazide, effect of formulation parameters, 1630
—substituted dibenz[*b,e*][1,4]oxazepine, micronized and surfactant coated compared to lyophilate with copolymer formulation, 1380
—sulfisoxazole acetyl, dicumarol, griseofulvin, effect of lipids, rats, 328
—sulfisoxazole, *in vivo* and *in vitro* evaluation, commercial dosage forms, 1494
systemic—related to chlorpromazine-induced miotic response, pharmacokinetic model, rabbits, 1593
Biological evaluation—tetrakis(acetylsalicylato)-μ-dicopper(II), anti-inflammatory activity, rats, 126
half-lives—model compounds, determined from urinary excretion and blood level data and compared, rats, 1341
Biosynthesis—deuterated riboflavin by fungus *Eremothecium ashbyii*, 362
Biotransformation, drug—quantitative structure–activity relationships for barbiturates, tertiary amines, and substituted imidazoles, physicochemical properties, 1651
—effect of ascorbic acid on half-life and excretion rate of acetaminophen, humans, 1218
4-Biphenylalkyl carboxylic acids—synthesis, effect on β-hydroxy-β-methylglutaryl coenzyme A reductase, rat liver microsomes, 1374
1-(4-Biphenylyl)pentanol—half acid ester series, synthesized, effect on rat liver β-hydroxy-β-methylglutaryl coenzyme A reductase, 548
Bis(2-ethylhexyl) phthalate—effect on chromosomes of human leukocytes and fetal lung cells, 1648
—effect on hexobarbital sleep time, role of phthalate, physical properties, mice, rats, 733
2,3-Bis(4-methoxyphenyl)indoles, trifluoromethyl substituted—fluorometric analysis, serum, urine, and feces, 1767
Bismuth subnitrate—coarse suspension, controlled flocculation by colloidally dispersed bentonite, 855
Bismuth subsalicylate—antinauseant and antiemetic properties evaluated, dogs and humans, 1398
Blood platelet aggregation—effect of Mannich bases and related compounds, rats, 482
withdrawal system—nonthrombogenic, use in measurement of total body clearance rate of sulfamethizole, dogs, 450
Boiling points—heteroatomic molecules, correlated with molecular connectivity indexes, 1806
Books
Adamantane: The Chemistry of Diamond Molecules, 934
Advances in Chromatography, Vol. 12, 934
Advances in Chromatography, Vol. 13, 934
Advances in Drug Research, Vol. 8, 162
Advances in Drug Research, Vol. 9, 162
Advances in Drug Research, Vol. 10, 934
Advances in Pharmaceutical Sciences, Vol. 4, 1711
Aliphatic Chemistry, Vol. 3, 1100
The Alkaloids, Vol. 5, 1712
Amino-acids, Peptides, and Proteins, Vol. 6, 466
Analytical Microbiology, 934
Angewandte Statistik, 162
Antibiotics and Milk, 634
Antibiotics, Vol. III, Mechanism of Action of Antimicrobial and Antitumor Agents, 633
APhA Drug Names, 1416
Les Applications Industrielles de la Microbiologie, 781
Basic Physiology for the Health Sciences, 634
Behavioral Pharmacology, 782
Beta-blockers—Present Status and Future Prospects, 1712
Biochemical Fluorescence Concepts, 634
Biochemistry and Pharmacology of Platelets, 934
Biochemistry of Antimicrobial Action, 2nd ed., 634
Biological Membranes. Their Structure and Function, 1846
Biopharmaceutics and Pharmacokinetics: An Introduction, 1846
Biosynthesis, Vol. 3, 634
Biotransformation der Arzneimittel. Eine systematische Übersicht, 634
British Pharmaceutical Codex Supplement 1976, 934
Cancer Therapy Abstracts, 1268
Carbohydrate Chemistry, Vol. 7, 634
Case Studies in Pharmacology, 934
Cell Patterning, 781
Central Cholinergic Systems and Behavior, 782
The Chemistry and Manufacture of Cosmetics, 934
Die Chemotherapeutischen und Pesticiden Wirkungen der Thiolreagenzien, 781
Chromatographic Analysis of the Environment, 634
The Ciba Foundation: An Analytic History 1949–1974, 634
Clinical Use of Combinations of Antibiotics, 934
The Clinical Uses of Levodopa, 634
Community Mental Health Journal Monograph Series, Number 9. Human Services Education and Practice: An Organic Model, 634
Contribution a la Determination de la Configuration et de la Conformation Moleculaires des Corticosteroides, 162
Controversies in Clinical Pharmacology and Drug Development, 934
Current and Future Trends in Community Psychology, 634
Current Developments in Psychopharmacology, Vol. 1, 781
Current Developments in Psychopharmacology, Vol. 2, 934
Cytochromes P-450 and b_5 Structure, Function, and Interaction. Advances in Experimental Medicine and Biology, Vol. 58, 634
Depression: Behavioral, Biochemical, Diagnostic and Treatment Concepts, 934
Detergency, Theory and Test Methods, Part II, 634
Deutzches Arzneibuch, 7. Ausgabe 1968, 634
Developments in Human Services, Vol. II, 634

Drug Action and Drug Resistance in Bacteria 2, 634
Drug and Chemical Blood Level Data, 162
Drug Design, Vol. VI, 634
Drug Disposition and Pharmacokinetics, 934
Drug Effects in Hospitalized Patients, 934
Drugs in Current Use and New Drugs, 162
Effects of Drugs on Clinical Laboratory Tests, 781
Electronic Biology and Cancer. A New Theory of Cancer, 934
Emulsions and Emulsion Technology, Part II, 161
Energy Transformations in Biological Systems. Ciba Foundation Symposium 31 (new series), 634
Environmental Chemistry, Vol. 1, 782
Europäisches Arzneibuch, Band II, 934
European Pharmacopoeia, Vol. III, 933
The Fate of Drugs in the Organism, A Bibliography Survey, Vols. 1 and 2, 633
The Filamentous Fungi, Vol. 1, Industrial Mycology, 634
Foreign Compound Metabolism in Mammals, Vol. 3, 634
Fundamentals of Clinical Pharmacokinetics, 933
The Future as an Academic Discipline, 934
The Future of Philanthropic Foundations, 782
Guidelines for Evaluation of Drugs for Use in Man. Report of a WHO Scientific Group, 634
Handbook of Enzyme Biotechnology, 634
Handbook of Experimental Pharmacology, Vol. 28, Part 3. Concepts in Biochemical Pharmacology, 634
Handbook of Experimental Pharmacology, Vol. 40, Organic Nitrates, 634
Handbook of Organosilicon Compounds, Vol. 1, 782
High-Speed Liquid Chromatography (Chromatographic Science Series Vol. 6), 1846
Hypnotics: Methods of Development and Evaluation, 934
Immobilized Enzymes, Antigens, Antibodies, and Peptides, 934
Immunity and Cancer in Man. Immunology Series, Vol. 3, 634
L'Immunotoxicologie, 934
Index Nominum 1975/76, 8th Ed., 162
Inflammation and Antiinflammatory Therapy, 934
Inhibitors of Nucleic Acid Synthesis, 781
Journal of Chromatography, Biomedical Applications, 1846
Journal of Toxicology and Environmental Health, 1268
Lecture Notes on Pharmacology, 934
Lipid Chromatographic Analysis, 2nd Ed., Vol. 1, 934
LSD—A Total Study, 781
Manual of Psychiatric Therapeutics, Practical Psychiatry and Psychopharmacology, 782
Microbial Drug Resistance, 934
Microbiology–1974, 1267
Microcrystal Polymer Science, 782
Molds, Mushrooms, and Mycotoxins, 781
Molecular Mechanisms of Gonadal Hormone Action: Advances in Sex Hormone Research, Vol. 1, 162
Neurological Complications of Oral Contraceptives, 633
Nonproprietary Names for Pharmaceutical Substances, 782
Notions de Pharmacie Galenique, 162
Official Methods of Analysis of the Association of Official Analytical Chemists, 12th Ed., 162
Ophthalmica, Pharmazeutische Grundlagen ihrer Zubereitung, Band 1, 782
The Organic Constituents of Higher Plants, 782
Organisch-Chemisches Halbmikro-Praktikum, 934
Outcome of Severe Damage to the Central Nervous System, 782
Ozone Chemistry and Technology: A Review of the Literature 1961–1974, 634
Pathogenic Microorganisms from Atypical Clinical Sources, 634
Perfumes, Cosmetics and Soaps, Vol. 2, 162
Pesticide Selectivity, 933
Pharmacie, 162
Pharmacokinetics of Hypnotic Drugs: Studies on the Pharmacokinetics and Biopharmaceutics of Barbiturates and Chloral Hydrate in Man, 934
Pharmacokinetics. Pharmacy and Related Subjects Series. Vol. 1, 1845
The Pharmacological Basis of Therapeutics, 5th Ed., 781
Pharmacology: An Introduction to Drugs, 1711
Pharmacology and Pharmacokinetics, 933
Pharmacology and Therapeutics. Part B: General and Systemic Pharmacology, 1268
Pharmacotherapy and Psychotherapy: Paradoxes, Problems and Progress, Vol. IX, 781
Pharmacy and the Law, 1845
Pharmazeutisches Taschenbuch, 934
Physical Organic Chemistry: The Fundamental Concepts, 934
Physical Pharmaceutics, 466
Principles of Pharmaceutical Marketing, 2nd Ed., 466
Problems Actuels de Biochimie Appliquee, 162
Problems of Drug Dependence 1975, Proceedings of the 37th Annual Scientific Meeting of the Committee on Problems of Drug Dependence, 162
Progress in Medicinal Chemistry, Vol. 11, 162
Progress in Medicinal Chemistry, Vol. 12, 1562
Propädeutische Arzneiformenlehre. Einfuhring in die Arzneiformenlehre und Laboratoriumspraxis, 934
Proteinase Inhibitors, Proceedings of the 2nd International Research Conference, 162
Protein-Metal Interactions, 162
Psychiatry in Broad Perspective, 782
Psychopharmacology, A Biological Approach, 782
Psychopharmacology Communications, Vol. 1, 781
Quantitative Thin Layer Chromatography, 1267
Radiological Health Training Resources, 1975, 782
Remington's Pharmaceutical Sciences, 933
Reviews of Physiology, Biochemistry and Pharmacology, 634
Selected Bibliography on Detection of Dependence-Producing Drugs in Body Fluids, 634
The Selectivity of Drugs, 781
Separation and Purification Methods, Vol. 3, 934
SI Units in Chemical Engineering and Technology, 634
Size at Birth, 781
Spektroskopische Methoden in der Pharmazie, Band I, 934
Spektroskopische Methoden in der Pharmazie, Band II, 934
The Structure and Function of Chromatin, 782
Symposium on Clinical Pharmacology, 1712
Synaptic Receptors, Isolation and Molecular Biology, 634
Terpenoids and Steroids, Vol. 5, 1416
A Textbook of Pharmaceutical Analysis, 2nd Ed., 465
The Theory and Practice of Industrial Pharmacy, 1267
Toxicology Annual 1974, 1416
The Toxicology Newsletter, Vol. 1, No. 1, 162
Toxicology Research Projects Directory, Vol. 1, No. 1, 934
Toxicology: The Basic Science of Poisons, 781
Trace Substances and Health. A Handbook, Part 1, 934
USAN and the USP Dictionary of Drug Names, 1268
Webster's Medical Speller, 1268
Weighing Designs (Statistics: Textbooks and Monographs Series, Vol. 12), 781
WHO Expert Committee on Specifications for Pharmaceutical Preparations. Twenty-Fifth Report, World Health Organization Technical Report Series No. 567, 634
Young Inner City Families: Development of Ego Strength Under Stress, 781

Boranes—synthesis of a decaboranemethionine derivative, a neutral polyhedral borane with protein-incorporating functions, potential tumor antibody-binding agent, 604

Bradykinin—pressor actions in perfused human placenta, effects of chlorpromazine, prochlorperazine, and trifluoperazine, 1498

9-Bromomethylacridine—quaternization reagent for fluorometric analysis of chlorpromazine and its sulfoxide, pharmaceutical formulations and blood levels, 689

***N*-Bromosuccinimide**—reagent for iodometric analysis of penicillins and cephalosporins, 300

Bromthymol blue—use in colorimetric analysis of pharmaceutically active substituted benzopyranopyridine, 1543

Bronchial delivery—substituted xanthone-2-carboxylic acids and sodium salts, intratracheal administration, solution and suspension compared, rat lungs, 1669

Bufuralol—spectrofluorometric analysis in blood and urine, 1230

Bulbocapnine—isolated from *Glaucium flavum* whole plant extract, 923

Bumetanide—analysis, radioimmunoassay, plasma and urine, compared to radiometric and spectrofluorometric methods, pharmacokinetic profiles, 701

Bupicomide—pharmacokinetic study by GLC analysis of fusaric acid metabolite, biological fluids, 596

Butaclamol—TLC–fluorometric analysis, human serum, 508

Butamben—controlled release from saturated solutions through silicone membrane, effect of caffeine, β-cyclodextrin, and povidone as complexing agents, 709

Butaperazine—adsorption onto quartz cells, kinetics, 630

Butyl rubber—stoppers, effect on GLC analysis of theophylline, blood, 735

3-*tert*-Butylsydnone—pharmacological and toxicological evaluation, 109

Butyrylcholinesterase—inhibition by substituted pyridine carbamates compared to their partition coefficients, 910

C

Caffeine—compressed mixtures with phenacetin or aspirin, dissolution rates compared, 1784

Calcium oxalate monohydrate—kinetics of dissolution and crystal growth, effects of various additives alone and in combination, 222

Calcium phosphate, dibasic—colored tablets, degree of mottling, effects of method and temperature of granule drying, granule size, compaction pressure, 198

—compressed tablets with varying proportions of intra- to extragranular starch, disaggregation, effect of compaction pressure, 1749

—deformation of aggregates measured during compaction, effect of pressure, granule thickness, 376

Cannabis sativa—cannabisativine isolated from ethanol extract of roots, 1084

Cannabisativine—isolated from roots of *Cannabis sativa*, 1084

Canrenone—analysis, high-speed liquid chromatography, pharmaceutical dosage forms, 138

Canscora decussata—loliolide isolated from extract of aerial parts, UV, IR, NMR, and mass spectral data, 1549

Carbamates—formed by reaction of trichloroacetyl isocyanate with corticosteroids, NMR analysis, 1214

Carbamazepine—self-induced decreases in steady-state serum concentrations, pharmacokinetic model proposed, 462

Carbamic acid esters—synthesized, screened for antifungal and antibacterial activities, 1085

Carbamides, 1-(1-naphthylacetyl)-3-substituted—synthesized, evaluated for anti-inflammatory and

antiproteolytic activity, 1078
Carbol-fuchsin solution—spectrophotometric analysis of resorcinol, effect of pH, decomposition products, 144
Carboxylic acids—apparent dissociation constants, effect of cycloamyloses, 379
Carboxymethyl carbodithioates—synthesized from 1-thioacylpiperidines, NMR spectra, TLC separation, 146
Cardenolides—hyrcanoside isolated from *Coronilla varia* seeds, cytotoxic and antileukemic activity screened, 912
Cardiotonic agents—digoxin, serum protein binding, normal and kwashiorkor serum, 914
agents, potential—3β-thiocyanato-14β-hydroxy-5β-card-20(22)-enolide synthesized and screened, 765
polypeptide—anthopleurin-A isolated from sea anemone, 1368
Cardiovascular functions—effects of dantrolene sodium, dogs and sheep, 1359
response—nitroglycerin, influence of body position, short-acting and sustained-release dosage forms, dogs, 308
Carotenoids—violaxanthin, transformation into loliolide and violoxin, 1549
Catechol—interaction with adenine, cytosine, thymine, and uracil, UV absorption studies, 892
Cathaphylline—isolated from *Catharanthus trichophyllus*, structure elucidated, cytotoxic activity screened, 366
Catharanthus alkaloids—isolation of nine alkaloids from *Catharanthus trichophyllus* roots, cytotoxic activity screened, structure elucidation of cathaphylline, 366
Cefamandole nafate—hydrolysis of formyl moiety, effect of pH, temperature, and carbonate or tromethamine concentration, 1175
Cell culture—hamster kidney cells, effect of sodium salicylate on generation and RNA synthesis, 756
Cellular respiration—effect of series of substituted imidazolocarbamides on NAD-dependent and NAD-independent oxidations, rat brain homogenates, 1010
Cellulose, microcrystalline—ground mixture with phenytoin, effect on dissolution and bioavailability, 1484
Cement, surgical—PMR analysis of methyl methacrylate monomer relative to polymer content, 280
Cephalosporin zwitterionic compounds—ionization constants calculated by combining spectrophotometric and potentiometric measurements, 1034
Cephalosporins—analysis, using *N*-bromosuccinimide, iodometric titration, 300
—stability in aqueous solutions, kinetics and mechanisms of degradation, effect of pH, 1563
Cephradine—fluorometric analysis, compared to microbiological bioassay, plasma, 768
—iodometric and spectrophotometric analyses, pharmaceutical formulations, 887
Chelating agents—edetate disodium, effect on cell envelope of *Pseudomonas aeruginosa*, electron microscope study, 76
agents—7-nitroso-8-hydroxyquinoline-5-sulfonic acid sodium salt used in colorimetric analysis of cobalt(II) in pharmaceutical formulations, 664
agents, site directed—synthesis of 2-formyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine thiosemicarbazone, potential antineoplastic agent, 297
Chiral shift reagent, europium—use in NMR determination of enantiomers of substituted isoxazolo[3,2-*b*][1,3]benzoxazin-9-one, 592
***N*-Chloramine** systems, soft—series with low chlorine potential synthesized from 2-amino-2-methyl-1-propanol, 1733
***N*-Chloramines,** soft—series with low chlorine potential, antimicrobial activity evaluated and compared, 1736
Chloramphenicol—dissolution rate, effect of crystallization in aqueous surfactant solutions, 1702
—effect on smooth muscle relaxation, guinea pig, 704
Chlordiazepoxide—kinetics and mechanisms of hydrolysis evaluated by differential absorbance spectroscopy, 1198
Chlorhexidine—gravimetric analysis, tetraphenylborate as precipitant, pharmaceutical formulations, 1251
Chlorine potentials—3-chloro-2-oxazolidinones evaluated, 1743
Chlorisondamine—effect on monoamine oxidase activity after bilateral adrenalectomy, rat organs, 92
***N*-Chloroamino acid** derivatives—synthesis, kinetic stability study, 553
2 - Chloro - 9-(3-dimethylaminopropyl)acridan phosphate—anaerobic photodecomposition to acridine derivative, 247
3-Chloro-2-oxazolidinones—antimicrobial activity screened, chlorine potentials evaluated, 1743
Chlorphenesin carbamate and β-isomer—high-pressure liquid chromatographic analysis, pharmaceutical formulations, 1802
Chlorpheniramine maleate—GLC analysis, commercial cold tablets, 924
Chlorpromazine and its sulfoxide—extraction from whole blood, fluorometric analysis, 694
and its sulfoxide—fluorometric analysis after quaternization with 9-bromomethylacridine, pharmaceutical formulations and blood levels, 689
—bioavailability and pharmacokinetics, evaluated by measurement of rectal temperature depression, rabbits, 1600
—effects on pressor actions of serotonin, angiotensin, and bradykinin in perfused human placenta, 1498
hydrochloride—effect on electrochemical behavior of flavin coenzymes, polarographic and chronopotentiometric investigation, 1758
—pharmacokinetic model relating induced miotic response to systemic bioavailability, rabbits, 1593
Chlorpropamide—GLC analysis, plasma, 576
—high-performance liquid chromatographic analysis in presence of metabolites, plasma, 1356
Chlortetracycline—polarographic analysis, pharmaceutical formulations, 1315
Cholecalciferol—high-performance liquid chromatographic analysis and separation from photochemical isomers and reaction products of provitamin, 1024
Cholesterol monohydrate—dissolution rate studies in bile acid–lecithin solutions, rotating-disk method, 685
Chromatography, reversed-phase partition—combined analyses, vitamins A, D, and E in multivitamin preparations, 968
—separation of pilocarpine and isopilocarpine in pharmaceutical preparations, 257
Chromosomes, human leukocyte and fetal lung cell—effect of incubation with bis(2-ethylhexyl) phthalate, 1648
Chronopotentiometry—investigation of effect of chlorpromazine and trifluoperazine hydrochlorides on electrochemical behavior of flavin coenzymes, 1758
Ciguatera toxins—bioassay using brine shrimp larvae, 1414
Citric acid—solid dispersion with primidone, effect of concentration, aging, and temperature, 1613
Clay adsorbents—montmorillonite, *in vitro* adsorption by various pharmaceuticals, dissolution and dialysis studies, mechanism of binding, 896
Clearance rate, total body—sulfamethizole, measured using nonthrombogenic constant blood-withdrawal system, dogs, 450
Clofibrate—microcapsules prepared, release rate studied, 1476
Clomiphene—stereochemistry of geometric isomers, structure–activity relationships, 148
Cloud point—aqueous solutions of nonionic surfactants, effect of inorganic additives, 979
CMC—nonionic surfactant solutions, effect of inorganic additives, 975
CNS activity—swertiamarin evaluated, 1547
activity—synthesis and evaluation of several thiocarbamides and thiazolidones, 443
agents—3-phenylpropylamines, GLC stability determination, 457
antitumor activity—substituted phenothiazines synthesized, screened, 1699
depressant activity—*Quercus infectoria* extracts of galls screened, mice, rats, and rabbits, 1791
stimulants—iproniazid, GLC analysis, urine, 878
stimulation, mescaline induced—effect of various mescaline antagonists evaluated, 1479
Coagulation, blood—effect of Mannich bases and related compounds, rats, 482
Cobalt(II)—colorimetric analysis, pharmaceutical formulations, 664
Cobb–Douglas production function—community pharmacies, prescription dispensing, total cost in relation to size, 204
Cobinamide—analysis by thermal decomposition of the cyano group, solid pharmaceutical preparations, 1831
Cocculus carolinus fruit—isolation and characterization of alkaloids and cyclitols, IR, UV, NMR, and mass spectra, TLC, 132
Codeine—GLC analysis, *n*-butyl chloride extraction, plasma, 427
Coenzymes, flavin—electrochemical behavior, effect of chlorpromazine and trifluoperazine hydrochlorides, 1758
Colestipol hydrochloride—effect on GI absorption of various drugs, rats, 1285
Colloidal dispersions—controlled flocculation of coarse suspensions, interaction of bismuth subnitrate with bentonite, 855
Color development—tetrazolium reaction, effect of varying solvents and dielectric constants of solvents, 1048
Colorimetry—analysis, amphetamine, commercial tablets, 105
—analysis, cobalt(II) in pharmaceutical formulations, 664
—analysis, gluaiacol *O*-methyltransferase, enzymatic activity, 1689
—analysis, niacinamide in multicomponent vitamin preparations, 65
—analysis, pharmaceutically active substituted benzopyranopyridine, 1543
—determination, hyoscyamine in mixtures, acid-dye technique, 614
—semiautomated analyses, pyrrobutamine phosphate and cyclopentamine hydrochloride, pharmaceutical mixtures, 1590
Column-confined dissolution—soluble solid into a liquid stream, equations derived, 1634
Compaction force—effect on tablet hardness, apparent density, and disintegration time, six matrixes, 1835
Compendial tests—changes in sample size, effects, 312
Complexation—effect of caffeine, β-cyclodextrin, and povidone on controlled release of butamben through silicone membrane, 709
Complexes, metal ion—Ca^{+2} and Mg^{+2} with tetracycline, circular dichroism spectral investigation of binding properties, 1728
metal ion, various—with anhydrotetracycline, potentiometric and spectral investigation of binding properties, 1794
platinum—antineoplastic activity related to chemical structure, biological and toxicological effects, methods of preparation, mechanism of action, pharmacokinetics, review, 315
Complex formation—adenine, cytosine, thymine, and uracil, with catechol, UV absorption studies, 892
—adenine, thymine, and uracil, with epinephrine, UV absorption studies, 982
—effect on diffusion of benzocaine from topical vehicles, sodium salicylate as complexing agent, 493
—oxovanadium(IV) and substituted 8-quinolinols,

spectrophotometric study in various solvents, 1364
Computerized automated system—utilized for determining dissolution rate profiles of solid dosage forms, 1234
Computer programs, Fortran—calculation of initial polyexponential estimates for use in pharmacokinetic modeling, 1006
Conformational constraints, intramolecular—2-substituted cyclohexanone phenylhydrazones, effect of ordered solvent structure, 1639
Conjugation—steric inhibition in 9-anthramide, effect of solvent, electronic absorption and fluorescence spectral study, 1833
Contact angles—pharmaceutical powders, determined by h–ϵ method, effect of particle size and porosity of cake, 843
Containers, glass—surface, effects of sulfur, ammonium bifluoride, and sulfuric acid treatments, scanning electron micrographs, 22
pharmaceutical—unit-dose packages, heat seals examined by calorimetry, IR spetroscopy, and thermomechanical analysis, 628
Contraceptives—progesterone, metabolism, mechanism of action, effects, toxicity, review, 783
Copolymers—methyl acrylate–methyl methacrylate copolymer tablets, simultaneous release of noninteracting drug–excipient mixtures, 1333
Copper–aspirin complex—synthesis, biological evaluation, anti-inflammatory activity, physical properties, 126
Coprecipitates—digitoxin and digoxin with inert solid carriers, dissolution and oral absorption, mice, 1753
Coprinus atramentarius—mushroom crude extract, aqueous fraction isolated, biological activity evaluated, 1774
Corneal drug absorption—pharmacokinetics, pilocarpine nitrate, rabbits, 150
penetration mechanism—pilocarpine, rate and extent of accumulation in aqueous humor and various cell layers, rabbits, 1816
Coronilla varia—seeds, alcoholic extract, cardenolide and three coumarins isolated and identified, cytotoxic and antileukemic activity screened, 912
Corticosteroids—NMR analysis of carbamates formed by reaction with trichloroacetyl isocyanate, 1214
Corydalis cava—alkaloids isolated, UV, IR, PMR, and mass spectra, 294
Cosmetics—formulation and technology, microbiological contamination, 1975 literature review, 935, 1101
Cosolvent systems, polar—solubility of nonelectrolytes, molecular and group surface area approach, 1488
Coumarin—spectrophotofluorometric analysis, alone and with umbelliferone, whole blood, 30
Coumarins—isolated from alcoholic extract of *Coronilla varia* seeds, cytotoxic and antileukemic activity screened, 912
substituted—high-resolution mass spectra, mode of fragmentation, structural interpretation, 1028
Counterions—effect on self-association of antihistaminic pyridine derivatives in aqueous solution, 1053
hydrophilic—effect on aqueous solubility of substituted phenanthrenemethanol antimalarial agent, 747
Creatinine—effect on aqueous solubility of nitrofurantoin, varying temperature and pH, 868
Crystal growth—calcium oxalate monohydrate, kinetics, effects of various additives alone and in combination, 222
systems, various—nonspherical particles, isotropic dissolution, equations derived, 1437
Cupric-ion-promoted hydrolysis—dicarboxylic acid hemiesters, effect of micellar sodium lauryl sulfate on rate, 1713
Cyanocobalamin—activity, effect of methylparaben sodium, autoclave temperature, pharmaceutical formulations, 745
—analysis by thermal decomposition of the cyano group, solid pharmaceutical preparations, 1831
Cyclazocine—injectable microcapsules, *in vivo* and *in vitro* release evaluated, 847
Cyclitols—isolation and characterization from *Cocculus carolinus* fruit, 132
Cyclization reaction kinetics—2-substituted cyclohexanone phenylhydrazones, effect of ordered solvent structure, 1639
Cycloamyloses—effect on apparent dissociation constants of carboxylic acids and phenols, stability constants for complex formation, 379
Cyclobenzaprine—GLC analysis, plasma and urine, 1253
metabolites—six isolated from rat urine, TLC, GLC, and mass spectral identification, 815
Cyclohexanone phenylhydrazones, 2-substituted—cyclization reaction kinetics, effect of ordered solvent structure on microenvironmental orientation and intramolecular conformational constraints, 1639
Cyclomethycaine—*in vitro* release from polymer matrixes, effect of plasticizers, 1519
Cyclopentamine hydrochloride—semiautomated colorimetric analysis, pharmaceutical mixtures, 1590
Cysteines, *N*-(*N*-substituted thiocarbamoyl)—synthesized and screened for antimicrobial activity, 1551
Cytochrome P-450 activity—effect of pregnenolone-16α-carbonitrile, male and female rats compared, 610
Cytotoxic activity—evaluated in three saponins isolated from sea cucumbers, 1558
agents, potential—substituted benzylidenecyclohexanones evaluated, 538
compounds—alcoholic extract of *Coronilla varia* seeds, cytotoxic and antileukemic activity screened, 912
Cytotoxicity—alkaloids from leaves and twigs of *Helietta parvifolia* isolated, evaluated, 561
—nine alkaloids isolated from *Catharanthus trichophyllus* screened, 366

D

Dantrolene metabolite—synthesis and structural elucidation of 5-hydroxyl-1-[[5-(*p*-nitrophenyl)furfurylidene]amino]hydantoin, 135
sodium—binding to human serum albumin, fluorescence quenching and difference spectrophotometry, interaction with cationic, anionic, and nonionic surfactants, 873
sodium—effects on respiratory and cardiovascular functions, dogs and sheep, 1359
Decomposition products, ascorbic acid—various tablet formulations, nature and extent of formation, 963
Degradation—cephalosporins in aqueous solutions, kinetics and mechanisms, effect of pH, 1563
—penicillin in acidic media, kinetic analysis, monitored by high-pressure liquid chromatography and UV spectroscopy, effect of temperature, buffer concentration, and ionic strength, 1165
Delivery devices—polymeric, hydrophilic implants, subcutaneous release of norgestomet, 488
Delmadinone acetate—pellet implants, *in vivo* dissolution profile, rats, 89
Demeclocycline—polarographic analysis, pharmaceutical formulations, 1315
6-Demethylgriseofulvin—griseofulvin metabolite, liquid–solid chromatographic analysis, urine, 441
Demoxepam—kinetics and mechanisms of hydrolysis evaluated by differential absorbance spectroscopy, 1198
Densities—alkanes, aliphatic alcohols, and carboxylic acids correlated with molecular connectivity, 1226
Density, apparent—six tablet matrixes, effect of various compaction forces, 1835
Dental plaque inhibitors, potential—series of substituted biguanides synthesized and screened, 1070
Derivatization—GC, methodologies, applications in analysis of pharmaceutical compounds, review, 163
Desmethylretinoic acid and vinylogs—wound-healing mechanism of action, effect on granuloma formation, 580
Detergents, nonionic—effect on activity of L-glutamic acid dehydrogenase, 1799
Deuteration—aluminum hydroxide gels, related to age of gel, 231
Dexamethasone acetate—structural and conformational features, effect of pretreatment on pharmacological action, plasma concentrations, and liver homogenate metabolism of zoxazolamine, rats, 1092
Diazepam—permeation through polydimethylsiloxane membranes, effect of excipients, 207
Dibenz[*c,e*]azepine derivatives—synthesis, antimalarial activity, 928
Dibenz[*b,e*][1,4]oxazepine, substituted—solubility, dissolution rate, and bioavailability, micronized and surfactant coated compared to lyophilate with copolymer formulation, 1380
Dicarboxylic acid hemiesters—cupric-ion-promoted hydrolysis, effect of micellar sodium lauryl sulfate on rate, 1713
Dicentrine—isolated from *Glaucium flavum* whole plant extract, 923
Dichlorodifluoromethane—adsorption on activated charcoal, isotherms compared, 56
Dichlorotetrafluoroethane—adsorption on activated charcoal, isotherms compared, 56
—tissue compartment distribution analysis, three-compartment open model, dogs, 60
Dicumarol—binding to human serum albumin, comparison of graphical and computerized methods of calculation of binding parameters, 1182
—effect of lipids on bioavailability, rats, 328
Dielectric constants—aqueous solutions of various tetramethyldicarboxamides, correlated with solubilizing properties, 1645
—solvents in tetrazolium reaction, effect on rate of color development and wavelength of maximum absorption, 1048
Difference spectrophotometry—study of binding of dantrolene sodium to human serum albumin, 873
—study of binding of tetracyclines to human serum albumin, 226
Differential absorbance spectroscopy—evaluation of kinetics and mechanisms of hydrolysis of chlordiazepoxide and demoxepam, 1198
Differential thermal analysis—aging of aluminum hydroxide gels monitored, 1391
Diffusion coefficients—determined in automated continuous-flow system, gerbil sebaceous pad, 727
—concentric right circular cylinders and concentric spheres, models for drug release from tubular devices, cylindrical systems, and vaginal or GI lumen, 154
flow cell—description, continuous monitoring of skin permeability *in vitro*, 210
—progesterone through rate-controlling membrane (polyethylene capsule), programmed release rate, cosolvent system, 648
—three-compartment apparatus developed, evaluated, and compared to other methods, synthetic membranes and isolated biological tissues studied using salicylamide, 564
Digestive enzymes—pepsin, mechanism of inhibition by dioctyl sodium sulfosuccinate, 1319
Digitoxin—coprecipitates with inert solid carriers, dissolution and oral absorption, mice, 1753
Digoxin—absorption, different methods of data interpretation, averaged pharmacological response data compared to simulated data with averaged parameters, 243
—coprecipitates with inert solid carriers, dissolution and oral absorption, mice, 1753
—serum protein binding, normal and kwashiorkor serum, 914
3′,4′-Dihydroseselins, 3′,4′-disubstituted—high-resolution mass spectra, mode of fragmentation, structural interpretation, 1028
Dimethyl polysiloxane—coatings, NMR analysis,

590
Dimethyl sulfoxide—effect on growth and permeability of human skin *in vitro*, diffusion flow monitoring cell described, 210
Dinoprost and dinoprostone—derivatives formed during *in vitro* incubation with prostaglandin 15-dehydrogenase, high-performance liquid chromatographic analysis, 1609
—high-pressure liquid chromatographic analysis of 15-epimer in bulk drug, 673
Dinoprostone—free acid and carbamoylmethyl ester, relative aqueous stabilities, effect of pH, 1844
Dioctyl sodium sulfosuccinate—effect on dissolution and intestinal absorption of sulfadiazine and sulfisoxazole, rats, 115
—mechanism of inhibition of pepsin activity, 1319
—rheopexic dispersions, formation of micelles, 1265
1,2 - Dioleoyl-3-(α-^{14}C-1-adamantoyl)-*sn*-glycerol—pancreatic lipase inhibitor, synthesized, 1243
Dioxanes, substituted—series synthesized, effect of substituents on antimicrobial activity, 1301
Diphenhydramine hydrochloride—spectrophotometric analysis, color complex with dipicrylamine, pharmaceutical formulations, 761
1,2-Diphenylvinyl compounds, substituted—various, stereochemistry of geometric isomers determined, literature correction, 1545
Dipicrylamine—color complex formation for spectrophotometric analysis of diphenhydramine hydrochloride, pharmaceutical formulations, 761
1,2-Di(4-piperazine-2,6-dione)propane—solubilization of enantiomers compared to racemate, potential use in intravenous formulations, 238
Disaggregation—compressed tablets of dibasic calcium phosphate, with varying proportions of intra- to extragranular starch, effect of compaction pressure, 1749
Disintegrating agents—intra- and extragranular, effect on particle size of disintegrated tablets, 1170
various—in veterinary bolus tablets, evaluated using dissolution testing apparatus, compared to *in vivo* absorption, cattle, 1823
Disintegration time—hard gelatin capsules *in vivo*, monitored by external scintigraphy, 1412
time, tablet—effect of various ratios of starch disintegrant to starch paste and various compression forces, 1694
time, tablet—six matrixes, effect of various compaction forces, 1835
Dispersions, rheopexic—dioctyl sodium sulfosuccinate, formation of micelles, 1265
solid—amine drugs, uniformity of distribution, molecular scale entrapment procedure, flocculated and deflocculated systems, 838
—solutions in porous media, gravimetric vapor pressure measurement, analysis of nonequilibrium and background effects, 1269
systems, solid—evaluation of dissolution profile of griseofulvin–succinic acid eutectic mixture system, effect of particle size, 1212
Disposition, drug—pharmacokinetic models, errors in instantaneous intravascular input assumptions, two- and three-compartment open models, 750
Dissociation constants, apparent—carboxylic acids and phenols, effect of cycloamyloses, complex formation, 379
Dissolution—calcium oxalate monohydrate, kinetics, effects of various additives alone and in combination, 222
—compressed two-component mixtures, rate correlated with composition, 1784
—delmadinone acetate pellet implants, effect of compression pressure, rats, 89
–dialysis rates—nitrofurantoin suspensions, effect of three viscosity grades of methylcellulose, 1618
—digitoxin and digoxin, coprecipitates with inert solid carriers, mice, 1753
drug—flow-through-type apparatus described, used to predict *in vivo* bioavailability, 1718
—griseofulvin from dispersion in succinic acid, profile evaluated, effect of particle size, 1212
isotropic—nonspherical particles, six crystal systems, equations derived, 1437
—methaqualone tablets, correlated with bioavailability, 529
—methylcellulose-coated tablets, effect of thermal gelation, 572
—model system, multisized drug powders, compared to other models, 1042
—nitroglycerin sublingual tablets, polarographic determination, 1691
—phenytoin, ground mixture with microcrystalline cellulose, 1484
—potassium chloride, a nondisintegrating hydrophilic solid, effect of hydrophobic coating materials, 182
rate analysis—potassium chloride slow release tablets, automated system, 349
rate—benzoic acid, effect of varying hydrodynamic conditions by varying sizes and shapes of dissolution vessels, 697
rate—cholesterol monohydrate in bile acid–lecithin solutions, rotating-disk method, 685
rate—timed-release tablets, continuous determination as a function of pH, 806
rate—wet granulations, effect of prolonged and excessive mixing, 1205
rates—chloramphenicol, sulfathiazole, prednisone, effect of crystallization in aqueous surfactant solutions, 1702
rates—solid nondisintegrating disk (potassium chloride), apparatus described, effect of solvent flow Reynolds number, 48
rates—sulfathiazole–povidone coprecipitates, compared to supercooled melt and crystalline forms of sulfathiazole, thermodynamic parameters, 355
rates—transformation factor described for prediction of plasma drug profiles, 601
—solid dosage forms, rate profiles determined using computerized automated system, 1234
—soluble solid in a column into a liquid stream, equations derived, 1634
—spironolactone tablet formulations with and without hydrochlorothiazide, effect of formulation parameters, 1630
—4-substituted benzoic acids, nondisintegrating disks, *in vitro*, 753
—sulfadiazine and sulfisoxazole, effect of dioctyl sodium sulfosuccinate and poloxamer 188, 115
—sulfathiazole polymorphs, effect of polyethylene glycol 4000, 302
tablet—effect of storage at various temperatures and humidity, 1746
testing apparatus—designed for veterinary bolus tablets, various disintegrating agents evaluated, compared to *in vivo* absorption, cattle, 1823
—tolbutamide, three single-particle models evaluated and compared, mathematical analysis, 1442
—USP test, sulfisoxazole, commercial dosage forms, 1494
Distribution—benzocaine from suppositories, effect of vehicle, drug concentration, and nonionic surfactants, rats, 832
coefficients—alkylpyridines, interpreted by modified regular solution theory, 743
coefficients—*p*-alkylpyridines, water and six organic solvents, effect of methylene group, 80
drug—intravenous anesthesia, nonlinear pharmacokinetic model described, 1001
drug—simultaneous determination in blood, organs, and tissues, pharmacokinetic model, demonstrated with thiopental in dogs, 717
kinetics—wetting during process of making tablet granulations, 992
tissue—naltrexone, mice, 712
tissue—studied, adamantyl-substituted organophosphorus compounds, 439
uniformity—amine drugs in solid dispersions studied, molecular scale entrapment procedure, effect of milling or particle-size fractionation, 838
volume—comparison of instantaneous input assumption and short-term zero-order infusion, tissue compartments, various drugs, 1541
volume—volume terms in pharmacokinetic modeling, single definition proposed as a function of time, 452
Disulfides, *N*-heterocyclic aminoethyl—series synthesized and screened for antiradiation activity, 1247
Diterpenes—isolated from aboveground portion of *Stemodia maritima*, PMR, IR, mass, and circular dichroism spectral identification, 778
Diuretic agents—bumetanide, analysis, radioimmunoassay, plasma and urine, pharmacokinetic profiles, 701
—furosemide, TLC analysis, urine, dogs and monkeys, 1456
—hydroflumethiazide, spectrofluorometric analysis, plasma and urine, 1208
—polythiazide, high-pressure liquid chromatographic analysis in pharmaceutical dosage forms, 1413
—spironolactone, dissolution and bioavailability, tablet formulations with and without hydrochlorothiazide, 1630
Dosage forms—aerosol, insulin zinc suspension in fluorocarbon propellant, evaluation of dose dispensed, sedimentation rate, particle-size distribution, and insulin potency, 567
—commercial cold tablets, simultaneous GLC analysis of chlorpheniramine maleate and phenylpropanolamine hydrochloride, 924
—compressed tablets, dibasic calcium phosphate with varying proportions of intra- to extragranular starch, disaggregation, effect of compaction pressure, 1749
—digitoxin and digoxin coprecipitates with inert solid carriers, dissolution and oral absorption, mice, 1753
—direct compression tablets, size, hardness, and dissolution, effect of storage at various temperatures and humidity, 1746
—injectable microcapsules, *in vivo* and *in vitro* release of cyclazocine evaluated, 847
—microcapsules, clofibrate, preparation described, release rate studied, 1476
—multicomponent analgesic tablets, spectrophotometric analysis of salicylamide, 1627
—nitroglycerin tablets, solutions dispersed in porous media, gravimetric vapor pressure measurement, 1269
—nitroglycerin tablets, vapor pressure, intertablet migration, effect of additives, 1278
—phenytoin and microcrystalline cellulose ground mixture, dissolution and bioavailability, compared to fine powder, 1484
solid—dissolution of methaqualone tablets correlated with bioavailability, 529
solid—tablets and capsules, dissolution rate profiles determined using computerized automated system, 1234
—solutions and suspensions of substituted xanthone-2-carboxylic acids and sodium salts, pulmonary absorption, rat lungs, 1669
—stabilized compressed nitroglycerin tablets prepared, bioavailability and stability compared to commercial products, 1466
—sublingual nitroglycerin tablets containing povidone, formulation and processing variables investigated, 558
—suppositories, absorption and distribution of benzocaine, rats, 832
—tablet granulations, distribution kinetics of wetting during preparation, 992
—tablet lubricants, effect on ejectability and tablet hardness, comparison of mixing and incorporation methods of formulation, 1155
—tablets, capsules, solutions, and intramuscular quinidine, pharmacokinetics and bioavailability compared, 1325
—tablets, disintegration time, hardness, effect of various ratios of starch disintegrant to starch paste and various compression forces, 1694
—tablets, effect of gelatin binder solution concentrations on starch paste granulations and

tableting characteristics, 313
—tablets, effect of intra- and extragranular disintegrating agents on particle size, 1170
—tablets, effect of mixing time, speed, and binder dilution on physical properties of tablets, 1559
—tablets, effect of starch paste viscosity on granule hardness and physical properties of tablets, 1561
—tablets, effects of five different film coatings on tablet hardness, 1291
—tablets, methylcellulose coated, effect of thermal gelation on dissolution, 572
—tablets, six matrixes, effect of various compaction forces on hardness, apparent density, and disintegration time, 1835
—tablets, spironolactone with and without hydrochlorothiazide, dissolution and bioavailability, effect of formulation parameters, 1630
—tablets, suspensions, emulsions, suppositories, aerosols, controlled-release devices, 1975 literature review, 935, 1101
—tablets, wet granulation preparation, fluoride content, effect of processing, dyes, flavors, citric acid, and lubricants, 932
—terminology regarding labeled and contained amounts, definitions suggested for the terms shelflife, outdate, expiration date, label date, 311
—time-released tablets, dissolution rate, continuous determination as a function of pH, 806
topical—development and screening, use of bioassays, review, 1417
Doxepin—GLC analysis of *cis*- and *trans*-isomers and desmethyl metabolite, plasma, 1068
Drug biotransformation interactions—effect of ascorbic acid on half-life and excretion rate of acetaminophen, humans, 1218
delivery systems—controlled release of butamben from saturated solutions through silicone membrane, effect of caffeine, β-cyclodextrin, and povidone as complexing agents, 709
delivery systems—progesterone diffusion through rate-controlling membrane (polyethylene capsule), 648
delivery, vaginal—*in situ* absorption of unbranched aliphatic alcohols, rabbits, 1574
delivery, vaginal—progesterone and hydrocortisone release from silicone matrix vaginal absorption, rabbits, 1578
disposition—bioavailability assessment under quasi- and nonsteady-state conditions, mathematical expressions, practical alternatives in study design, 512
disposition—two-compartment open model, equation derived for time required for constancy of drug fraction in Compartment 1, 1140
of abuse—systematic identification using spot tests, 774, 775
of abuse—TLC identification, spray reagents and solvent systems selected and developed, 1585
–protein binding—dantrolene sodium to human serum albumin, 873
–receptor interactions—β-haloethylamines, stereoselectivity of α-adrenolytic activity studied, rats, 544
release—controlled, norgestomet from hydrophilic polymeric delivery devices, 488
release—from methyl acrylate–methyl methacrylate copolymer tablets, effect of water-soluble excipients, 1333
release—*in vitro* from polymer matrixes, effect of plasticizers, 1519
release tests—flow-through-type dissolution apparatus described, used to predict *in vivo* bioavailability, 1718
release time—hard gelatin capsules *in vivo*, monitored by external scintigraphy, 1412
release—tubular devices, cylindrical systems, and vaginal or GI lumen, concentric right circular cylinders and concentric spheres as models, 154

E

Edetate disodium—effect on cell envelope of *Pseudomonas aeruginosa*, electron microscopy study, 76
—effect on GI absorption of acetazolamide, rats, 677
Editorials
A Challenge to the Drug Industry (June)
Dissecting the Labyrinth (September)
Dissolution Test Blossoms (April)
An "Equal Opportunity" Journal (January)
In the Name of Liberty (August)
The Lesson from Kepone (February)
Passing the Baton at FDA (November)
The Price of a "Free Press" (May)
Research in the Future (October)
Scientific Research Freedom (December)
Self-serving Trade Secrets (July)
The Sum of Its Parts (March)
Electrochemical analysis—nitrofurantoin, urine, compared to colorimetric analysis, 599
behavior—flavin coenzymes, effect of chlorpromazine and trifluoperazine hydrochlorides, 1758
Electrochemistry—of drug action, electrochemical reduction and biochemical properties of ferredoxins studied using ac polarography, 1471
Electrolytes—effect on Krafft and cloud points of aqueous solutions of nonionic surfactants, 979
—effect on self-association of antihistaminic pyridine derivatives in aqueous solution, 1053
Electrophoretic mobility—kaolin, effect of pretreatment with anionic and cationic materials, various pH values, 373
Electroreduction—ferredoxins, studied using ac polarography, effect of pH, 1471
Elimination, drug—effect of cholestasis, two-compartment pharmacokinetic model studied, 1346
kinetics—alcohol from human blood, Michaelis–Menten equation, 152
phase data—model compounds, urinary and blood level data compared, rats, 1341
profile—emepronium bromide, electron-capture GC analysis in human serum, 1707
—renal and GI, fluphenazine enanthate and decanoate esters, dogs, 502
Ellagic acid—isolated from shilajit (Indian rock exudate) and *Euphorbia royleana* plant, 772
Emepronium bromide—electron-capture GC analysis in human serum, elimination profile described, 1707
Emetic activity—*N*-substituted derivatives of apomorphine screened, 1682
Emphysema, papain induced—lung changes evaluated by infiltration with vinyl acetate to form casts, rats, 1082
Emulsions—phase inversion temperature correlated with kinetics of globule coalescence, long-term stability measured, polyoxyethylene alkyl ether as stabilizer, 517
—system stability and stability of incorporated drugs, evaluated by diffuse reflectance spectroscopy, compared to visible coalescence and particle counter techniques, 216
Enantiomers—β-haloethylamines, synthesis, stereoselectivity of α-adrenolytic activity studied, rats, 544
—β-hydroxynorleucine, separation, comparison of biological activity, 534
—ibuprofen, isomeric inversion determined by characterization of major urinary metabolites, 269
—physical properties compared to racemic substance, potential use in pharmaceutical formulations, 238
—substituted isoxazolo[3,2-*b*][1,3]benzoxazin-9-one, NMR determination using europium chiral shift reagent, 592
Enthalpy—hydrogen bonding between various psychotropic drugs with phenol, IR and NMR spectral measurement, related to differences in activity, 1066
Enzyme activity—effect of thiocarbamides and thiazolidones on NAD-dependent oxidation, 443
activity—L-glutamic acid dehydrogenase, effect of various nonionic detergents, 1799
activity—guaiacol *O*-methyltransferase, colorimetric analysis, 1689
inhibitors, liver microsomal—proadifen and two substituted ethylamines screened for anticonvulsant activity, rats, 1245
Enzymes—acetylcholinesterase and butyrylcholinesterase, inhibition by substituted pyridine carbamates compared to their partition coefficients, 910
—β-hydroxy-β-methylglutaryl coenzyme A reductase, effect of 4-biphenylylalkyl carboxylic acids, rat liver microsomes, 1374
—β-hydroxy-β-methylglutaryl coenzyme A reductase, inhibition by series of arylalkenyl and arylepoxy hydrogen succinates and glutarates, 724
—mammalian liver xanthine oxidase and aldehyde oxidase, oxidation of pteridine derivatives, 1150
—monoamine oxidase, deamination of tyramine and tryptamine, effect of 4-methoxyphenethylamine and *N*-methylated homologs, 1539
Epinephrine—automated fluorometric analysis in lidocaine hydrochloride injection, 1463
—interaction with adenine, thymine, and uracil UV absorption studies, 982
prodrug—synthesized, screened for adrenergic activity, rabbit eye homogenate and plasma, human plasma, 1510
Ergocalciferol—high-performance liquid chromatographic analysis and separation from photochemical isomers and reaction products of provitamin, 1024
Ergosterol—isolated from *Parmelia caperata*, UV, IR, and mass spectral data, 737
Erythromycin—intestinal secretion, rabbit midjejunal segments, 417
stearate—effect of hydrochloric acid at gastric pH, commercial dosage forms, 497
Esters, aromatic—nuclear substituted, preparation, IR, NMR, and mass spectra, comparison of antimicrobial activity with related cyclic analogs, 38
Ethylcellulose films—*in vitro* drug release, effect of plasticizers, 1519
1 - Ethyl - 3-(3′-dimethylaminopropyl)carbodiimide—hydrochloride and methiodide salts, antitumor activity compared, mice, 631
Ethylestrenol—effect on toxicity of parathion and paraoxon, compared to norbolethone and spironolactone, rats, 595
Etoxadrol hydrochloride—IR spectra, solid-state anomalies, 1400
Euphorbia royleana plant—chemical constituents determined, compared to extracts of shilajit (Indian rock exudate), 772
Europium—chiral shift reagent, use in NMR determination of enantiomers of substituted isoxazolo[3,2-*b*][1,3]benzoxazin-9-one, 592
—NMR shift reagents, interaction with amphetamines and methoxylated derivatives, 412
Excretion—fluphenazine base, enanthate, and decanoate, comparison of slow-release characteristics, effect of route of administration, dogs, 1310
—furosemide, TLC analysis, urine, dogs and monkeys, 1456
rate—data used in deriving pharmacokinetic models for estimating *in vivo* skin permeability coefficients, 1396
renal—sulfamethizole, pharmacokinetic analysis, 463
urinary—probenecid and metabolites, effect of dose, 861
urinary—rate of clearance of bethanidine, compared to blood levels, humans, 140
urinary—tetraethylammonium bromide, effect of stress and pretreatment with steroids, rats, 1838

F

Fenclorac—GLC analysis, pharmaceutical dosage formulations, 1686
Fenoprofen—binding to human serum albumin, comparison of graphical and computerized methods of calculation of binding parameters, 1182
Ferredoxins—electrochemical reduction and biochemical properties studied using ac polarography, 1471
Film coatings—five different, effects on tablet hardness, 1291
Filtration rate—pharmaceutical suspensions, sulfamerazine, correlation with ratio of final to initial suspension settling height, 420
Fish toxins—ciguatera, bioassay using brine shrimp larvae, 1414
Flavin coenzymes—electrochemical behavior, effect of chlorpromazine and trifluoperazine hydrochlorides, 1758
Flocculation, controlled—coarse suspensions by colloidally dispersed solids, interaction of bismuth subnitrate with bentonite, 855
Floxuridine—role of 5′-nucleotide phosphodiesterase in antitumor activity, mice, 384
Flufenamic acid—bioavailability, hard and soft gelatin capsules, dogs, humans, 455
Fluorescence quenching—study of binding of dantrolene sodium to human serum albumin, 873
Fluoride—content in tablets prepared by wet granulation method, effect of processing, dyes, flavors, citric acid, and lubricants, 932
Fluorocarbon aerosol propellants—adsorption on activated charcoal, Langmuir isotherm and Brunauer, Emmett, and Teller equation compared, 56
aerosol propellants—dichlorotetrafluoroethane, tissue compartment, distribution analysis, three-compartment open model, dogs, 60
aerosol propellants—solubility of trichloromonofluoromethane in dog blood and tissue homogenates, 53
5-Fluorodeoxyuridine-5′-(5-iodo-3-indolyl) phosphate—role of 5′-nucleotide phosphodiesterase in antitumor activity, mice, 384
Fluorometry—analysis, automated, epinephrine in lidocaine hydrochloride injection, 1463
—analysis, cephradine in plasma, 768
—analysis, chlorpromazine and its sulfoxide after extraction from whole blood, 694
—analysis, chlorpromazine and its sulfoxide, pharmaceutical formulations and blood levels, 689
—analysis, hydralazine in dosage forms, 274
—analysis, trifluoromethyl-substituted 2,3-bis-(4-methoxyphenyl)indoles in serum, urine, and feces, 1767
—analysis, verapamil, biological fluids and tissues, 431
–TLC—analysis, butaclamol in human serum 508
Fluphenazine—base, enanthate, and decanoate esters, comparison of slow-release characteristics, effect of route of administration, dogs, 1310
—enanthate and decanoate esters, rates of release and elimination in urine and feces, dogs, 502
Foil packages—heat seals, relationship of sealing temperature to incidence of defective packages, vacuum–dye, seal strength, and pressurized ammonia vapor tests for defects, 1061
2-Formyl - 3 - hydroxy-4,5-bis(hydroxymethyl)-pyridine thiosemicarbazone—synthesized, screened for antineoplastic activity, 297
Fourier transform technique—carbon-13 magnetic resonance spectra of various antihistamines, 1019
Fragmentation—Beckmann rearrangement of 3-oximino-4-chromanone after acylating, 397
Fungi—*Fusarium oxysporum* cultured, trichothecenes isolated, phytotoxic and dermatitic properties evaluated, 160
Furancarbamic acid esters—synthesized, screened for antifungal and antibacterial activities, 1085
Furosemide and metabolite—TLC analysis, urine, dogs and monkeys, 1456
Fusaric acid—active metabolite of bupicomide, GLC analysis, biological fluids, 596
Fusarium oxysporum—cultured, trichothecenes isolated, phytotoxic and dermatitic properties evaluated, 160

G

Ganglionic blocking agents—tetraethylammonium bromide, toxicity and urinary excretion, effect of stress and pretreatment with steroids, rats, 1838
Gastric acid inactivation—erythromycin stearate, effect of hydrochloric acid at gastric pH, commercial dosage forms, 497
GC—analysis, *s*-triazines synthesized from biguanides, 525
—derivatization methodologies, applications in analysis of pharmaceutical compounds, review, 163
electron capture—analysis, emepronium bromide in human serum, 1707
Gelatin capsules—hard and soft, effect on bioavailability of flufenamic acid, dogs, humans, 455
capsules, hard—disintegration and drug release times *in vivo* monitored by external scintigraphy using technetium Tc 99m, 1412
Gels—aluminum hydroxide, aging mechanism studied, effect of anions, 1192
—aluminum hydroxide, aging mechanism studied, effect of sorbitol, 1195
aluminum hydroxide—differential thermal analysis, development of order during aging, 1391
—aluminum hydroxide, kinetics of acid neutralization, reactivity related to gel structure, 1255
—aluminum hydroxide, polymer structure of initial precipitate from reaction of aluminum chloride or sulfate with ammonium hydroxide, 1188
Gentianaceae—*Swertia chirata,* CNS activity of swertiamarin evaluated, 1547
Geometric isomers—various substituted 1,2-diphenylvinyl compounds, stereochemistry determined, literature correction, 1545
Germacranolides—six new tagitinins isolated from whole plant extract of *Tithonia tagitiflora,* screened for antileukemic activity, 918
Girard reagent T—reaction with hydrocortisone, separation from prednisolone, plasma, 461
Glass—ampuls and vials, internal surface, effect of sulfur, ammonium bifluoride, and sulfuric acid treatments, scanning electron micrographs, 22
Glaucium contortuplicatum—phytochemical investigation, whole plant extract, sinoacutine isolated, 755
Glaucium flavum—dried whole plant extract, dicentrine, bulbocapnine, and salutaridine isolated and identified, 923
GLC—analysis, aprindine in pharmaceutical formulations, 1322
—analysis, belladonna alkaloids, pharmaceutical formulations, 680
—analysis, benoxaprofen and isomeric impurities, 1305
—analysis, chlorpropamide and tolbutamide, plasma, 576
—analysis, codeine in plasma, 427
—analysis, cyclobenzaprine, plasma and urine, 1253
—analysis, (6,7-dichloro-2-methyl-1-oxo-2-phenyl-5-indanyloxy)acetic acid in biological fluids, 1770
—analysis, fenclorac in pharmaceutical dosage formulations, 1686
—analysis, fusaric acid (active metabolite of bupicomide), biological fluids, 596
—analysis, griseofulvin in plasma, compared to spectrofluorometric method, 370
—analysis, *l*-2-hydroxy-*N*-cyclopropylmethylmorphinan in human plasma and urine, 1827
—analysis, ibuprofen in plasma, effect of varying solid support materials, 1710
—analysis, iproniazid in urine, 878
—analysis, *cis*- and *trans*-isomers and desmethyl metabolite of doxepin, plasma, 1068
—analysis, lidocaine and monoethylglycinexylidide (major metabolite), blood, 608
—analysis, lidocaine, plasma or blood, 926
—analysis, methotrimeprazine base and sulfoxide, plasma, 1329
—analysis, 3,4-methylenedioxyamphetamine and 4-methoxyamphetamine, plasma and urine, human, dog, 188
—analysis, nylidrin in urine, 1352
—analysis, phenprocoumon in plasma, phenytoin as internal standard, 387
—analysis, phenylpropanolamine, plasma, 740
—analysis, pilocarpine, biological fluids, 1724
—analysis, pilocarpine, rabbit aqueous humor, 1262
—analysis, pyrithyldione in putrified brain and intestine, 1393
—analysis, quinidine and hydroquinidine in human plasma, compared to fluorometric method, 96
—analysis, salicylic acid, different silylating reagents and different reaction vessels compared, 1530
—analysis, simultaneous, chlorpheniramine maleate and phenylpropanolamine hydrochloride, commercial cold tablets, 924
—analysis, sodium cyclopentylsulfamate and metabolites, rat and rabbit urine, 1841
—analysis, theophylline in blood, effect of butyl rubber stoppers, 735
—analysis, thioridazine, mesoridazine, metabolites, and seven phenothiazine derivatives, plasma, 667
derivatization reagent—synthesis of *O*-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine hydrochloride, 625
—determination, permethylation, barbiturate derivatives, 288
electron capture—analysis, 2,4,5-trichlorophenoxyacetic acid, mouse blood, urine, and feces, 1810
—evaluation, kinetics and mechanism of degradation of mibolerone aqueous solutions, 1777
–mass spectrometry—analysis, tricyclic antidepressants, plasma, 261
—simultaneous analysis, phenytoin and major metabolite, plasma, 1240
—stability determination, 3-phenylpropylamines, CNS agents, 457
Glucocorticoids—dexamethasone acetate and pregnenolone-16α-carbonitrile, structural features, prophylactic activity against zoxazolamine, rats, 1092
—hydrocortisone base and phosphate, simultaneous high-pressure liquid chromatographic analysis, 1087
—prednisone and prednisolone, serum radioimmunoassay, dogs, 997
—^{14}C-triamcinolone acetonide, synthesis, aqueous solubility determined, radioisotopic method, 429
Glucuronides—hydroxyphenylalkylaminoethanol-type drugs, mass spectral analysis, 1513
L-Glutamic acid dehydrogenase—effect of various nonionic detergents on activity, 1799
Glutarates, arylalkenyl and arylepoxy—substituted series, synthesis, effect on β-hydroxy-β-methylglutaryl coenzyme A reductase, 724
Glutathione, reduced—effect on GI absorption of acetazolamide, rats, 677
Glutethimide—solubility assessed using dielectric constants of aqueous solutions of various tetramethyldicarboxamides, 1645
Granulations, starch paste—effect of gelatin binder solution concentrations, tableting characteristics, 313
starch paste—effect of mixing time, speed, and binder dilution on physical properties of tablets, 1559
starch paste—effect of starch paste viscosity on granule hardness and physical properties of

tablets, 1561
tablet—distribution kinetics of wetting during preparation, 992
wet—physical aspects, effect of prolonged and excessive mixing, 1205
Granules—consolidation during compaction, dibasic calcium phosphate aggregate deformation measured, effect of pressure, granule thickness, 376
Granuloma formation—effect of desmethylretinoic acid and vinylogs, 580
Gravimetry—analysis, chlorhexidine in pharmaceutical formulations, tetraphenylborate as precipitant, 1251
Griseofulvin—bioavailability, use of fractional urinary excretion data questioned, 1099
—dissolution from dispersion in succinic acid, profile evaluated, effect of particle size, 1212
—effect of lipids on bioavailability, rats, 328
—GLC analysis in plasma, compared to spectrofluorometric method, 370
metabolite—6-demethylgriseofulvin, liquid–solid chromatographic analysis, urine, 441
Guaiacol *O*-methyltransferase—colorimetric analysis of enzymatic activity, 1689
Guanethidine—rotameric conformations in aqueous solution, 612
Guanoclor—rotameric conformations in aqueous solution, 612

H

***N*-Halo derivatives**—low chlorine potential, soft *N*-chloramines, antimicrobial activity evaluated and compared, 1737
—series of low chlorine potential, soft *N*-chloramines synthesized from 2-amino-2-methyl-1-propanol, 1733
—synthesis of *N*-chloroamino acid derivatives, kinetic stability study, 553
β-Haloethylamines, chiral—synthesis, stereoselectivity of α-adrenolytic activity studied, rats, 544
Halomorphides, α and β—NMR determination of configuration of halogen or C-ring, analgesic potencies, toxicity, interaction with narcotic receptors studied, 902
Hardness, granule—effect of prolonged and excessive mixing, 1205
tablet—effect of storage at various temperatures and humidity, 1746
tablet—effect of various ratios of starch disintegrant to starch paste and various compression forces, 1694
tablet—effects of five different film coatings, 1291
tablet—six matrixes, effect of various compaction forces, 1835
testers, tablet—motorized pendulum type, method for checking calibration and determining accuracy and precision, three testers compared, 1072
Helenium microcephalum—microhelenin-A, potential antitumor agent, isolated and identified, 1410
Helietta parvifolia—leaves and twigs, alkaloids isolated, cytotoxicity evaluated, 561
Hepatotoxic agents—carbon tetrachloride, screened for anticonvulsant activity, rats, 1245
Herbicides—2,4,5-trichlorophenoxyacetic acid, electron-capture GLC and radiochemical analyses, mouse blood, urine, and feces, 1810
Heteroatomic molecules—molecular connectivity indexes calculated, correlated with boiling points and molar refractions, 1806
Heterocycles—substituted pyrimido[1,2-*b*]pyridazines and pyridazino[2,3-*a*]-*s*-triazines synthesized, screened for antimicrobial activity, 1505
Hexobarbital—sleep time, effect of bis(2-ethylhexyl) phthalate, mice, rats, 733
Hexyl *p*-aminobenzoate—solubility in mixed polar solvent systems, 1488
High-performance liquid chromatography—analysis and separation, ergocalciferol or cholecalciferol, 1024
—analysis, chlorpropamide or tolbutamide in presence of metabolites, plasma, 1356
—analysis, 15-methylprostaglandin E_2 and methyl ester, separation from C-15-epimers, 1533
—analysis, prostaglandins formed during *in vitro* incubation with prostaglandin 15-dehydrogenase, 1609
—analysis, tetracycline in pharmaceutical preparations, 400
High-pressure liquid chromatography—analysis, acetaminophen, biological fluids, compared to radioisotope method, 1064
—analysis, chlorphenesin carbamate and β-isomer in pharmaceutical formulations, 1802
—analysis, dinoprost and its 15-epimer, 673
—analysis, isoniazid and pyridoxine hydrochloride in mixtures, 1536
—analysis, morphine in commercial samples of paregoric, 1697
—analysis, phenol and resorcinol, pharmaceutical dosage forms, 1706
—analysis, polythiazide in pharmaceutical dosage forms, 1413
—analysis, sulfamethazine, sulfamerazine, sulfathiazole, and acetyl derivatives, pure solutions and cattle urine, 1606
—analysis, theophylline, plasma, 865
—analysis, thiothixene, pharmaceutical formulations, 1090
—analysis, tolbutamide in serum, 1502
—reversed-phase, ion-pairing approach, simultaneous analysis, hydrocortisone base and phosphate, prepared samples and injectable solutions, 1087
—used to monitor degradation of penicillin in acidic media, kinetic analysis, 1165
High-speed liquid chromatography—analysis, canrenone, pharmaceutical dosage forms, 138
—analysis, procaine, pharmaceutical preparations, 606
Histamine—19 analogs synthesized, biological actions compared, blood pressure, gastric secretion, and nasal decongestant screens, 98
L-Histidine—IR spectra, solid-state anomalies, 1400
Hormones—progesterone, production, metabolism, mechanism of action, effects, clinical use, toxicity, review, 783
Hydralazine—fluorometric analysis, dosage forms, 274
Hydrocarbons, saturated—solvents for testosterone propionate and related esters, 656
Hydrochlorothiazide—effect on dissolution and bioavailability of spironolactone in tablet formulations, 1630
Hydrocortisone—base and phosphate, simultaneous high-pressure liquid chromatographic analysis, prepared samples and injectable solutions, 1087
—reaction with Girard reagent T, separation from prednisolone, plasma, 461
—release from silicone matrix, vaginal absorption, rabbits, 1578
Hydrodynamic conditions—effect on dissolution rate of benzoic acid by varying sizes and shapes of dissolution vessels, 697
Hydroflumethiazide—spectrofluorometric analysis, plasma and urine, 1208
Hydrogen bonding—various psychotropic drugs with phenol, IR and NMR spectral measurement, related to differences in activity, 1066
Hydrolysis—cefamandole nafate formyl moiety, effect of pH, temperature, and carbonate or tromethamine concentration, 1175
—chlordiazepoxide and demoxepam, kinetics and mechanisms, evaluated by differential absorbance spectroscopy, 1198
cupric ion promoted—dicarboxylic acid hemiesters, effect of micellar sodium lauryl sulfate on rate, 1713
enzymatic—isomers of β-hydroxynorleucine compared, 534
—oximes to ketones, synthesis of 1,2-indandione, 134
Hydrophobicity—correlated with 5-hydroxytryptamine uptake by thrombocytes, 1014
Hydroquinidine—GLC analysis in human plasma, compared to fluorometric analysis, 96
Hydroxocobalamin—analysis by thermal decomposition of the cyano group, solid pharmaceutical preparations, 1831
***p*-Hydroxybenzoic acid**—aryloxyalkyl esters synthesized and screened for antibacterial and antifungal activity *in vitro*, 1074
***l*-2-Hydroxy-*N*-cyclopropylmethylmorphinan**—GLC analysis, human plasma and urine, 1827
6-Hydroxydopamine—effect on monoamine oxidase activity after bilateral adrenalectomy, rat organs, 92
β-Hydroxy-β-methylglutaryl coenzyme A reductase—effect of 4-biphenylylalkyl carboxylic acids, rat liver microsomes, 1374
—rat liver, effect of half acid esters of 1-(4-biphenylyl)pentanol, 548
5-Hydroxy-1-[[5-(*p*-nitrophenyl)furfurylidene]-amino]hydantoin—dantrolene metabolite, synthesis and structural elucidation, 135
β-Hydroxynorleucine—isomers separated, *N*-chloroacetyl derivatives prepared, enzymatic hydrolysis and microbiological growth inhibitory activity of isomers compared, 534
Hydroxyphenylalkylaminoethanols—mass spectral analysis of glucuronides, 1513
5-Hydroxy-5-phenyl-1-azabicyclo[5.4.0]undecanes epimers—synthesized, analgesic activity evaluated, 1389
5-Hydroxytryptamine—uptake by thrombocytes correlated with structure–activity, quantum chemical, and hydrophobicity factors, effect of various tryptamine derivatives, 1014
Hydroxyurea and substituted hydroxyureas—NMR spectra correlated with structural features, solvent-dependent differences observed, 585
Hyoscyamine—colorimetric determination using acid-dye technique, mixtures containing belladonna or hyoscyamus tincture, 614
—GLC analysis, pharmaceutical formulations of belladonna extract, 680
Hypocholesterolemic agents—clofibrate, microcapsules, preparation described, release rate studied, 1476
potential—4-biphenylylalkyl carboxylic acids synthesized, effect on β-hydroxy-β-methylglutaryl coenzyme A reductase, rat liver microsomes, 1374
potential—series of arylalkenyl and arylepoxy hydrogen succinates and glutarates, synthesis, effect of β-hydroxy-β-methylglutaryl coenzyme A reductase, 724
—series of half acid esters of 1-(4-biphenylyl)-pentanol synthesized, effect on rat liver β-hydroxy-β-methylglutaryl coenzyme A reductase, 548
Hypoglycemic agents, oral—GC and mass fragmentographic analysis, *s*-triazines, 525
Hypotensive agents, potential—substituted pyrrolo[1,2-*a*][1,3]diazepine screened, rats, 908

I

Ibuprofen—GLC analysis in plasma, effect of varying solid support materials, 1710
—isomeric inversion of enantiomers, determined by characterization of major urinary metabolites, 269
Imidazole derivatives—synthesis of 19 histamine analogs, structure–activity relationships, 98
Imidazoles, substituted—effect on epoxidation of aldrin, quantitative structure–activity relationships, physicochemical properties, 1651
Imidazolocarbamides, substituted—synthesized, screened for anticonvulsant activity, effect on cellular respiratory activity, 1010
Imipramine—comparison of observed and predicted first-pass metabolism, 1063
Immunological adjuvants—hydrophilic micelles containing drug molecules, polymerization, 1763
Implants—delmadinone acetate pellets, effect of compression pressure on *in vivo* dissolution profile, rats, 89

—hydrophilic, subcutaneous release of norgestomet, 488
1,2-Indandione—synthesis by hydrolysis of 2-oximino-1-indanone, 134
Indanyloxyacetic acid, substituted—GLC analysis, biological fluids, 1770
Influenza vaccines—preparation of poly(methyl methacrylate) adjuvants, evaluation by hemagglutination, antibody binding, and electron microscopy, 1624
Inhibitors, pancreatic lipase—1,2-dioleoyl-3-(α-^{14}C-1-adamantoyl)-*sn*-glycerol synthesized, 1423
Injection route—subcutaneous *versus* intraperitoneal, effect on acute toxicity of tetracycline, mice, 916
Inorganic additives—effect on CMC and surface properties, nonionic surfactant solutions, 975
—effect on Krafft and cloud points of aqueous solutions of nonionic surfactants, 979
Instrumentation—in pharmaceutical technology, 1975 literature review, 935, 1101
Insulin zinc—aerosol dosage form, evaluation of dose dispensed, sedimentation rate, particle-size distribution, and insulin potency, 567
Interactions, drug biotransformation—effect of ascorbic acid on half-life and excretion rate of acetaminophen, humans, 1218
—prednisone and salicylate, dogs, 773
Intestinal secretion—erythromycin, rabbit midjejunal segments, 417
Intravenous input assumption, instantaneous—compared to short-term zero-order infusion, volume of distribution calculations, various drugs, 1541
Iodometry—analysis, cephradine, pharmaceutical formulations, 887
Ionization constants—cephalosporin zwitterionic compounds, calculated by combining spectrophotometric and potentiometric measurements, 1034
kinetics—phenylbutazone, relative concentrations and pKa's of enol and diketo forms calculated, effect of acids and bases, 1161
Ion-pairing—application to high-pressure liquid chromatography, simultaneous analysis of hydrocortisone base and phosphate, 1087
Iproniazid—GLC analysis, urine, 878
Iron(II)-bathophenanthroline chelate—ion associations with sulfa drugs, used in preparation of electrodes for potentiometric analysis of sulfa drugs, 435
IR spectroscopy—characterization of thiohydantoins and thiobarbiturates, 1258
—detection of development of order in deuterated aluminum hydroxide gels, 231
—solid-state anomalies, lysine monohydrochloride, etoxadrol hydrochloride, thiamine hydrochloride, and L-histidine, 1400
Isomeric inversion—ibuprofen enantiomers, determined by characterization of major urinary metabolites, 269
Isomers, geometric—various substituted 1,2-diphenylvinyl compounds, stereochemistry determined, literature correction, 1545
Isoniazid—high-pressure liquid chromatographic analysis in mixtures with pyridoxine hydrochloride, 1536
Isopilocarpine—chromatographic separation and UV analysis, pharmaceutical preparations, in presence of pilocarpine, compared to USP methods, 257
Isoquinolines, substituted—synthesized, effectiveness as topical mosquito repellents evaluated, 1404
Isosorbide dinitrate—polarographic analysis, compared to IR and automated colorimetric methods, six commercial formulations, 118
Isothiocyanate derivatives—synthesized and screened for antimicrobial activity, 1551
Isotopes, stable—^{2}H- and ^{13}C-substituted tobacco plants cultured, sealed growth chambers, isotope substrates conserved and recycled, 1096
Isotropic dissolution—nonspherical particles, six crystal systems, equations derived, 1437
Isoxazoles, tri- and tetramethylene—synthesized by condensation of 1,4-dianions with esters followed by acid cyclization, 1408

J

K

Kaolin—electrophoretic mobility and adsorptive properties, effect of pretreatment with anionic and cationic materials, various pH values, 373
Keratolytic agents—resorcinol, high-pressure liquid chromatographic analysis, pharmaceutical dosage forms, 1706
—salicylic acid, GLC analysis, 1530
Ketoses—structural functions related to sweetness, 1222
Kinetics, distribution—wetting during process of making tablet granulations, 992
Krafft point—aqueous solutions of nonionic surfactants, effect of inorganic additives, 979

L

Lacrimal fluids—human, normal and irritant induced, binding of sulfisoxazole to protein fractions, 437
Levarterenol—potentiation by conformationally defined analogs of amphetamine, rat vas deferens, 920
Levodopa—bioavailability, effect of route of administration, oral, intravenous, and hepatoportal catheter compared, dogs, 822
melanin—affinity and capacity of drug binding evaluated, various sympathomimetic amines, 1057
Lichens—*Parmelia caperata,* isolation of pinastric acid and ergosterol, UV, IR, and mass spectral data, 737
Lidocaine—GLC analysis in blood, 608
—GLC analysis, plasma or blood, 926
hydrochloride—injection solution, automated fluorometric analysis of epinephrine content, 1463
Linear regression methods—both variables measured subject to error, equations derived, 1562
Lipid–protein interactions—L-glutamic acid dehydrogenase activity, effect of various nonionic detergents, 1799
Lipids—effect on bioavailability of sulfisoxazole acetyl, dicumarol, and griseofulvin, rats, 328
Lipophilicity—spirolactones, correlated quantitatively with plasma protein binding, 1337
Liquid–solid chromatography—analysis, 6-demethylgriseofulvin, urine, 441
Literature review—pharmaceutical sciences, 1975, 935, 1101
Lolilolide—isolated from *Canscora decussata* aerial parts, transformation from violaxanthin, UV, IR, NMR, and mass spectral data, 1549
Lubricants, tablet—effect on ejectability and tablet hardness, comparison of mixing and incorporation methods of formulation, 1155
Lung infiltration—vinyl acetate, casts formed, papain induced emphysematous changes evaluated, rats, 1082
Lupeol—isolated from *Sarracenia flava,* screened for antitumor activity, 284
Lysine monohydrochloride—IR spectra, solid-state anomalies, 1400

M

Magnesium carbonate, agglomerated—spray dried, acid-neutralizing velocity, 770, 771
Magnetic resonance spectroscopy, carbon-13—various antihistamines, spectra determined using pulse Fourier transform technique, 1019
Malnutritic serum—digoxin binding, compared to normal serum, 914
Mangiferin—CNS activity, effect of swertiamarin, 1547
Mannich bases—effect on mitochondrial function in yeast, human epidermoid carcinoma cultures, blood platelet aggregation, blood clotting, rats, 482
Maritimol—isolated from *Stemodia maritima,* PMR, IR, mass, and circular dichroism spectral identification, 778
Mass fragmentography—analysis, *s*-triazines synthesized from biguanides, 525
—analysis, tricyclic antidepressants, plasma, 261
Mass spectrometry—analysis, glucuronides from sympathomimetic hydroxyphenylalkylaminoethanols, 1513
—determination of products of phenylbutazone degradation by oxidation and hydrolysis, 68
—structure elucidation of biosynthesized deuterated riboflavin, 362
Mass spectroscopy, high resolution—3′,4′-disubstituted 3′,4′-dihydroseselins, mode of fragmentation, structural interpretation, 1028
Medazepam—pKa determination, spectrophotometric and solubility methods compared, 1094
Melanin, synthetic—prepared by action of mushroom tyrosinase on levodopa, affinity and capacity of drug binding evaluated, various sympathomimetic amines, 1057
Melting-point diagrams—solid solution systems, consistency relations, 158
Membrane permeation—controlled release of butamben from saturated solutions through silicone membrane, effect of caffeine, β-cyclodextrin, and povidone as complexing agents, 709
—diazepam through polydimethylsiloxane, effect of excipients, 207
Membranes, biological—everted rat small intestine, effect of sodium alkyl sulfates on release of protein, 1460
natural—gerbil sebaceous pad in automated continuous-flow system, diffusion coefficients, 727
rate controlling—polyethylene capsule, progesterone diffusion, 648
Mepartricin—polymorphic forms related to toxicity, mice, 905
Mescaline antagonists, potential—synthesized and screened for effect on mescaline-induced CNS stimulation, 1479
Mesoionic compounds—substituted pyrimido[1,2-*b*]pyridazines and pyridazino[2,3-*a*]-*s*-triazines series synthesized, antimicrobial activity screened, 1505
Mesoridazine and metabolites—GLC analysis, plasma, 667
Mesuprine—fluorometric analysis after trihydroxyindole reaction, pharmaceutical formulations, 763
Metabolism, drug—quantitative structure–activity relationships for barbiturates, tertiary amines, and substituted imidazoles, 1651
first pass—imipramine, comparison of observed and predicted values, 1063
first pass—nortriptyline, predicted using plasma flow rates, compared to observed rates, 1535
—probenecid, urinary excretion as a function of dose, 861
—progesterone, biosynthesis, concentration in body fluids and tissues, review, 783
saturable first pass—sulfisoxazole acetyl, rats, 334
Metabolites, cyclobenzaprine—six isolated from rat urine, TLC, GLC, and mass spectral identification, 815
—protriptyline, isolated from rat urine, characterized by TLC, GLC, and GLC–mass spectrometry, 810
Metal-ion complexes—Ca^{+2} and Mg^{+2} with tetracycline, circular dichroism spectral investigation of binding properties, 1728
various—with anhydrotetracycline, potentiometric and spectral investigation of binding properties, 1794
Methadyl acetate—TLC analysis, metabolism by rat liver microsomal preparations, 137
Methanesulfonanilides—trihydroxyindole reaction applied, fluorometric analysis of soterenol and mesuprine, 763
Methapyrilene hydrochloride—*in vitro* release from

polymer matrixes, effect of plasticizers, 1519
—release from methyl acrylate–methyl methacrylate copolymer tablets, effect of water-soluble excipients, 1333
—semiautomated UV spectrophotometric analysis, pharmaceutical mixtures, 1590
Methaqualone—solid dosage forms, dissolution rate correlated with bioavailability, 529
—spectrophotometric pKa determination, 460
Methionine analog—synthesis of a neutral polyhedral borane with protein-incorporating functions, potential tumor antibody-binding agent, 604
Methotrexate—biliary secretion, effect of coadministration of probenecid, rats, 1348
Methotrimeprazine—base and sulfoxide, GLC analysis, plasma, 1329
4-Methoxyamphetamine—GLC analysis, mass spectrum, plasma and urine, human, dog, 188
4-Methoxyphenethylamine and *N*-methylated homologs—effect on monoamine oxidase-catalyzed deamination of tyramine and tryptamine, 1539
Methylacrylate–methylmethacrylate copolymer—tablets, simultaneous release of noninteracting drug–excipient mixtures, 1333
Methylation, enzymatic—guaiacol *O*-methyltransferase, colorimetric analysis, 1689
Methylcellulose—tablet coating, effect of thermal gelation on dissolution, 572
—three viscosity grades, effect on dissolution–dialysis rates of nitrofurantoin suspensions, 1618
3,4-Methylenedioxyamphetamine—GLC analysis, mass spectrum, plasma and urine, human, dog, 188
Methyl methacrylate—PMR analysis, ratio of monomer to polymer content, surgical acrylic cement, 280
Methylparaben sodium—effect on cyanocobalamin activity, autoclave temperature, pharmaceutical formulations, 745
15-Methylprostaglandin E_2 and methyl ester—high-performance liquid chromatographic analysis and separation from C-15-epimers, 1533
Metronidazole—polarographic analysis, biological fluids, 112
Mibolerone—aqueous solutions, kinetics and mechanism of degradation, GLC evaluation, 1777
Micelles—formation in rheopexic dispersions of dioctyl sodium sulfosuccinate, 1265
—formation, solubilization of naphthalene in aqueous sodium cholate solutions compared to sodium decanesulfonate, method for study of self-association, 882
hydrophilic—containing drug molecules, polymerization, use as immunological adjuvants, 1763
Micellization—sodium lauryl sulfate, effect on rate of cupric-ion-promoted hydrolysis of dicarboxylic acid hemiesters, 1713
Microbiological assay—growth inhibitory activity of isomers of β-hydroxynorleucine compared, 534
Microcapsules—clofibrate, preparation described, release rate studied, 1476
injectable—*in vivo* and *in vitro* release of cyclazocine evaluated, 847
Microhelenin-A—potential antitumor agent, isolated from *Helenium microcephalum*, NMR spectral identification, 1410
Miotic response—chlorpromazine induced, related to systemic bioavailability, pharmacokinetic model, rabbits, 1593
Mitochondrial activity—effect of Mannich bases and related compounds, yeast, 482
—substituted benzylidenecyclohexanones evaluated, yeast, 538
Models, pharmacokinetic—equation derived for the time required for constancy of drug fraction in Compartment 1, effect of absorption and elimination rate constants, 1140
Molar refractions—heteroatomic molecules, correlated with molecular connectivity indexes, 1806
Molecular connectivity—correlated with other topological indexes, molecular surface areas, and aqueous solubilities, various monofunctional compounds, 801
connectivity—expanded series, correlated with densities of alkanes, aliphatic alcohols, and carboxylic acids, 1226
connectivity—heteroatomic molecules, correlated with boiling points and molar refractions, 1806
orbital calculations—preferred conformations of niridazole and derivative, 1704
scale drug entrapment—utilized to prepare solid dispersions of amine drugs, uniformity of distribution studied, 838
structure—9-anthramide, effect of solvent, electronic absorption and fluorescence spectral study, 1833
Monoamine oxidase—activity, effect of bilateral adrenalectomy, 6-hydroxydopamine, chlorisondamine, rat organs, 92
activity—effect of various substituted anilinobenzylidenes, rat brain homogenate, 1678
activity—screened in substituted thiobenzoxazoles and thiobenzothiazoles, 405
—deamination of tyramine and tryptamine, effect of 4-methoxyphenethylamine and *N*-methylated homologs, 1539
inhibitors—iproniazid, GLC analysis, urine, 878
Monoethylglycinexylidide—major metabolite of lidocaine, GLC analysis, blood, 608
Montmorillonite—*in vitro* adsorption by various pharmaceuticals, dissolution and dialysis studies, mechanism of binding, 896
Morphinan, substituted—*l*-2-hydroxy-*N*-cyclopropylmethylmorphinan, GLC analysis in human plasma and urine, 1827
Morphine—high-pressure liquid chromatographic analysis in commercial samples of paregoric, 1697
Mottling—colored tablets, effects of method and temperature of granule drying, granule size, compaction pressure, 198
—surface of colored tablets, effects of several formulation variables, 200
Mucus system, gastric—rheological evaluation using rotational and creep viscometry, effect of borate ions and tetracycline on viscosity, 828
Multivitamin preparations—combined analyses, vitamins A, D, and E, reversed-phase partition chromatography, 968
Muscle relaxant activity—chloramphenicol, effect on smooth muscles, guinea pig, 704
Mushrooms—*Coprinus atramentarius* crude extract, methanolic fraction isolated, biological activity evaluated, 1774
Mydriatic agents, potential—(*R*)-(−)-*m*-trimethylacetoxy-α-[(methylamino)methyl]benzyl alcohol hydrochloride synthesized and screened, 929

N

Naltrexone—plasma protein binding in humans, monkeys, dogs, guinea pigs, rats, and mice, tissue distribution in mice, 712
Nanoparts—hydrophilic micelles containing drug molecules, polymerization, use as immunological adjuvants, 1763
Naphthalene—solubility in aqueous sodium cholate solutions, method for study of self-association, 882
Narcotic antagonists—cyclazocine, *in vivo* and *in vitro* release from injectable microcapsules evaluated, 847
Neoplastic proliferation—effect of BCG vaccine, mice, 339
Niacinamide—colorimetric analysis, multicomponent vitamin preparations, 65
Niridazole and derivative—preferred molecular conformations, effect on biological activity, 1704
Nitrofurantoin—electrochemical analysis, compared to colorimetric analysis, urine, 599
—solubility in aqueous solutions, effect of urea and creatinine, varying temperature and pH, 868
—suspensions, dissolution–dialysis rate, effect of three viscosity grades of methylcellulose, 1618
Nitrogen–halogen compounds—3-chloro-2-oxazolidinones, antimicrobial activity screened, chlorine potentials evaluated, 1743
Nitrogen heterocycles—series of *N*-heterocyclic aminoethyl disulfides synthesized and screened for antiradiation activity, 1247
Nitroglycerin—bioavailability and stability, stabilized compressed tablet compared to commercial products, 1466
—effect of body position on cardiovascular response, short-acting and sustained-release dosage forms, dogs, 308
—sublingual tablets containing povidone, formulation and processing variables investigated, effect of compaction pressure on hardness and disintegration time, 558
—sublingual tablets, polarographic dissolution test, 1691
—tablets, gravimetric vapor pressure measurement, analysis of nonequilibrium and background effects, 1269
—vapor pressure in sublingual molded tablets, intertablet migration, effect of additives, 1278
Nitroimidazoles—polarographic analysis, biological fluids, 112
NMR spectroscopy—analysis, amyl nitrite, drug entity and inhalant dosage form, 235
—analysis, benoxaprofen and isomeric impurities, 1305
—analysis, carbamates of corticosteroids formed by reaction with trichloroacetyl isocyanate, 1214
—analysis, dimethyl polysiloxane coatings, 590
—analysis, phenylglycine and derivatives in four-component mixture, 738
—determination, enantiomers of 7-chloro-3,3a-dihydro-2-methyl-2*H*,9*H*-isoxazolo[3,2-*b*][1,3]benzoxazin-9-one using europium chiral shift reagent, 592
—determination of configuration of halogen on C-ring of μ- and β-halomorphides, 902
—hydroxyurea and substituted hydroxyureas, spectra correlated with structural features, solvent-dependent differences observed, 585
—structure elucidation of biosynthesized deuterated riboflavin, 362
—study of amphetamines and methoxylated derivatives, interaction with europium shift reagents, stereospecificity of shifting process, 412
Nonelectrolytes—solubility in mixed aqueous solvent systems, 1488
Nonionic surfactants—Krafft and cloud points, effect of inorganic additives, 979
Norbolethone—effect on toxicity of parathion and paraoxon, compared to ethylestrenol and spironolactone, rats, 595
***l*-Norepinephrine**—inhibition of synaptosomal accumulation by a series of *N*-substituted phentermines, corresponding amphetamines, and 3-substituted propylamines, compared, 122
Norepinephrine, tritiated—liquid scintillation spectroscopic analysis, effects of various compounds on uptake and release, mouse heart, 1556
Norgestomet—subcutaneous release from hydrophilic implants, matrix-controlled kinetic mechanism, 488
Nortriptyline—first-pass metabolism predicted using plasma flow rates, compared to observed rates, 1535
Nucleic acid bases—adenine, cytosine, thymine, and uracil, interaction with catechol, UV absorption studies, 892
—adenine, thymine, and uracil, interaction with epinephrine, UV absorption studies, 982
5′-Nucleotide phosphodiesterase—activation of antitumor compounds, mice, 384
Nylidrin—GLC analysis, urine, 1352

Nystatin—polymorphic forms related to toxicity, mice, 905

O

Ocular penetration—pilocarpine, related to differences in age, rabbits, 1095
Ointment bases—white petrolatum, percutaneous absorption of salicylic acid and sodium salicylate, effect of nonionic surfactants, 1780
Oncolytic activity—adamantyl-substituted organophosphorus compounds screened, 439
Ophthalmic cholinergic agents—pilocarpine base and salts, topically applied, effect on tear film pH, rabbits, 1654
—pilocarpine, GLC analysis in biological fluids, 1724
—pilocarpine, GLC analysis, rabbit aqueous humor, 1262
—pilocarpine, mechanism of corneal penetration, rabbits, 1816
—pilocarpine nitrate, topically applied, precorneal disposition, 1295
Orbitals, molecular—calculations for substituted benzoic acid series, atomic charge distributions, effect of hydroxyl and ester groups, preferred conformations, pharmacokinetics, structure–activity relationships, 851
Organophosphorus compounds—adamantyl substituted, synthesis, oncolytic activity and tissue distribution screened, 439
Orientation, microenvironmental—2-substituted cyclohexanone phenylhydrazones, effect of ordered solvent structure, 1639
Ornidazole—polarographic analysis, biological fluids, 112
Orthogonal least squares—linear regression methods, both variables measured subject to error, equations derived, 1562
Oxidations, NAD dependent and independent—effect of series of substituted imidazolocarbamides, rat brain homogenates, 1010
NAD dependent—pyruvate and α-ketoglutarate, effect of phenothiazines, 391
NAD dependent—screened in substituted thiobenzoxazoles and thiobenzothiazoles, 405
photochemical—benzaldehyde, antioxidant efficiency of various polyhydric phenols, 1447
—pteridine derivatives by mammalian liver xanthine oxidase and aldehyde oxidase, 1150
–reduction systems—ferredoxins studied using ac polarography, effect of pH, 1471
Oximes—hydrolysis, synthesis of 1,2-indandione and other ketones, 134
3-Oximino-4-chromanone—Beckmann fragmentation study after acylating, 397
Oxovanadium(IV)—complex formation with substituted 8-quinolinols, spectrophotometric study in various solvents, 1364
Oxytetracycline—polarographic analysis, pharmaceutical formulations, 1315
Oxytocic agents—dinoprost and dinoprostone derivatives formed during *in vitro* incubation with prostaglandin 15-dehydrogenase, high-performance liquid chromatographic analysis, 1609
—dinoprostone free acid and carbamoylmethyl ester, relative aqueous stabilities, effect of pH, 1844

P

Packages, unit dose—heat seals examined by calorimetry, IR spectroscopy, and thermomechanical analysis, 628
Pancreatic imaging agents, potential—3-[(2-aminoethyl)selenyl]alanine synthesized, toxicological evaluation, 623
Lipase inhibitor—1,2-dioleoyl-3-(α-^{14}C-1-adamantoyl)-*sn*-glycerol synthesized, 1243
Parabens—synthesized and screened for antibacterial and antifungal activity *in vitro,* 1074
Paraoxon—toxicity in rats, effect of ethylestrenol, norbolethone, and spironolactone, 595
Parathion—toxicity in rats, effect of ethylestrenol, norbolethone, and spironolactone, 595
Paregoric—high-pressure liquid chromatographic analysis of morphine and benzoic acid, commercial samples, 1697
Parenteral containers—glass, scanning electron micrographs, surface view, 22
Palmella caperata—isolation of pinastric acid and ergosterol, UV, IR, and mass spectral data, 737
Particle size—disintegrated tablets, effect of intra- and extragranular disintegrating agents, 1170
size distribution—numerical solution, multisized drug powders, model system for dissolution, 1042
Particles, nonspherical—isotropic dissolution, six crystal systems, equations derived, 1437
Partition coefficients—*p*-alkylpyridines, water and six organic solvents, 80
—determined for series of substituted biguanides, 1070
—determined in automated continuous-flow system, gerbil sebaceous pad, 727
—salicylic acid, effect of polysorbate 80, rats, 621
—substituted pyridine carbamates, compared with acetylcholinesterase and butyrylcholinesterase inhibitory potencies, 910
Partitioning—4-substituted benzoic acids, nondisintegrating disks, *in vitro,* 753
Pasteurella avicida—determination of homogeneity of emulsified suspension, UV measurement of extracted cell contents, 433
—analysis, using *N*-bromosuccinimide, iodometric titration, 300
Penicillin—degradation in acidic media, kinetic analysis, monitored by high-pressure liquid chromatography and UV spectroscopy, effect of temperature, buffer concentration, and ionic strength, 1165
***O*-(2,3,4,5,6-Pentafluorobenzyl)hydroxylamine hydrochloride**—GLC derivatization reagent, synthesized from pentafluorobenzyl bromide, 625
Pentylenetetrazol—pharmacokinetic studies following intravenous and oral administrations, dogs, 1038
Pepsin activity—mechanism of inhibition by dioctyl sodium sulfosuccinate, 1319
Pericyazine embonate—effect of various pharmaceutical formulations on duration of biological activity, dogs, 1665
Permeability coefficients, skin—estimated using pharmacokinetic models, in terms of excretion rates and tissue absorption, 1396
—human skin *in vitro,* effect of dimethyl sulfoxide, 210
—oral mucosa to alcohol and urea series, radioisotope transfer, streaming potential, dogs, 129
—unbranched aliphatic alcohols, vaginal absorption, rabbits, 1574
Permeation—diazepam through polydimethylsiloxane membranes, effect of excipients, 207
Permethylation—barbiturates with methylsulfinylmethide carbanion and methyl iodide, GLC separation, 288
Petrolatum, white—ointment base, percutaneous absorption of salicylic acid and sodium salicylate, effect of nonionic surfactants, 1780
pH—effect on acute toxicity of tetracycline, mice, 916
—tear film, effect of topically applied pilocarpine, base and salts compared, rabbits, 1654
Pharmaceutical formulations, various—phenothiazines, effect on duration of biological activity, dogs, 1665
sciences—1975 literature review of pharmaceutics, 935, 1101
Pharmacies—total cost function in relation to size, prescription dispensing, Cobb–Douglas production function, 204
Pharmacokinetic analysis—renal excretion mechanisms, sulfamethizole, 463
—model for estimating *in vivo* skin permeability coefficients in terms of excretion rates and tissue absorption, 1396
—model proposed, description of self-induced decreases in steady-state serum concentrations of carbamazepine, 462
model—proposed for simultaneous determination of drug distribution with time in blood, organs, and tissues, demonstrated with thiopental in dogs, 717
modeling—calculation of initial polyexponential parameter estimates by a Fortran computer program, 1006
modeling—single definition for all volume terms proposed as a function of time, 452
models—chlorpromazine-induced miotic response related to systemic bioavailability, rabbits, 1593
models—errors in instantaneous intravascular input assumptions, two- and three-compartment open models, 750
models, nonlinear—described for intravenous anesthetics methohexital and thiopental, 1001
models, two compartment—equation derived for time required for constancy of drug fraction in Compartment 1, effect of absorption and elimination rate constants, 1140
Pharmacokinetics—bumetanide, plasma and urine, radioimmunoassay, 701
—chlorpromazine, evaluated by measurement of rectal temperature depression, rabbits, 1600
—dichlorotetrafluoroethane, tissue compartment distribution analysis, three-compartment open model, dogs, 60
—effect of cholestasis on drug half-life and elimination, two-compartment model studied, 1346
—fluphenazine base, enanthate, and decanoate, comparison of slow-release characteristics, effect of route of administration, dogs, 1310
—furosemide, dogs and monkeys compared, 1456
—model compounds, urinary excretion and blood level data compared, rats, 1341
—naltrexone, humans, monkeys, dogs, guinea pigs, rats, and mice, 712
—nortriptyline, first-pass metabolism predicted using plasma flow rates, compared to observed rates, 1535
—pentylenetetrazol, intravenous and oral administrations, dogs, 1038
—platinum complexes, distribution, retention, and excretion, review, 315
—progesterone, receptor characterization, nuclear interactions, receptor concentration, review, 783
—quinidine, different dosage forms compared, 1325
—substituted benzoic acids, related to molecular orbital calculations, 851
—2,4,5-trichlorophenoxyacetic acid, mice, 1810
Pharmacological activity—duration and intensity, effect of plasma protein binding of drugs, 1264
Pharmacology—screening of 3-*tert*-butylsydnone, 109
Phase inversion temperature—emulsions, correlated with kinetics of globule coalescence, 517
Phenacetin—compressed mixtures with aspirin or caffeine, dissolution rates compared, 1784
Phenol—high-pressure liquid chromatographic analysis, pharmaceutical dosage forms, 1706
Phenols—apparent dissociation constants, effect of cycloamyloses, 379
polyhydric—antioxidant efficiency in photooxidation of benzaldehyde, 1447
Phenolsulfonphthalein—absorption and intestinal transport, alpha tocopherol-deficient rats, 344
Phenothiazines—chlorpromazine, prochlorperazine, and trifluoperazine, effects on pressor actions of serotonin, angiotensin, and bradykinin in perfused human placenta, 1498
—derivatives containing bis(β-chloroethyl)aminopropyl side chain synthesized, CNS antitumor activity screened, 1699
—effect of various pharmaceutical formulations on duration of biological activity, dogs, 1665
—seven derivatives, GLC analysis, plasma,

667
substituted—antihemolytic and antiproteolytic activities investigated, 758
—synthesis, effects on NAD-dependent oxidations, anticonvulsant activity screened, mice, 391
Phenprocoumon—GLC determination from human plasma, phenytoin as internal standard, 387
Phentermines, *N*-substituted—inhibition of synaptosomal accumulation of *l*-norepinephrine, 122
Phenylbutazone—analysis, automated method, human plasma and urine, 86
—ionization kinetics, relative concentrations and pKa's of enol and diketo forms calculated, effect of acids and bases, 1161
—mass spectral and pyrolytic behavior of products of degradation by oxidation and hydrolysis, 68
Phenylephrine prodrug—(*R*)-(−)-*m*-trimethylacetoxy-α-[(methylamino)methyl]benzyl alcohol hydrochloride synthesized, mydriatic activity screened, 929
Phenylglycine and derivatives—NMR analysis in four-component mixture, 738
Phenylhydrazones, 2-substituted cyclohexanone —cyclization reaction kinetics, effect of ordered solvent structure on microenvironmental orientation and intramolecular conformational constraints, 1639
Phenylpropanolamine—GLC analysis, plasma, 740
hydrochloride—GLC analysis, commercial cold tablets, 924
Phenytoin and major metabolite—simultaneous GLC analysis, plasma, 1240
—dissolution and bioavailability, ground mixture with microcrystalline cellulose compared to fine powder, 1484
—radioiodinated derivatives, potential tumor imaging agents, tissue distribution studies, rats, 285
Photochromism—*N,N*-disubstituted piperazines in solid state, effects of temperature, dissolution, and prolonged storage, 1452
Photodecomposition, anaerobic—acridan derivative converted to acridine derivative in visible light through energy transfer, riboflavin 5-phosphate as catalyst, 247
Photoirradiation—spectrophotometric determination of sodium nitroprusside and degradation products, compared to polarographic data, 44
Photooxidation—benzaldehyde, antioxidant efficiency of various polyhydric phenols, 1447
Phthalate ester—bis(2-ethylhexyl) phthalate, effect on chromosomes of human leukocytes and fetal lung cells, 1648
ester—bis(2-ethylhexyl) phthalate, effect on hexobarbital sleep time, mice, rats, 733
plasticizer—effect of polyvinyl chloride on blood compatibility, quantified by attenuated total reflectance spectroscopy, 670
Phytotoxins—trichothecenes isolated from *Fusarium oxysporum,* activity evaluated, 160
Pigments—synthetic melanin, affinity and capacity of drug binding, various sympathomimetic amines, 1057
Pilocarpine—chromatographic separation and UV analysis, pharmaceutical preparations, in presence of isopilocarpine, compared to USP methods, 257
—differences in ocular penetration related to differences in age, rabbits, 1095
—GLC analysis, biological fluids, 1724
—GLC analysis, rabbit aqueous humor, 1262
—mechanism of corneal penetration, rate and extent of accumulation in aqueous humor and various cell layers, rabbits, 1816
nitrate—pharmacokinetics, corneal absorption, rabbits, 150
nitrate—topically applied, precorneal disposition, effect of tear turnover, instilled solution drainage, and nonproductive absorption, 1295
—topically applied bases and salts, effect on tear film pH, rabbits, 1654
Pinastric acid—isolated from *Parmelia caperata,* UV, IR, and mass spectral data, 737
Piperazines, *N,N'*-disubstituted—photochromism in solid state, effects of temperature, dissolution, and prolonged storage, 1452
—*N,N'*-disubstituted, synthesis, anti-inflammatory, antiproteolytic, and anticonvulsant properties screened, 409
pKa—spectrophotometric determination, methaqualone, 460
values—determined for series of substituted biguanides, 1070
Plant antigens—isolated from tissue cultures, allergenic activity screened, 102
culture—^{2}H- and ^{13}C-substituted tobacco plants cultured, sealed growth chambers, isotope substrates conserved and recycled, 1096
Plaque inhibitors, potential—series of substituted biguanides synthesized and screened, 1070
Plasma drug profiles—predicted from dissolution rates, transformation factor described, 601
protein binding—effect on duration and intensity of pharmacological activity of drugs, 1264
protein binding—spirolactones, quantitatively correlated with lipophilicity, 1337
proteins—compared to bovine whole blood and purified albumin fraction binding of salicylate and sulfathiazole, 33
Plasticizers—bis(2-ethylhexyl phthalate, effect on chromosomes of human leukocytes and fetal lung cells, 1648
Platinum complexes—antineoplastic activity related to chemical structure, biological and toxicological effects, methods of preparation, mechanism of action, pharmacokinetics, review, 315
PMR spectroscopy—analysis, methyl methacrylate in surgical acrylic cement, 280
Polarity, solid surface—quantitated by measurement of surface free energy and contributions of polar and nonpolar forces, effect of substituent groups, 1145
Polarography, ac—study of electroreduction and biochemical properties of ferredoxins, 1471
—analysis, isosorbide dinitrate, compared to IR and automated colorimetric methods, six commercial formulations, 118
—analysis, nitroimidazoles, biological fluids, 112
—analysis, tetracycline, oxytetracycline, chlortetracycline, and demeclocycline in pharmaceutical formulations, 1315
—analysis, tinidazole, commercial tablets, 736
—determination of dissolution of nitroglycerin sublingual tablets, 1691
—investigation of effect of chlorpromazine and trifluoperazine hydrochlorides on electrochemical behavior of flavin coenzymes, 1758
Polar solvents, mixed—solubility of nonelectrolytes, molecular and group surface area approach, 1488
Poloxamer 188—effect on dissolution and intestinal absorption of sulfadiazine and sulfisoxazole, rats, 115
Polyamide films—*in vitro* drug release, effect of plasticizers, 1519
Polydimethylsiloxane—membranes, permeation of diazepam, effect of excipients, 207
Polyethylene capsule—rate-controlling membrane, progesterone diffusion, programmed release rate, 648
glycol 4000—effect on dissolution properties of two sulfathiazole polymorphs, 302
Polyexponential parameter estimates—pharmacokinetic modeling, calculation by a Fortran computer program, 1006
Polymer films—free and applied, effect of different types of absorbents on moisture transmission, 521
matrixes—*in vitro* drug release of benzocaine, cyclomethycaine, and methapyrilene hydrochloride, effect of plasticizers, 1519
structure—aluminum hydroxide gel, initial precipitate from reaction of aluminum chloride or sulfate with ammonium hydroxide, 1198
Polymerization—hydrophilic micelles containing drug molecules (nanoparts), use as immunological adjuvants, 1763
Poly(methyl methacrylate) adjuvants—for influenza vaccine, preparation, evaluation by hemagglutination, antibody binding, and electron microscopy, 1624
Polymorphic forms—polyene antibiotics mepartricin and nystatin, relationship to toxicity in mice, 905
—substituted dibenz[*b,e*][1,4]oxazepine, solid dispersion, solubility, dissolution rate, and bioavailability, 1380
Polyoxyethylene alkyl ether—as stabilizer in emulsions, 517
Polysorbate 80—effect on apparent partition coefficient and absorption of salicylic acid, rat intestine, 621
Polythiazide—high-pressure liquid chromatographic analysis, pharmaceutical dosage forms, 1413
Polyvinyl chloride—blood compatibility, effect of phthalate plasticizer, quantified by attenuated total reflectance spectroscopy, 670
Potassium chloride disk—effect of hydrophobic coating materials on dissolution, 182
—slow release tablets, dissolution rate analysis by automated system, 349
Potentiometry—analysis, sulfamerazine and sulfisomidine, liquid membrane electrode sensitive to sulfa drugs, 435
—investigation of complexation of anhydrotetracycline with various metal ions, 1794
Povidone—two grades used in sublingual nitroglycerin tablets, formulation and processing variables investigated, 558
Powders, multisized—model system for dissolution, compared to other models, 1042
pharmaceutical—contact angles and wetting determined by h–ϵ method, effect of particle size and porosity of cake, 843
Precorneal disposition—pilocarpine nitrate, topically applied, effect of tear turnover, instilled solution drainage, and nonproductive absorption, 1295
Prednisolone—separation from hydrocortisone with Girard reagent T, applicability to radioimmunological determination, 461
—serum concentration after administration of prednisolone or prednisone, radioimmunoassay, dogs, 997
Prednisone—dissolution rate, effect of crystallization in aqueous surfactant solutions, 1702
—effect on plasma salicylate concentrations, dogs, 773
—serum concentration after administration of prednisone or prednisolone, radioimmunoassay, dogs, 997
Pregnenolone-16α-carbonitrile—effect on hepatic cytochrome P-450 and aniline hydroxylase activity, male and female rats compared, 610
—structural and conformational features, effect of pretreatment on pharmacological action, plasma concentrations, and liver homogenate metabolism of zoxazolamine, rats, 1092
Prescription dispensing—community pharmacies, total cost function in relation to size, Cobb–Douglas production function, 204
Preservatives—phenol, high-pressure liquid chromatographic analysis, pharmaceutical dosage forms, 1706
—substituted benzoic acids, molecular orbital calculations, pharmacokinetics, structure–activity relationships, 851
Primidone—solid dispersion with citric acid, effect of concentration, aging, and temperature, 1613
Probenecid and metabolites—urinary excretion as a function of dose, 861
—effect on biliary secretion of methotrexate, rats, 1348
Procaine—high-speed liquid chromatographic analysis, pharmaceutical preparations, 606
Prochlorperazine—effects on pressor actions of serotonin, angiotensin, and bradykinin in perfused human placenta, 1498
Prodrugs—epinephrine prodrug synthesized, screened for adrenergic activity, rabbit eye homogenate and plasma, human plasma,

1510
—(*R*)-(−) - *m*-trimethylacetoxy-α-[(methylamino)methyl]benzyl alcohol hydrochloride synthesized, mydriatic activity screened, 929
Progesterone—diffusion through polyethylene capsule, programmed release rate, 648
—production, metabolism, mechanism of action, effects, clinical use, toxicity, review, 783
—release from silicone matrix, vaginal absorption, rabbits, 1573
1-Propanols, 2,3-bis(alkylthiocarbamoylthio)—synthesized and screened for antimicrobial activity, 1551
Propellants—solubility of trichloromonofluoromethane in dog blood and tissue homogenates, 53
Propylamines, 3-substituted—inhibition of synaptosomal accumulation of *l*-norepinephrine, 122
Prostaglandins—dinoprost and its 15-epimer, analysis, high-pressure liquid chromatography, 673
—dinoprostone free acid and carbamoylmethyl ester, relative aqueous stabilities, effect of pH, 1844
—formed during *in vitro* incubation with prostaglandin 15-dehydrogenase, high-performance liquid chromatographic analysis, 1609
—15-methylprostaglandin E_2 and methyl ester, high-performance liquid chromatographic analysis and separation from C-15-epimers, 1533
Protein binding—digoxin, normal and kwashiorkor serum, 914
plasma—naltrexone, humans, monkeys, dogs, guinea pigs, rats, and mice, 712
—polyhedral borane synthesized, potential tumor antibody-binding agent, 604
—sulfisoxazole to protein fractions of human tears, normal and irritant induced, 437
Protriptyline—three metabolites isolated from rat urine, characterized by TLC, GLC, and GLC–mass spectrometry, 810
Pseudomonas aeruginosa—cell envelope, effect of benzalkonium chloride and edetate disodium, electron microscopic study, 76
Psychotomimetic agents, potential—sulfur analogs of substituted phenylalkylamines synthesized, 1554
Psychotropic drugs—enthalpy of hydrogen bonding with phenol, IR and NMR spectral measurement, related to differences in activity, 1066
Pteridine derivatives—oxidation by mammalian liver xanthine oxidase and aldehyde oxidase, 1150
Pyridazino[2,3 - *a*] - *s*-triazine-2,4-diones—synthesized, *in vitro* antimicrobial activity screened, 1505
Pyridine, *p*-alkyl—distribution and partition coefficients, water and six organic solvents, 80
carbamates, substituted—partition coefficients compared with acetylcholinesterase and butyrylcholinesterase inhibitory potencies, 910
derivatives—antihistamines, aggregation in aqueous solution, effect of counterions on self-association, 1053
Pyridoxine hydrochloride—high-pressure liquid chromatographic analysis in mixtures with isoniazid, 1536
Pyridylethylamine derivatives—synthesis of 19 histamine analogs, structure–activity relationships, 98
Pyrimido[1,2-*b*]pyridazine - 2,4 - diones—synthesized, *in vitro* antimicrobial activity screened, 1505
Pyrithyldione—GLC analysis, putrified brain and intestine, 1393
Pyrolysis—behavior of products of phenylbutazone degradation by oxidation and hydrolysis, 68
Pyrrobutamine phosphate—semiautomated colorimetric analysis, pharmaceutical mixtures, 1590
Pyrrolo[1,2-*a*][1,3]diazepine, substituted—synthesis, antimalarial, antineoplastic, antiviral, and CNS activity in mice, hypotensive, anti-inflammatory, diuretic, and antidiabetic activity in rats, 908

Q

Quantum chemical factors—correlated with 5-hydroxytryptamine uptake by thrombocytes, 1014
Quercus infectoria—extracts of galls, analgesic, antidiabetic, and CNS depressant activity screened, mice, rats, and rabbits, 1791
Quinidine—GLC analysis in human plasma, compared to fluorometric analysis, 96
—pharmacokinetics and bioavailability of different dosage forms compared, 1325
sulfate—nonaqueous titrimetric analysis of base after barium acetate precipitation of sulfate, pure compound and synthetic tablets, 424
Quinine sulfate—nonaqueous titrimetric analysis of base after barium acetate precipitation of sulfate, pure compound and synthetic tablets, 424
Quinolines, substituted—synthesized, effectiveness as topical mosquito repellents evaluated, 1404
8-Quinolinols, substituted—complex formation with oxovanadium(IV), spectrophotometric study in various solvents, 1364
Quinoxalines, substituted—synthesized, effectiveness as topical mosquito repellants evaluated, 1404

R

Radioactive labels—*in vivo* loss of tritium, urine and plasma levels compared, 1261
Radiochemistry—analysis, 2,4,5-trichlorophenoxyacetic acid, mouse blood, urine, and feces, 1810
—tritiated norepinephrine, liquid scintillation spectroscopic analysis, mouse heart, 1556
Radioimmunoassay—analysis, bumetanide, plasma and urine, compared to radiometric and spectrofluorometric methods, 701
Radioisotopic methods—determination of aqueous solubility of ^{14}C-triamcinolone acetonide, 429
Radiopharmaceuticals—radioiodinated phenytoin derivatives, potential tumor imaging agents, tissue distribution studies, rats, 285
Radioplatinum compounds—labeling, distribution, use, review, 315
Radioprotective agents, potential—series of *N*-heterocyclic aminoethyl disulfides and aminoethanethiosulfuric acids synthesized and screened, 1247
Relaxants, skeletal muscle—chlorphenesin carbamate and γ-isomer, high-pressure liquid chromatographic analysis in pharmaceutical formulations, 1802
skeletal muscle—dantrolene sodium, effects on respiratory and cardiovascular functions, dogs and sheep, 1359
smooth muscle—theophylline, high-pressure liquid chromatographic analysis, plasma, 865
Release rate—clofibrate from microcapsules, 1476
programmed—progesterone diffusion through rate-controlling membrane (polyethylene capsule), 648
Renal excretion—salicylates, effect of formulation and dose, rats, 447
stone formation—calcium oxalate monohydrate, kinetics of dissolution and crystal growth, effects of various additives alone and in combination, 222
Repellents, mosquito—substituted quinolines, quinoxalines, and isoquinolines synthesized and evaluated, 1404
Resorcinol—high-pressure liquid chromatographic analysis, pharmaceutical dosage forms, 1706
—spectrophotometric analysis in presence of phenol, effect of pH, decomposition products, 144
Respiratory functions—effects of dantrolene sodium, dogs and sheep, 1359
Retinyl compounds—desmethylretinoic acid and vinylogs, wound-healing mechanism of action, effect on granuloma formation, 580

Review articles
Arrhythmias and Antiarrhythmic Drugs: Mechanism of Action and Structure–Activity Relationships, 467, 635
Bioassays Used in Development of Topical Dosage Forms, 1417
Derivatization in Gas Chromatography, 163
Mechanisms of Solid-State Reactions of Drugs, 1
Pharmaceutical Sciences—1975: Literature Review of Pharmaceutics, 935, 1101
Platinum Complexes: A New Class of Antineoplastic Agents, 315
Progesterone: An Overview and Recent Advances, 783
Reynolds number—effect on dissolution rate of nondisintegrating potassium chloride solid disk, apparatus described and evaluated, 48
Rheological evaluation—gastric mucus system, rotational and creep viscometry, 828
Rheopexic dispersions—dioctyl sodium sulfosuccinate, formation of micelles, 1265
Riboflavin—deuterated, biosynthesis by fungus *Eremothecium ashbyii*, isolation, structure determination by NMR and mass spectrometry, 362
RNA synthesis—hamster kidney cells in culture, effect of sodium salicylate, 756

S

Salicylamide—diffusion across synthetic membranes and isolated biological tissues, three-compartment apparatus developed, evaluated, and compared to other methods, 564
—spectrophotometric analysis in tablets containing other drugs, 1627
Salicylate—absorption and intestinal transport, alpha tocopherol-deficient rats, 344
—binding to bovine whole blood, plasma proteins, and purified albumin fractions compared, 33
—concentration in rat kidney, effect of formulation and dose, 447
—plasma concentrations, effect of prednisone, dogs, 773
Salicylic acid—apparent partition coefficient and absorption, rat intestine, effect of polysorbate, 80, 621
—compressed mixture with aspirin, dissolution rate compared to other mixtures, 1784
—GLC analysis, different silylating reagents and different reaction vessels compared, 1530
—percutaneous absorption from ointment bases containing dimethyl sulfoxide, effect of nonionic surfactants, rabbits, 1780
Salts—substituted phenanthrenemethanol antimalarial agent, effect of hydrophilic counterions on aqueous solubility, 747
Saluretic agents—(6,7-dichloro-2-methyl-1-oxo-2-phenyl-5-indanyloxy)acetic acid, GLC analysis in biological fluids, 1770
Salutaridine—isolated from *Glaucium flavum* whole plant extract, 923
Sampling—effect of sample size, USP and NF tests for content uniformity, dissolution, disintegration, and weight variation, changes from previous editions, 312
Saponins—isolated from sea cucumbers, structures partially determined, antineoplastic and cytotoxic activity evaluated, 1558
Sarracenia flava—constituents isolated, identified, and screened for antitumor activity, 284
Scanning electron microscopy—internal surface, glass ampuls and vials, effect of sulfur, ammonium bifluoride, and sulfuric acid treatments, 22
Scintigraphy, external—disintegration and drug release times of gelatin capsules monitored, 1412
Scopolamine—GLC analysis, pharmaceutical formulations of belladonna extract, 680
Sea anemone—extract, cardiotonic polypeptide anthopleurin-A isolated, 1368
Sea cucumber—three saponins isolated and identified, screened for antineoplastic and cytotoxic activity, 1558

Seals, heat—foil packages, relationship of sealing temperature to incidence of defective packages, vacuum-dye, seal strength, and pressurized ammonia vapor tests for defects, 1061
heat—unit-dose packages, examined by calorimetry, IR spectroscopy, and thermomechanical analysis, 628
Sedatives—cyclobenzaprine, GLC analysis, plasma and urine, 1253
—cyclobenzaprine, six metabolites isolated from rat urine, TLC, GLC, and mass spectral identification, 815
—pyrithyldione, GLC analysis in putrified brain and intestine, 1393
Selenium heterocycles—synthesis and antibacterial activity of 4-substituted (1,2,3-selenadiazol-5-yl)carbamic acid esters and sulfur analogs, 304
Seleno amino acids, aliphatic—synthesis of 3-[(2-aminoethyl)selenyl]alanine, potential pancreatic imaging agent, toxicological evaluation, 623
Serotonin—pressor actions in perfused human placenta, effects of chlorpromazine, prochlorperazine, and trifluoperazine, 1498
Shear stress and rate—thixotropic systems, data used in construction of equilibrium flow curve, 1385
Shilajit—chemical constituents determined, compared to extracts of *Euphorbia royleana* plant, 772
Silicone matrix system—release of progesterone and hydrocortisone, vaginal absorption, rabbits, 1578
membrane—controlled release of butamben, effect of caffeine, β-cyclodextrin, and povidone, 709
Silicones—NMR analysis of dimethyl polysiloxane coatings, 590
Silylating reagents, various—compared in GLC analysis of salicylic acid, 1530
Sinoacutine—isolated from whole plant extract of *Glaucium contortuplicatum,* 755
β-Sitosterol and its β-D-glucoside—isolated from whole plant extract of *Tithonia tagitiflora,* 918
—isolated from *Sarracenia flava,* screened for antitumor activity, 284
Size, tablet—effect of storage at various temperatures and humidity, 1746
Skin, human—effect of dimethyl sulfoxide on growth and permeability *in vitro,* 210
permeability coefficients—estimated using pharmacokinetic models, in terms of excretion rates and tissue absorption, 1396
Sodium alkyl sulfates—effect on release of protein from everted rat small intestine, 1460
Sodium cholate—solvent for naphthalene, method for study of self-association, 882
Sodium cyclopentylsulfamate and metabolites—GLC analysis, rat and rabbit urine, 1841
Sodium lauryl sulfate—micellization, effect on rate of cupric-ion-promoted hydrolysis of dicarboxylic acid hemiesters, 1713
Sodium nitroprusside—spectrophotometric determination, photodegradation products, compared to polarographic data, 44
Sodium salicylate—effect on diffusion of benzocaine from topical vehicles, 493
—effect on hamster kidney cells in culture, generation time, RNA synthesis, 756
—percutaneous absorption from ointment bases containing dimethyl sulfoxide, effect of nonionic surfactants, rabbits, 1780
Solid dispersion systems—primidone with citric acid, effect of concentration, aging, and temperature, 1613
dosage forms—solid-state reaction mechanisms, applications, review, 1
solution systems—melting-point diagrams, consistency relations, thermodynamic analysis, 158
-state reactions—mechanisms, effect of crystal structure, drugs and related compounds, applications, review, 1
supports, GLC—effect on ibuprofen analysis, 1710
Solids, pharmaceutical—wettability evaluated by measurement of surface free energy and contributions of polar and nonpolar forces, effect of substituent groups, 1145
soluble—dissolution in a column into a liquid stream, equations derived, 1634
two component—dissolution rate correlated with composition, 1784
Solubility, aqueous—correlated with topological indexes, various monofunctional compounds, 801
aqueous—salts of substituted phenanthrene-methanol antimalarial agent, effect of hydrophilic counterions, 747
aqueous—^{14}C-triamcinolone acetonide, radioisotopic method, 429
—5,5-disubstituted barbiturates in straight-chain alcohols, 277
—medazepam, pKa determination, compared to spectrophotometric method, 1094
—nitrofurantoin in aqueous solutions, effect of urea and creatinine, varying temperature and pH, 868
—nonelectrolytes in mixed aqueous solvent systems, molecular and group surface area approach, 1488
studies—sulfathiazole–povidone coprecipitates, dissolution rates, compared to supercooled melt and crystalline forms of sulfathiazole, thermodynamic parameters, 355
—testosterone propionate and related esters in various organic solvents, 656
Solubilization—enantiomers compared to racemates, pharmaceutical formulations, 238
—method for study of self-association, naphthalene in aqueous solutions of sodium cholate compared to sodium decanesulfonate, 882
oxygen—by various concentrations of dog lung surfactant, 142
Solubilizing properties—aqueous solutions of various tetramethyldicarboxamides, correlated with dielectric constants, 1645
Solvent-dependent conformational system—hydroxyurea and substituted hydroxyureas, detected by NMR spectroscopy, 585
—effect on molecular structure of 9-anthramide, electronic absorption and fluorescence spectral study, 1833
flow—Reynolds number, effect on dissolution rate of nondisintegrating solid disk (potassium chloride), 48
structure, ordered—effect on cyclization reaction kinetics of 2-substituted cyclohexanone phenylhydrazones, 1639
systems—effect on rate of color development and wavelength of maximum absorption of formazan, tetrazolium reaction, 1048
Sophora secundiflora—seeds, alkaloids and amino acids isolated and identified, toxicity investigated in rats, 352
Sorbitol—effect on aging mechanism of aluminum hydroxide gel, 1195
Soterenol—fluorometric analysis after trihydroxyindole reaction, pharmaceutical formulations, 763
Spectrofluorometry—analysis, bufuralol in blood and urine, 1230
—analysis, hydroflumethiazide, in plasma and urine, 1208
Spectrometry, circular dichroism—investigation of binding properties of tetracycline complexes with Ca^{+2} and Mg^{+2}, 1728
UV–visible, fluorescence, and circular dichroism—investigation of binding properties of anhydrotetracycline with various metal ions, 1794
Spectrophotofluorometry—analysis, coumarin and umbelliferone, alone and together, whole blood, 30
Spectrophotometry—analysis, cephradine, pharmaceutical formulations, 887
—analysis, diphenhydramine hydrochloride, pharmaceutical formulations, 761
—analysis, resorcinol in presence of phenol, effect of pH, decomposition products, 144
—analysis, salicylamide in tablets containing other drugs, 1627
—analysis, Schiff base derivatives of *p*-aminophenol, alone or in presence of degradation products or acetaminophen, 71
charge transfer—analysis, weak and strong UV-absorbing alkaloids in binary mixtures, 986
—determination of composition of complexes of oxovanadium(IV) and substituted 8-quinolinols in various solvents, 1364
differential—analysis, theophylline in pharmaceutical formulations, 1178
probe—2-(4′-hydroxybenzeneazo)benzoic acid, study of binding of tetracyclines to human serum albumin, 226
Spectroscopy, diffuse reflectance—evaluation of stability of emulsions and active components in emulsions, compared to visible coalescence and particle counter techniques, 216
liquid scintillation—analysis, tritiated norepinephrine, mouse heart, 1556
Spirolactones—lipophilicity and plasma protein binding determined and correlated quantitatively, 1337
Spironolactone—dissolution and bioavailability, tablet formulations with and without hydrochlorothiazide, effect of formulation parameters, 1630
—effect on toxicity of parathion and paraoxon, compared to ethylestrenol and norbolethone, rats, 595
Spleen weight—effect of BCG vaccine, mice, 339
Spot tests—systematic identification of drugs of abuse, 774, 775
Spray drying—agglomerated magnesium carbonate, acid-neutralizing velocity, 770, 771
Stability—aprindine in pharmaceutical formulations, effect of dry heat, refluxing, UV light, and varying pH, 1322
aqueous—dinoprostone free acid and carbamoylmethyl ester, effect of pH, 1844
—ascorbic acid in various tablet formulations, nature and extent of formation of decomposition products, 963
—cephalosporins in aqueous solutions, kinetics and mechanisms of degradation, effect of pH, 1583
long term—emulsions, polyoxyethylene alkyl ether as stabilizer, 517
—mibolerone aqueous solutions, kinetics and mechanism of degradation, GLC evaluation, 1777
—nitroglycerin, stabilized compressed tablet compared to commercial products, 1466
—nitroglycerin sublingual molded tablets, vapor pressure, intertablet migration, effect of additives, 1278
—solids, solutions, injectable products, antibiotics, and vitamins, kinetics, 1975 literature review, 935, 1101
Starch—effect of various ratios of disintegrant to paste on tablet disintegration time and hardness, 1694
intra- and extragranular—varying proportions in dibasic calcium phosphate compressed tablets, disaggregation, effect of compaction pressure, 1749
paste granulations—effect of gelatin binder solution concentrations, tableting characteristics, 313
paste granulations—effect of mixing time, speed, and binder dilution on physical properties of tablets, 1559
paste granulations—effect of starch paste viscosity on granule hardness and physical properties of tablets, 1561
Stemodia maritima—aboveground portion extracted, diterpenes isolated and identified, 778
Stemodinol—isolated from *Stemodia maritima,* PMR, IR, mass, and circular dichroism spectral identification, 778
Stereochemistry—geometric isomers of various substituted 1,2-diphenylvinyl compounds determined, literature correction, 1545

—α- and β-halomorphides, NMR determination of configuration of halogen on C-ring, 902
Steroids—pretreatment, effect on toxicity and urinary excretion of tetraethylammonium bromide, rats, 1838
—progesterone and hydrocortisone, release from silicone matrix, vaginal absorption, rabbits, 1578
Stimulants—pentylenetetrazol, pharmacokinetic studies following intravenous and oral administrations, dogs, 1038
Strength, tablet—testers, motorized pendulum type, method for checking calibration and determining accuracy and precision, three testers compared, 1072
Streptococcus faecalis—inhibition by long chain aliphatic monoamines, quantitative structure–activity relationships, 1525
Stress—effect on toxicity and urinary excretion of tetraethylammonium bromide, rats, 1838
Structure–activity factors—correlated with 5-hydroxytryptamine uptake by thrombocytes, 1014
relationships—5- and 6-substituted 8-aminoquinolines synthesized and screened for antimalarial activity, 1527
relationships—antiarrhythmic drugs, review, 467, 635
relationships—barbiturates, tertiary amines, and substituted imidazoles, biotransformation, physicochemical properties, 1651
relationships—4-biphenylylalkyl carboxylic acids synthesized, effect on β-hydroxy-β-methylglutaryl coenzyme A reductase, 1374
relationships—*N*-chloramine derivatives of α-aminoisobutyric acid and 2-amino-2-methyl-1-propanol evaluated for antimicrobial activity, 1736
relationships—3-chloro-2-oxazolidinones and antimicrobial activity, 1743
relationships—clomiphene, geometric isomers, 148
relationships—conformationally defined analogs of amphetamine, potentiation of levarterenol in rat vas deferens, 920
relationships—dexamethasone acetate and pregnenolone-16α-carbonitrile, structural features, prophylactic activity against zoxazolamine, rats, 1092
relationships—dibenz[*c,e*]azepines synthesized and screened for antimalarial activity, 928
relationships—effect of Mannich bases and related compounds on mitochondrial function in yeast, human epidermoid carcinoma cultures, blood platelet aggregation and blood clotting, rats, 482
relationships—19 histamine analogs, 98
relationships—inhibition of synaptosomal accumulation of *l*-norepinephrine by *N*-substituted phentermines, amphetamines, and 3-substituted propylamines, 122
relationships—isothiocyanate derivatives synthesized, screened for antimicrobial activity, 1551
relationships—long chain aliphatic monoamine inhibition of *Streptococcus faecalis*, 1525
relationships—4-methoxyphenethylamine and *N*-methylated homologs, effect on monoamine oxidase-catalyzed deamination of tyramine and tryptamine, 1539
relationships—mono- and dialkylated 4-aminobenzothiazoles, antimalarial activity, 618
relationships—1-(1-naphthylacetyl)-3-substituted carbamides synthesized and evaluated for anti-inflammatory and antiproteolytic activity, 1078
relationships—niridazole and derivative, preferred molecular conformations, effect on biological activity, 1704
relationships—photochromism of series of *N,N*-disubstituted piperazines, 1452
relationships—platinum complexes, antineoplastic activity, review, 315
relationships—series of β-haloethylamines, stereoselectivity of adrenolytic activity studied, rats, 544
relationships—series of imidazolocarbamides, anticonvulsant activity, cellular respiratory activity, 1010
relationships—series of substituted biguanides synthesized and screened for ability to inhibit dental plaque, 1070
relationships—sodium alkyl sulfates, effect on release of protein from everted rat small intestine, 1460
relationships—4-substituted benzoic acids, *in vitro* dissolution and partitioning from nondisintegrating disks, 753
relationships—substituted benzoic acids, molecular orbital calculations related to mechanism of action, 851
relationships—substituted benzylidenecyclohexanones evaluated for antitumor and cytotoxic activity, effect on mitochondrial function in yeast, 538
relationships—*N*-substituted derivatives of apomorphine screened for emetic activity, 1682
relationships—substituted dioxanes synthesized, effect of substituents on antimicrobial activity, 1301
relationships—substituted phenothiazines, anticonvulsant activity, 391
relationships—substituted phenothiazines evaluated for antihemolytic and antiproteolytic activities, 758
relationships—substituted phenothiazines synthesized, screened for CNS antitumor activity, 1699
relationships—*N,N'*-substituted piperazines, anti-inflammatory, antiproteolytic, and anticonvulsant properties, 409
relationships—substituted pyrimido[1,2-*b*]pyridazines and pyridazino[2,3-*a*]-*s*-triazines synthesized, antimicrobial activity screened, 1505
relationships—substituted quinolines, quinoxalines, and isoquinolines synthesized and evaluated for effectiveness as topical mosquito repellents, 1404
relationships—sweetness of ketoses related to structural functions, 1222
relationships — thienopyrimidinonemercaptoacetic acids and ethyl esters, screened for analgesic, anti-inflammatory, anticonvulsant, and antimicrobial activity, 660
relationships—thiosulfonates synthesized, antimicrobial screening, 1692
relationships—various cephalosporins, stability in aqueous solutions, kinetics and mechanisms of degradation, effect of pH, 1563
relationships—various mescaline antagonists screened for effect on mescaline-induced CNS stimulation, 1479
relationships—various substituted anilinobenzylidenes synthesized and screened for effect on monoamine oxidase activity and anticonvulsant properties, 1678
Succinates, arylalkenyl and arylepoxy—substituted series, synthesis, effect on β-hydroxy-β-methylglutaryl coenzyme A reductase, 724
Sulfadiazine—dissolution and intestinal absorption, effect of dioctyl sodium sulfosuccinate and poloxamer 188, rats, 115
Sulfamates, substituted—sodium cyclopentylsulfamate, GLC analysis, rat and rabbit urine, 1841
Sulfamerazine—and metabolites, high-pressure liquid chromatographic analysis, pure solutions and cattle urine, 1606
—flocculated and coagulated suspension structures, settling profiles and filtration rates, 420
—potentiometric analysis, liquid membrane electrode sensitive to sulfa drugs, 435
Sulfamethazine—and metabolites, high-pressure liquid chromatographic analysis, pure solutions and cattle urine, 1606
—veterinary bolus tablets, dissolution testing apparatus described, various disintegrating agents evaluated and compared to *in vivo* absorption, cattle, 1823
Sulfamethizole—measurement of total body clearance rate, nonthrombogenic constant blood-withdrawal system, dogs, 450
—renal excretion mechanisms, pharmacokinetic analysis, 463
Sulfathiazole—and metabolites, high-pressure liquid chromatographic analysis, pure solutions and cattle urine, 1606
—binding to bovine whole blood, plasma proteins, and purified albumin fractions compared, 33
—dissolution rate, effect of crystallization in aqueous surfactant solutions, 1702
—polymorphs, effect of polyethylene glycol 4000 on dissolution properties, 302
–povidone coprecipitates—dissolution rates, solubility studies, compared to supercooled melt and crystalline forms of sulfathiazole, thermodynamic parameters, 355
Sulfisomidine—potentiometric analysis, liquid membrane electrode sensitive to sulfa drugs, 435
Sulfisoxazole acetyl—effect of lipids on bioavailability, rats, 328
acetyl—saturable first-pass metabolism, rats, 334
—binding to protein fractions of human tears, normal and irritant induced, 437
—dissolution and intestinal absorption, effect of dioctyl sodium sulfosuccinate and poloxamer 188, rats, 115
—weight variation, dissolution, and bioavailability, *in vivo* and *in vitro* evaluation, commercial dosage forms, 1494
Sulfonylureas—chlorpropamide or tolbutamide, high-performance liquid chromatographic analyses in presence of metabolites, plasma, 1356
Sulfur analog of busulfan—synthesized, antimicrobial screening, 1692
analogs—psychotomimetic substituted phenylalkylamines synthesized, 1554
heterocycles—synthesis and antibacterial activity of 4-substituted (1,2,3-thiadiazol-5-yl)carbamic acid esters and selenium analogs, 304
Suppositories—absorption and distribution of benzocaine, rats, 832
Surface properties—nonionic surfactant solutions, effect of inorganic additives, 975
Surfactants, aqueous—crystallization of chloramphenicol, sulfathiazole, and prednisone in polysorbate 80, effect on dissolution rates, 1702
—cationic, anionic, and nonionic, interaction with dantrolene sodium, 873
—dioctyl sodium sulfosuccinate and poloxamer 188, effect on dissolution and intestinal absorption of sulfadiazine and sulfisoxazole, rats, 115
—dioctyl sodium sulfosuccinate, mechanism of inhibition of pepsin activity, 1319
—dioctyl sodium sulfosuccinate, rheopexic dispersions, formation of micelles, 1265
lung—oxygen solubilization at various surfactant concentrations, 142
nonionic—aqueous solutions, effect of inorganic additives on Krafft and cloud points, 979
nonionic—effect of inorganic additives on CMC and surface properties, 975
nonionic—effect on percutaneous absorption of salicylic acid and sodium salicylate from ointment bases containing dimethyl sulfoxide, rabbits, 1780
—polysorbate 80, effect on apparent partition coefficient and absorption of salicylic acid, rat intestine, 621
—sodium alkyl sulfates, effect on release of protein from everted rat small intestine, 1460
Suspensions, coarse—controlled flocculation by colloidally dispersed solids, interaction of bismuth subnitrate with bentonite, 855
drug—nitrofurantoin, dissolution–dialysis rates, effect of three viscosity grades of methylcellulose, 1618
—settling profiles and filtration rates, flocculated and coagulated structures of sulfamerazine, effects of filter bed parameters on refiltration

rates, 420
Sweeteners—sodium cyclopentylsulfamate, GLC analysis, rat and rabbit urine, 1841
Sweetness—related to structural functions of ketoses, 1222
Swertiamarin—CNS activity evaluated, interaction with mangiferin, 1547
Sydnones—pharmacological and toxicological evaluation of 3-*tert*-butylsydnone, 109
Sympathomimetic amines—binding to synthetic melanin, affinity and capacity evaluated, 1057

T

Tablet granulations—distribution kinetics of wetting during preparation, 992
hardness—effects of five different film coatings, 1291
hardness testers—motorized pendulum type, method for checking calibration and determining accuracy and precision, three testers compared, 1072
lubricants—effect on ejectability and tablet hardness, comparison of mixing and incorporation methods of formulation, 1155
Tablets, colored—degree of mottling, effects of method and temperature of granule drying, granule size, compaction pressure, 198
colored—effects of several formulation variables on mottling, 200
compressed—dibasic calcium phosphate with varying proportions of intra- to extragranular starch, disaggregation, effect of compaction pressure, 1749
direct compression—size, hardness, and dissolution, effect of storage at various temperatures and humidity, 1746
—disintegration time, hardness, effect of various ratios of starch disintegrant to starch paste and various compression forces, 1694
—effect of intra- and extragranular disintegrating agents on particle size, 1170
—six matrixes, effect of various compaction forces on hardness, apparent density, and disintegration time, 1835
—stabilized compressed nitroglycerin tablets prepared, bioavailability and stability compared to commercial products, 1466
sublingual molded—nitroglycerin, vapor pressure, intertablet migration, effect of additives, 1278
veterinary bolus—dissolution testing apparatus described, various disintegrating agents evaluated and compared to *in vivo* absorption, cattle, 1823
—water-soluble drug in methyl acrylate–methyl methacrylate copolymer tablets, effect of water-soluble excipients, 1333
—wet granulation preparation, fluoride content, effect of processing, dyes, flavors, citric acid, and lubricants, 932
Taste physiology—structural functions of ketoses related to sweetness, 1222
Tear film pH—effect of topically applied pilocarpine, base and salts compared, rabbits, 1654
Technetium Tc 99m—used in scintigraphic monitoring of disintegration and drug release times of gelatin capsules *in vivo,* 1412
Technology, pharmaceutical—sterility, dosage forms, cosmetics, packaging equipment, dental products, biomedical devices, 1975 literature review, 935, 1101
Terminology—regarding labeled and contained amounts in dosage forms, definitions suggested for the terms shelflife, outdate, expiration date, label date, 311
Testosterone propionate—related esters, solubility in various organic solvents, 656
Test specifications—USP and NF tests for content uniformity, dissolution, disintegration, and weight variation, sample size changes from previous editions, 312
Tetracycline—analysis, high-performance liquid chromatography, pharmaceutical preparations, 400
—complexes with Ca^{+2} and Mg^{+2}, circular dichroism spectral investigation of binding properties, 1728
—effect of pH and route of injection on acute toxicity, mice, 916
—polarographic analysis, pharmaceutical formulations, 1315
Tetracyclines—binding to human serum albumin, related to ring substituents, difference spectrophotometry, spectrophotometric probe, 226
Tetramethylammonium bromide—toxicity and urinary excretion, effect of stress and pretreatment with steroids, rats, 1838
Tetrakis(acetylsalicylato) - μ-dicopper(II)—synthesis, biological evaluation, anti-inflammatory activity, physical properties, 126
Tetramethyldicarboxamides—aqueous solutions, dielectric constants correlated with solubilizing properties, 1645
Tetraphenylborate—use as precipitant in gravimetric analysis of chlorhexidine, 1251
Tetrazolium reaction—effect of varying solvents and dielectric constants of solvents on rate of color development and wavelength of maximum absorption of formazan, 1048
Theophylline—analysis, differential spectrophotometry, pharmaceutical formulations, 1178
—GLC analysis, effect of butyl rubber stoppers, blood, 735
—high-pressure liquid chromatographic analysis, plasma, 865
Thermal decomposition—simultaneous analysis of cyanocobalamin, cobinamide, and hydroxocobalamin, solid pharmaceutical preparations, 1831
gelation—effect on dissolution of methylcellulose-coated tablets, 572
Thermodynamics, solution—four alkyl *p*-aminobenzoate esters, equilibrium solubilities in alcohols, 252
Thiamine hydrochloride—IR spectra, solid-state anomalies, 1400
Thiazolidones—synthesis, evaluation of CNS activity, effect on NAD-dependent oxidation, 443
Thienopyrimidinonemercaptoacetic acids and ethyl esters—synthesized, screened for analgesic, anti-inflammatory, anticonvulsant, and antimicrobial activity, 660
1-Thioacylpiperidines—used in synthesis of carboxymethyl carbodithioates, 146
Thiobarbiturates—characterization by IR spectroscopy, 1258
Thiobenzothiazoles, substituted—synthesis and characterization, anticonvulsant activity, effect on NAD-dependent oxidation, monoamine oxidase activity, 405
Thiobenzoxazoles, substituted—synthesis and characterization, anticonvulsant activity, effect on NAD-dependent oxidation, monoamine oxidase activity, 405
Thiocarbamides—synthesis, evaluation of CNS activity, effect on NAD-dependent oxidation, 443
Thiocardenolides—3β - thiocyanato-14β - hydroxy-5β-card-20(22)-enolide synthesized, screened for cardiotonic activity and effect on sodium- and potassium-activated adenosine triphosphatase, 765
Thiohydantoins—characterization by IR spectroscopy, 1258
Thiopental—distribution in blood, organs, and tissues, pharmacokinetic model for simultaneous determination proposed, dogs, 717
Thioridazine and metabolites—GLC analysis, plasma, 667
Thiosulfonates—synthesis of tetramethylene bis(methanethiosulfonate) and 2,4-dichlorophenyl methanethiosulfonate, antimicrobial screening, 1692
Thiosulfuric acids, aminoethane—series synthesized and screened for antiradiation activity, 1247
Thiothixene—high-pressure liquid chromatographic analysis, pharmaceutical formulations, 1090
Thioureas, *N*-substituted *N'*-*p*-sulfonamidophenyl—synthesized and screened for antimicrobial activity, 1551
Thixotropic systems—equilibrium flow curve constructed from shear stress and shear rate data, apparent rate constants calculated, 1385
Thrombocytes—uptake of 5-hydroxytryptamine correlated with structure–activity, quantum chemical, and hydrophobicity factors, effect of various tryptamine derivatives, 1014
Tinidazole—polarographic analysis, commercial tablets, 736
Tissue distribution—radioiodinated phenytoin derivatives, potential tumor imaging agents, rats, 285
levels—various drugs, comparison of instantaneous input assumption and short-term zero-order infusion, various drugs, 1541
Tithonia tagitiflora—whole plant alcoholic extract, isolation of six new germacranolides, β-sitosterol, and its β-D-glucoside, screened for antileukemic activity, 918
Titrimetry—analysis, quinine sulfate and quinidine sulfate, pure compound and synthetic tablets, 424
iodometric—analysis of penicillins and cephalosporins, 300
TLC—analysis and separation of methadyl acetate from metabolites, rat liver microsomes, 137
—analysis, furosemide and metabolite, urine, dogs and monkeys, 1456
–fluorometry—analysis, butaclamol in human serum, 508
—identification, drugs of abuse, spray reagents and solvent systems selected and developed, 1585
—separation, Schiff base derivatives of *p*-aminophenol in presence of degradation products or acetaminophen, 71
Tobacco plants—*Nicotiana tabacum,* ^{2}H- and ^{13}C-substituted, cultured in sealed growth chambers, isotope substrates conserved and recycled, 1096
Tolbutamide—dissolution, three single-particle models evaluated and compared, mathematical analysis, 1442
—GLC analysis, plasma, 576
—high-performance liquid chromatographic analysis in presence of metabolites, plasma, 1356
—high-pressure liquid chromatographic analysis, compared to GLC analysis, serum, 1502
Topical dosage forms—development and screening, use of bioassays, review, 1417
vehicles—effect of sodium salicylate on diffusion of benzocaine, 493
Topically applied drugs—pilocarpine nitrate, precorneal disposition, 1295
Topological indexes—Wiener number, *Z*-value, and branching (connectivity) index compared, correlated with molecular surface areas and aqueous solubilities, various monofunctional compounds, 801
Toxicity—α- and β-halomorphides compared, 902
—platinum complexes, effects in various animals, review, 315
potential—bis(2-ethylhexyl)phthalate, effect on chromosomes of human leukocytes and fetal lung cells, 1648
—progesterone, cell growth inhibition, prenatal and neonatal exposure, review, 783
—relationship to polymorphic forms of polyene antibiotics mepartricin and nystatin, mice, 905
—tetracycline, effect of pH and route of injection, mice, 916
—tetraethylammonium bromide, effect of stress and pretreatment with steroids, rats, 1838
Toxins, ciguatera—bioassay using brine shrimp larvae, 1414
Tranquilizers—butaclamol, TLC–fluorometric analysis, human serum, 508
—butaperazine, adsorption onto quartz cells, kinetics, 630
—chlorpromazine and its sulfoxide, extraction from whole blood, fluorometric analysis, 694
—chlorpromazine and trifluoperazine hydrochlorides, effect on electrochemical behavior

of flavin coenzymes, 1758
—chlorpromazine, bioavailability and pharmacokinetics, evaluated by measurement of rectal temperature depression, rabbits, 1600
—chlorpromazine, fluorometric analysis, pharmaceutical formulations and blood levels, 689
—chlorpromazine, pharmacokinetic model relating induced miotic response to systemic bioavailability, rabbits, 1593
—fluphenazine base, enanthate, and decanoate esters, comparison of slow-release characteristics, effect of route of administration, dogs, 1310
—medazepam, pKa determination, 1094
—thiothixene, high-pressure liquid chromatographic analysis, pharmaceutical formulations, 1090
—trifluoperazine hydrochloride and embonate and pericyazine embonate, effect of various pharmaceutical formulations on duration of biological activity, dogs, 1665
Transformations, intra- and intermolecular —acetylsalicylic acid in nonhydroxylic solvents, reaction mechanisms, 776
Transport rates, GI—effect of alpha tocopherol deficiency, rats, 344
Triamcinolone acetonide, ^{14}C-labeled—synthesized, aqueous solubility determinad, radioisotopic method, 429
Tri- and tetramethyleneisoxazoles—synthesized by condensation of 1,4-dianions with esters followed by acid cyclization, 1408
***s*-Triazines,** substituted—synthesized from biguanides, GC and mass fragmentographic analysis, 525
Trichloroacetyl isocyanate—reaction with corticosteroids to form carbamates, application to NMR analysis, 1214
Trichloromonofluoromethane—adsorption on activated charcoal, isotherms compared, 56
—solubility in dog blood and tissue homogenates, 53
2,4,5-Trichlorophenoxyacetic acid—electron-capture GLC and radiochemical analyses, mouse blood, urine, and feces, pharmacokinetics, 1810
Trifluoperazine—effects on pressor actions of serotonin, angiotensin, and bradykinin in perfused human placenta, 1498
hydrochloride and embonate—effect of various pharmaceutical formulations on duration of biological activity, dogs, 1665
hydrochloride—effect on electrochemical behavior of flavin coenzymes, polarographic and chronopotentiometric investigation, 1758
Trihydroxyindole reaction—with methanesulfonanilides, fluorometric analysis of soterenol and mesuprine, 763
Triterpenes—isolated from shilajit (Indian rock exudate) and *Euphorbia royleana* plant, 772
Tritium-labeled drugs—*in vivo* loss of tritium, urine and plasma analyses compared, 1261
Tromethamine—buffer system for dissolution rate studies of timed-release tablets as a function of pH, 806
Tryptamine—derivatives, effect on 5-hydroxytryptamine uptake by thrombocytes, 1014
—monoamine oxidase-catalyzed oxidative deamination, effect of 4-methoxyphenethylamine and *N*-methylated homologs, 1539
Tumor imaging agents—radioiodinated phenytoin derivatives, tissue distribution studies, rats, 285
Tyramine—monoamine oxidase-catalyzed oxidative deamination, effect of 4-methoxyphenethylamine and *N*-methylated homologs, 1539

U

Umbelliferone—spectrophotofluorometric analysis, alone and with coumarin, whole blood, 30
Undecanes, substituted cyclic—epimers synthesized, analgesic activity evaluated, 1389
Urea—effect on aqueous solubility of nitrofurantoin, varying temperature and pH, 868
series—absorption through oral mucosa, radioisotope transfer, streaming potential, dogs, 129
Uricosuric agents—probenecid and metabolites, effect of dose, 861
—probenecid, effect on biliary secretion of methotrexate, rats, 1348
Urinary excretion data, fractional—value in griseofulvin bioavailability studies questioned, 1099
UV-absorbing alkaloids, strong and weak—binary mixtures, charge-transfer spectrophotometric analysis, 986
analysis—pilocarpine and isopilocarpine in pharmaceutical preparations, 257
—light-induced color changes, *N,N*-disubstituted piperazines in solid state, effects of temperature, dissolution, and prolonged storage, 1452
spectrophotometry—absorption studies, interactions of adenine, cytosine, thymine, and uracil, with catechol, 892
spectrophotometry—absorption studies, interaction of adenine, thymine, and uracil with epinephrine, 982
spectrophotometry—pKa determination, medazepam, compared to solubility method, 1094
spectrophotometry—semiautomated analysis, methapyrilene hydrochloride, pharmaceutical mixtures, 1590
spectroscopy—used to monitor degradation of penicillin in acidic media, kinetic analysis, 1165

V

Vaccines, bacterial—determination of homogeneity of emulsified suspension of *Pasteurella avicida*, UV measurement of extracted cell contents, 433
influenza—preparation of poly(methyl methacrylate) adjuvants, evaluation by hemagglutination, antibody binding, and electron microscopy, 1624
Vapor pressure—gravimetric measurement, pure materials and solutions dispersed in porous media, analysis of nonequilibrium and background effects, 1269
—nitroglycerin, sublingual molded tablets, effect of additives, 1278
Vasodilators, coronary—nitroglycerin, bioavailability and stability, stabilized compressed tablet compared to commercial products, 1466
coronary—nitroglycerin, polarographic determination of dissolution of sublingual tablets, 1691
—nitroglycerin, effect of body position on cardiovascular response, short-acting and sustained-release dosage forms, dogs, 308
peripheral—nylidrin, GLC analysis in urine, 1352
Vauquelinia corymbosa—chloroform extract of leaves and stems, uvaol, ursolic acid, and betulinic acid isolated, screened for antitumor activity, 1407
Verapamil—fluorometric analysis, biological fluids and tissues, 431
Veterinary bolus tablets—dissolution testing apparatus described, various disintegrating agents evaluated and compared to *in vivo* absorption, cattle, 1823
Vinyl acetate—lung infiltration, casts formed, papain-induced emphysematous changes evaluated, rats, 1082
Violaxanthin—transformation into loliolide and violoxin, 1549
Virus vaccines, influenza—preparation of poly(methyl methacrylate) adjuvants, evaluation by hemagglutination, antibody binding, and electron microscopy, 1624
Viscometry—rotational and creep, rheological evaluation of gastric mucus system, 828
Viscosity—gastric mucus system, effect of borate ions and tetracycline, 828
—thixotropic systems, equilibrium flow curve constructed, apparent rate constants calculated, 1385
—three grades, methylcellulose, effect on dissolution–dialysis rates of nitrofurantoin suspensions, 1618
Vitamin A—related compounds—desmethylretinoic acid and vinylogs, wound-healing mechanism of action, effect on granuloma formation, 580
Vitamin E—deficiency, effect on intestinal transport and absorption of barbital, phenolsulfonphthalein, and salicylate, rats, 344
Vitamins—ascorbic acid, stability in various tablet formulations, nature and extent of formation of decomposition products, 963
—colorimetric analysis of niacinamide in multicomponent preparations, 65
—combined analyses, vitamins A, D (ergocalciferol), and E in multivitamin preparations, reversed-phase partition chromatography, 968
—cyanocobalamin, activity, effect of methylparaben sodium, autoclave temperature, pharmaceutical formulations, 745
—cyanocobalamin, cobinamide, and hydroxocobalamin, simultaneous analysis by thermal decomposition of the cyano group, solid pharmaceutical preparations, 1831
—ergocalciferol and cholecalciferol, high-performance liquid chromatographic analysis and separation from photochemical isomers and reaction products of provitamins, 1024
—pyridoxine hydrochloride, high-pressure liquid chromatographic analysis in mixtures with isoniazid, 1536
Volume of distribution—comparison of instantaneous input assumption and short-term zero-order infusion, tissue compartments, various drugs, 1541
—terms in pharmacokinetic modeling, single definition proposed as a function of time, 452

W

Warfarin—binding to human serum albumin, effect of temperature, 1673
sodium—automated analysis, commercial dosage forms, 1522
Weight variation product assay—USP test, sulfisoxazole, commercial dosage forms, 1494
Wettability—pharmaceutical solids, evaluated by measurement of surface free energy and contributions of polar and nonpolar forces, effect of substituent groups, 1145
Wetting—pharmaceutical powders, effect of particle size and porosity of cake, 843
Wiener number—correlated with other topological indexes, molecular surface areas, and aqueous solubilities, various monofunctional compounds, 801

X

Xanthine oxides—mammalian liver, oxidation of pteridine derivatives, 1150
Xanthone-2-carboxylic acids, substituted—pulmonary absorption after intratracheal administration, solution and suspension compared, rat lungs, 1669

Y

Z

Zoxazolamine—effect of pretreatment with dexamethasone acetate and pregnenolone-16α-carbonitrile on pharmacological action, plasma concentrations, and liver homogenate metabolism, rats, 1092
***Z*-value**—correlated with other topological indexes, molecular surface areas, and aqueous solubilities, various monofunctional compounds, 801
Zwitterionic compounds, cephalosporins—ionization constants calculated by combining spectrophotometric and potentiometric measurements, 1034